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SUMMARY 
 The endocannabinoid system (ECS) regulates numerous cellular and physiological 
processes. Nowadays, the system comprises two G protein-coupled receptors named CB1 
and CB2 receptor, and the endogenous ligands anandamide (N-arachidonoylethanolamide: 
AEA) and 2-arachidonylglycerol (2-AG). The CB1 receptor is mainly expressed in the central 
nervous system, whereas the CB2 receptor is mainly expressed by peripheral cells including 
immune and bone cells. Unlike the CB1 receptor, CB2 receptor activation does not induce 
psychoactive negative effects. Together with its expression pattern, the CB2 receptor thus 
offers a great potential for the treatment of different immune related diseases. The CB2 
receptor became a target of choice for the development of new drugs. 
 A genetic variation within the human gene coding for the CB2 receptor was 
discovered ten years ago. This genetic variation results in the amino acid exchange from 
glutamine to arginine at protein position 63 (Q63R), which is localized in the first intracellular 
loop of the G protein. As a consequence, the signaling activity of the receptor is generally 
reduced. To address the functional differences between these human variants of the CB2 
receptor in vivo, humanized targeting vectors were generated and subsequently used for the 
generation of chimeric mice by injecting targeted ES cells into blastocysts. Due to the lack of 
germ-line transmission, new engineering technologies (CRISPR/Cas9 system and TALENs) 
were designed and tested for their ability to target the Cnr2 locus. The study presented here 
revealed that applying the CRISPR/Cas9 technology tremendously improved the 
homologous recombination efficiency in ES cells. In order to assess the functional 
differences between the human CB2 receptor variants in vitro, recombinant viral vectors 
were developed using the innate ability of lentiviruses to deliver genetic material into non-
dividing cells. Due the low transduction efficiencies measured in bone marrow-derived 
macrophages (BMMs) for all viral vectors generated, lentiviruses were not further used 
during the study. 
 Since its discovery, CB2 receptor activation has been shown to inhibit activation, cell 
motility and secretion of inflammatory mediators in different kinds of immune cells. In this 
study, the anti-inflammatory role played by murine CB2 receptor activation was analysed in 
BMMs. Different pro- and anti-inflammatory activation states of BMMs were induced and 
characterized. Under pro-inflammatory conditions, CB2 activation had no effect on pro-
inflammatory cytokine (TNFα) release. Gene expression analysis revealed that genes 
encoding cannabinoid receptors are differentially regulated upon stimulation with different 
combination of pro-inflammatory substances. Finally, CB2 receptor activation with different 
agonists did not modulate the phagocytic activity of zymosan particles by BMMs. Hence, the 
data presented here could not clearly confirm an anti-inflammatory role of murine CB2 
receptor in BMMs. 
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6  Introduction 
 
1 INTRODUCTION 
1.1 Discovery of the endocannabinoid system 
“Cannabis is a generic term used to denote the several psychoactive preparations of the 
plant Cannabis sativa. It is by far the most widely cultivated, trafficked and abused illicit 
drug.” (WHO, 2013). Nowadays cannabis is mainly used for recreational purposes due to its 
psychotropic effects. But in ancient history, a lot of evidences show that this drug was 
presumably used for medical or divinatory purposes. The last concrete example is the recent 
discovery of a 2700-year-old grave near Turpan, in North China, containing a shaman and a 
large cache of cannabis (789 grams). Scientists supposed that the cannabis was used for 
pharmaceutical, psychoactive or divinatory purposes (Russo et al., 2008). Moreover 
evidences for cannabis use can be traced back for more than 4000 years (Murray et al., 
2007). 
 Cannabis interest rose among scientists who clearly wanted to identify and elucidate 
the drug and its effects. Like for the discovery of the opioid system, which started by the 
chemical synthesis of heroin by morphine diacetylation in the late 1800s, research on 
cannabinoid system started, in 1965 (Mechoulam and Gaoni, 1965), with the isolation and 
synthesis of the active constituent of Hashish: Δ1-tetrahydrocannabinol (THC) by Raphael 
Mechoulam and colleague. Twenty years later, the molecular target of this substance was 
identified in the rat brain (Devane et al., 1988) ad cloned (Matsuda et al., 1990). This first 
cannabinoid receptor was named the cannabinoid receptor 1 (CB1). This step initiated the 
research era of the so-called endocannabinoid system (ECS). Few years later a second 
target was identified. While CB1 was found to be extremely abundant in the brain, and was 
immediately suggested to be responsible for THC psychoactivity, the second target was 
discovered in rat spleen and was consecutively cloned (Munro et al., 1993). This receptor 
was named the cannabinoid receptor 2 (CB2). The molecular characterization of THC 
binding sites opened the way for the identification of endogenous lipid mediators or ligands. 
The term cannabinoid compound encompasses three categories of compounds. Those 
derived from the Cannabis sativa plant (phytocannabinoids), synthetically derived 
compounds (synthetic cannabinoids), as well as endogenous compounds, which were shown 
to bind to CB1 and CB2 receptors (endocannabinoids). The two major endocannabinoids 
(eCBs) anandamide (N-arachidonoylethanolamide: AEA) (Devane et al., 1992) and 2-
arachidonylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al., 1995) are the most 
extensively studied. The system comprising the two receptors and the endogenous ligands 
was then referred to as the endocannabinoid system (ECS). Investigations of this system 
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became really interesting with the emergence and use of transgenic animals lacking the CB1 
(Zimmer et al., 1999) and the CB2 receptor (Buckley et al., 2000). Nowadays, many 
transgenic animal models related to the ECS exist: form receptors to enzymes involved in the 
synthesis or degradation of the endogenous ligands. 
 However, researches on the ECS did not fully elucidate the mechanisms, targets and 
signaling pathways. And it is well accepted that the endocannabinoid system does not 
involve only two receptors and two ligands. During the last past years, G coupled protein 
receptors (GPCR) were identified and were thought to be new members of the cannabinoid 
receptor family, like GPR55 and GPR18. As GPR55 being a real cannabinoid receptor is still 
under debate (Gasperi et al., 2013), GPR18 is considered as a really good candidate to be 
the third  cannabinoid receptor but further investigations are still required (Console-Bram et 
al., 2014). 
1.2 ECS: the global view 
To better understand the ECS system, it is necessary to dissect the effects occurring via the 
CB1 and the CB2 receptors. Unlike the CB1 receptor which is expressed at high levels in the 
central nervous system (CNS), the CB2 receptor is found predominantly in the periphery and 
more precisely in cells of hematopoietic and mesenchymal cell lineages. The differential 
expression pattern of these receptors leads to different physiological effects. In the CNS, 
endocannabinoids act as powerful regulators of synaptic function. Defined as a retrograde 
signaling system, endocannabinoids are synthesized at the postsynaptic site and released in 
the synaptic cleft. They bind at the CB1 receptor expressed at the presynaptic site, to 
suppress transmitter release in a transient or long-lasting manner, at both excitatory and 
inhibitory synapses (Alger, 2012; Katona and Freund, 2012). As CB1 activation by THC or 
other synthetic cannabinoid is inducing psychoactive effects, many scientists started to 
concentrate their efforts to study the CB2 receptor whose activation does not induce such 
negative effects. 
 
 As described in figure 1, CB1 and CB2 receptors, are Gi/o coupled GPCR. Binding of 
ligands (eCBs or other agonists) to these receptors activates several cellular signaling 
pathways and leads to the inhibition of adenylyl cyclase and stimulation via ceramide 
production of several mitogen-activated protein (MAP) kinases (extracellular-signal-regulated 
kinase: ERK, c-Jun N-terminal kinase: JNK, p38 and p42/44). It also results in the activation 
of the PI3 kinase (phosphatidylinositol-3-kinase), protein kinase B-Akt pathway, and gene 
transcription. Moreover, both receptors modulate high voltage-activated calcium channels or 
inwardly rectifying potassium channels (Atwood and Mackie, 2010; Bifulco et al., 2008; 
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Fernandez-Lopez et al., 2013). Unlike the ability of the CB1 receptor activation to inhibit 
synaptic transmission in the CNS, the CB2 receptor activation in immune cells has been 
shown to inhibits activation, cell motility and secretion of inflammatory mediators (Basu and 
Dittel, 2011; Tanasescu and Constantinescu, 2010). This receptor became a target of choice 
for the development of new pharmacological compounds to treat immune related diseases. 
However, during drug discovery process an important point rose while trying to target 
specifically the CB2 receptor. In fact different pharmacological responses to identical drugs 
were reported in different species (Bingham et al., 2007; Mukherjee et al., 2004; Yao et al., 
2006) thus leading to difficulties during the development of drugs targeting specifically the 
human CB2 receptor. 
 
 
Figure 1: Main signaling pathways activated by cannabinoid receptors. 
AC: adenylyl cyclase; EMN: neutral sphingomyelinase enzyme; EM: sphingomyelin; FAN: factor 
associated with neutral sphingomyelinase activation; N, P/Q: voltage-dependent calcium channels 
type N, P/Q; PKA: protein kinase A; PKB/Akt: protein kinase B; ERK: extracellular signal-regulated 
kinase; JNK: c-Jun N-terminal kinase; FAK: focal adhesion kinase; PI3K: phosphoinositide-3 kinase. 
David Fernández-López
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Cannabinoids: Well-Suited Candidates for the Treatment of Perinatal Brain Injury review Brain Sci. 
2013, 3(3), 1043-1059; doi:10.3390/brainsci3031043,  
 
 Physiological consequences of ECS modulation has been extensively studied since 
the discovery of the system and the growing use of transgenic mouse models. The system 
was shown to play a role in many physiologic processes and diseases, as few examples: 
neurotransmission, aging, inflammation/migration, neuropathic and inflammatory pain, 
metabolic syndromes, osteoporosis, drug addiction and liver diseases (Baldassarre et al., 
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2013; Bilkei-Gorzo, 2012; Castillo et al., 2012; Guindon and Hohmann, 2009; Idris, 2010; 
Oliere et al., 2013; Rom and Persidsky, 2013; Silvestri and Di Marzo, 2013). 
1.3 The cannabinoid receptor 2: from mice to human 
1.3.1 The cannabinoid receptor 2  
The cannabinoid receptor 2 was discovered by a polymerase chain reaction (PCR)-based 
strategy designed to isolate G-protein-coupled receptors (GPCR) in differentiated myeloid 
cells and based on its similarity in amino-acid sequence to the CB1 receptor (Munro et al., 
1993). The human CB1 and CB2 receptors share approximately 44 % amino acid similarity. 
As the CB1 amino acid sequence is really highly conserved across human and rodent 
species, the CB2 receptor is a bit less, but still well conserved, across human and murine 
species. The human CNR2 gene and its mouse ortholog Cnr2, are located on chromosomes 
1p36 and 4QD3, respectively. As for the CB1 receptor, the CB2 receptor is composed of the 
non-coding exons 1a and 1b, and a single coding exon 2. The coding exon 2 open reading 
frame (ORF) contains 1083 base pairs (bp) for the human gene and 1044 bp for the mouse 
one, resulting in a 360 amino acid long human CB2 receptor protein and a 347 amino acid 
long mouse one. An open reading frame alignment of the human CB2 (hCB2) and the mouse 
CB2 (mCB2) nucleic acid sequences revealed 82 % homology. An alignment of the hCB2 
and mCB2 peptide sequences revealed 83 % homology. The main differences observed 
between the mouse and the human peptide sequences are located at the N and C terminal 
regions of the protein and in the extra and intra cellular loops whereas the most conserved 
regions are the transmembrane domains of the protein. 
1.3.2 Genetic variations within the human cannabinoid receptor 2 gene 
Among mammalian species, individuals are identical over most of their genomes. Thus, only 
a relatively small number of genetic differences have resulted in the striking variation seen 
among individuals within the same species, mainly due to single base changes also defined 
as single nucleotide polymorphisms or SNPs. SNPs can be found in intronic regions (within 
introns), and in 5' or 3' untranslated regions of genes. Studying the role played by those 
SNPs located in non coding exon is challenging. Moreover SNPs are also located in coding 
exons of genes. When the nucleotide substitution does not change the amino acid, it is called 
a synonymous SNPs whereas nucleotide substitution that result in a change to the amino 
acid is defined as a nonsynonymous SNPs. The cannabinoid receptor 2 and its single coding 
exon was extensively studied for the presence of nonsynonymous SNPs within the ORF and 
their roles and consequences. In 2005, Doctor Karsak and colleagues discovered three 
interesting nonsynonymous SNPs within the CNR2 gene that were associated with human 
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osteoporosis (Karsak et al., 2005) and few years later with hand bone strength phenotypes 
(Karsak et al., 2009). One of the discovered SNPs was referenced under the name 
rs2229579 and the genetic variation was the result of the amino acid exchange from histidine 
to tyrosine at protein position 316 (H316Y), which is localized at the C-terminal part of the 
protein. The two others nonsynonymous SNPs discovered were located on adjacent 
nucleotides, named rs2502992–rs2501432 and resulting in the amino acid exchange from 
glutamine to arginine at protein position 63 (Q63R), which is localized in the first intracellular 
loop of the G coupled protein. 
 
 In 2010, Carrasquer and colleagues tested the CB2 receptor variant containing the 
amino acid arginine at the position 63 (hCB2Arg63) for the functional significance of this 
mutation. Using site-directed mutagenesis and HEK293 cells transfected with the CB2 
variants, they showed in ligand-induced cyclic AMP accumulation assays that cannabinoid 
agonists like WIN55212-2 and 2-AG had reduced efficacy in cells expressing the hCB2Arg63 
as compared with the wild type receptor hCB2Gln63. This was the first demonstration of a 
reduced signaling of the polymorphic variant as compared to the wild type receptor. 
Moreover these findings strengthen the idea that the CB2 polymorphic receptor may 
contribute to the etiology of certain diseases (Carrasquer et al., 2010). The hCB2Arg63 
variant was further investigated in different human case/control samples and for different 
diseases in which the CB2 receptor was supposed to play a role as depicted in figure 2. 
 
 
 
Figure 2: Involvement of human CB2 variant in different diseases. 
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 Not much is known about the cannabinoid receptor 2 distribution pattern due to a lack 
of specific antibodies (Baek et al., 2013). Due to the therapeutic advantage of targeting the 
CB2 receptor without interfering with the CB1, many scientists have spent efforts and energy 
to identify expression of the CB2 receptor in the central nervous system and particularly in 
neurons without clear evidence (Atwood and Mackie, 2010). However, different groups of 
scientists investigated the genetic associations between CNR2 gene polymorphisms and 
disease altering the central nervous system like for example schizophrenia. A genetic 
association was found between the CNR2 gene polymorphisms Q63R and schizophrenia in 
a Japanese and a Han Chinese independent case/control populations (Ishiguro et al., 2010b; 
Tong et al., 2013). The two teams of scientists found that the hCB2Arg63 variant was 
significantly increased among schizophrenic patients compared with control subjects. And 
their results indicate an increased risk of schizophrenia for people with low CB2 receptor 
function. Associations between the R63Q polymorphisms of the CNR2 gene and eating 
disorders (Ishiguro et al., 2010a), alcoholism (Ishiguro et al., 2007) and depression (Onaivi et 
al., 2008) were found in Japanese case/control populations. 
 
 Today, it is clear that the CB2 receptor plays an important role in the peripheral 
system especially in pain (Anand et al., 2009) and immune system (Cabral and Griffin-
Thomas, 2009) regulations. Some scientific groups focussed their efforts to show a genetic 
association between the CNR2 gene polymorphisms Q63R and immune diseases. In 2005, 
Sipe and colleagues showed a genetic association between the Q63R dinucleotide 
polymorphism and endocannabinoid-induced inhibition of T lymphocyte proliferation (Sipe et 
al., 2005) . Again, T lymphocyte expressing the hCB2Arg63 variant showed a lower function 
of the CB2 receptor resulting in a twofold reduction of endocannabinoid-induced inhibition of 
proliferation compared with cells expressing the hCB2Gln variant. An interesting point from 
this study is that the authors found significant results using N-arachidonylglycine which is an 
agonist for the CB2 receptor, but also for the GPR18 receptor, as it was recently showed by 
McHugh et al., (McHugh et al., 2014; McHugh et al., 2012). Moreover the reduced 
endocannabinoid inhibitory response was only "nearly significant" using 2-AG agonist and 
these effects were only partially blocked using a specific CB2 receptor antagonist. Altogether 
these results indicate the major role played by the CB2 receptor and the genetic variant in 
autoimmune disease but also the necessity to identify the precise role of the CB2 receptor 
and the GPR18 receptor in immune cells. 
 
 Following this discovery, genetic associations between the Q63R dinucleotide 
polymorphism in the CNR2 gene and autoimmune disorders were investigated. An 
association was found by two different groups in two different case/control populations 
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(Egyptian and Italian) between the hCB2Arg63 variant and the immune thrombocytopenia, 
which is an autoimmune disorder resulting in significant defects in immune self-tolerance 
(Mahmoud Gouda and Mohamed Kamel, 2013; Rossi et al., 2011b). An Italian group showed 
also that the hCB2Arg63 variant increases the risk of celiac disease which is an autoimmune 
disorder of the small intestine. They raised the point that genotyping the CNR2 gene for this 
dinucleotide polymorphism could be a novel molecular biomarker and maybe interesting for 
future therapeutic intervention (Rossi et al., 2012b). 
 
 Finally, as no specific CB2 antibody exist, it is difficult to claim where the CB2 
receptor is expressed. Real time expression of the CB2 gene performed since the discovery 
of the receptor showed the presence of CB2 mRNA in the liver and the spleen with the 
highest, or more precisely, with "detectable" levels. Some genetic associations between the 
CNR2 gene polymorphisms Q63R and liver diseases were found, principally in Italian 
case/control populations. The same group found in obese Italian children with fatty liver, or 
steatosis, that the hCB2Arg63 variant is associated with liver damage progression due to a 
defect in the modulation of hepatic inflammation state (Rossi et al., 2012a; Rossi et al., 
2011a). Another Italian group showed that the hCB2Gln variant is associated with more 
severe inflammation and hepathocellular necrosis in patients with HCV infection (Coppola et 
al., 2014). These results corroborate the idea of a hepatoprotective role for the CB2 receptor, 
and the two CB2 genetic variants could play an hepatoprotective role depending on the liver 
disease. 
 
 Altogether, these findings are in concordance with the demonstration of a reduced 
signaling of the hCB2Arg63 variant and its implication in different diseases, or process, 
making the CB2 receptor a target of choice for the development of new drugs. To perform a 
deeper investigation of the two human variants, it is more than necessary to assed the 
functional differences in vivo by the generation of humanized mice harboring both CB2 
receptor variants and in vitro by the development of  different techniques in order to express 
and characterized the human CB2 receptor variants. The next part will be dedicated to the 
introduction of the different technologies which were used during this work, in order to 
achieve the in vivo and in vitro characterization of the human CB2 variants. 
 
1.4 Aim of the study: functional testing of the CB2 receptor 
The present PhD work is divided into three aims which finally converged into one unique 
direction: clarifying the CB2 receptor function based on the generation of different tools. The 
first aim consists in the generation of CB2 receptor humanized mice using embryonic stem 
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(ES) cells or new engineering technologies. The second aim consists in developing 
recombinant viral vectors containing the human CB2 receptor variants using the innate ability 
of lentiviruses to deliver genetic material into a chosen infected cell type. Finally a third aim 
consists in the characterization of the CB2 receptor role in different functions played by 
immune cells such as macrophages. 
1.4.1 Generation of Humanized CB2 mice with conventional and new DNA 
engineering strategies 
The unique way to understand the functional consequences in vivo of the genetic variations 
present among the human CB2 receptor gene is to generate two mutant mouse models 
containing the two different variants of the human gene identified. In order to achieve this, 
genomic engineering techniques based on homologous recombination (HR) in ES cells using 
a targeting constructs and new engineering technologies were used. 
1.4.1.1 ES cells based strategies 
Nowadays, genomic engineering techniques based on HR in ES cells are widely used for the 
generation of mutant mouse models, which are essential tools for biomedical research to 
analyze gene functions in disease processes. In some instances these techniques have also 
been used to generate mice in which a human disease-associated gene variant replaced the 
cognate mouse gene. Such “humanized” mice can provide important information about the 
role of specific protein variants and they may be useful for drug development (Scheer et al., 
2013).  
 
 The generation of transgenic mice started in the early 1980s with the direct 
microinjection of cloned DNA into the pronuclei of fertilized eggs resulting into transgenic 
mice in which the transgene is stably integrated into the genome. The main disadvantage of 
this technique is the random integration of the transgene, because neither the copy number 
nor the site of integration is controlled. These limitation was overcome in the late 1980s with 
the generation and use of ES cells to generate transgenic animals. ES cells were derived 
from preimplantetion embryos and present the remarkable ability to colonize a host embryo, 
including its germ line (Evans and Kaufman, 1981; Martin, 1981). These cells, which can be 
cultured in large numbers, yields the possibility of selecting genetic modifications in culture 
and obtaining corresponding mice via the generation of germ line chimeras (Babinet, 2000). 
This is generally achieved by the use of targeting vectors. Despite their widespread use, the 
generation of transgenic animals via techniques based on ES cells is time consuming and 
extremely costly. 
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1.4.1.2 New engineering technologies 
Novel DNA engineering technologies for the generation of mutant alleles have been 
developed during the last five years and are based on the introduction of double-strand 
breaks (DSBs) into a target gene locus by sequence specific nucleases (Gaj et al., 2013). 
For this purpose, either zinc-finger nucleases or transcription activator-like effector nucleases 
(TALENs) have been engineered to recognize and cleave specific DNA sequences (Zinc 
finger: (Hockemeyer et al., 2009), TALEN: (Cermak et al., 2011; Hockemeyer et al., 2011; Li 
et al., 2011)). The resulting DSBs in the targeted DNA sequence can be repaired by either of 
two mechanisms, nonhomologous end joining (NHEJ) or homology directed repair (HDR) 
(Porteus and Carroll, 2005; Urnov et al., 2005). NHEJ leads to small genetic modifications 
such as deletions or insertions (indels) that can cause disruption of genetic loci and lead to 
the generation of gene knockout animal. On the other hand the HDR allows either precise 
modification of a target sequence or precise introduction of a specific sequence into the 
targeted site. Thus when a small double-stranded or single stranded template of DNA is 
supplied consecutively to these DNA engineering tools, HR is stimulated by double strand 
breaks and lead to precise genetic engineering (Hockemeyer et al., 2011; Wang et al., 
2013b).  
 
 Nevertheless, cloning of these nucleases still requires a considerable effort, which 
offsets their advantages to some extent. Recently, the very powerful and much simpler 
CRISPR/Ca9s system for the introduction of targeted DSBs has been developed (Li et al., 
2013a; Menke, 2013). It is based on the discovery that many eu- and archea-bacteria detect 
and destroy invading phages using ribonucleoprotein complexes composed of “clustered 
regularly interspaced short palindrome repeat” CRISPR-RNAs (crRNAs), trans-activating 
crRNAs (tracrRNA), and CRISPR-associated (Cas) proteins. In particular, Cas9 from 
Streptococcus pyogenes has been directed by single-guide or guide RNAs (sgRNA, gRNA), 
a fusion of crRNA and tracrRNA, to produce DSBs at specific genomic locations (Chylinski et 
al., 2013). Thus, the system can be adapted to target different genomic locations simply by 
modifying the sequence-specific motive in the sgRNA (Cong et al., 2013; Wang et al., 
2013b).  This system has been used to enhance the frequency of gene targeting by 
homologous repair in C. elegans (Chen et al., 2013; Dickinson et al., 2013), as well as 
protoplasts from Arabidopsis thaliana and Nicotiana benthamiana (Li et al., 2013b). 
 
 In this study a TALEN pair and a CRISPR/Cas9 system were developed and tested 
for their efficiency to produce DSBs within the coding exon of the Cnr2. Furthermore, the 
potential of the CRISPR/Cas9 system to enhance the efficiency of “humanizing” the mouse 
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Cnr2 gene in mouse embryonic stem cells was assessed, revealing the potential of this 
technology for the further generation of "humanized" transgenic animals. 
1.4.2 Generation of hCB2 recombinant viral vectors 
The basic concept of viral vectors is to harness the innate ability of viruses to deliver genetic 
material into the infected cell. Unfortunately, viruses deliver different genes whose products 
are hazardous to the host and lead to pathogenesis. The basic principle of turning these 
pathogens into delivery systems relies on the ability to separate the components needed for 
replication from those capable of causing disease (Verma and Weitzman, 2005). As 
represented in figure 3, the parental virus genome consists of genes involved in replication, 
production of the virion, genes responsible of the pathogenicity of the virus. This viral 
genome is flanked by cis-acting sequences that provide the viral origin of replication and the 
signal for encapsidation. Lentiviral delivery systems were created by separating this viral 
genome in two parts: one packaging construct consisting of the gene responsible for the 
replication and the production of structural proteins. The vector construct consists of the 
transgene construct containing a promoter, the gene of interest, and a posttranscriptional 
regulatory element. This vector construct is flanked by the cis-acting sequences. Both 
constructs are then transfected into packaging cells like 293T cells. These cells are derived 
from human embryonic kidney cells (HEK293 cells) and the "T" means that it express the 
Large T antigen which is important for increasing the replication of plasmids containing a 
SV40 origin. The lentiviral packaging and vector constructs contain this SV40 origin of 
replication. 
 
 
 
Figure 3: Principle of generating a viral vector. 
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A) Converting a virus into a recombinant viral vector. Schematic of a generic viral genome is shown 
with genes that are involved in replication, production of the virion, and pathogenicity of the virus. The 
cis-acting sequences represented by the red boxes flanking the parental virus genomes provide the 
viral origin of replication and the signal for encapsidation. The packaging construct contains only 
genes that encode functions required for replication and structural proteins. The vector construct 
contains the essential cis-acting sequences and the transgene cassette that contains the required 
transcriptional regulatory elements. LTR: long terminal repeat. B) The packaging and vector constructs 
are introduced into the packaging cell (293T cells) by transfection. Proteins required for replication and 
assembly of the virion are expressed from the packaging construct, and the replicated vector genomes 
are encapsidated into virus particles to generate the recombinant viral vector. Picture and legend 
modified from original: Inder M. Verma and Matthew D. Weitzman. Gene therapy: twenty-first century 
medicine. Annu Rev Biochem. 2005;74:711-38. 
 
 The lentiviruses are a subgroup of retroviruses that integrate into the genomes of 
non-dividing cells. Consequently, these viruses have the most potential for primary cells such 
as bone marrow-derived macrophages human CB2 genes delivery.  
1.4.3 Immune cells characterization 
BMMs are primary macrophage cells, derived from bone marrow cells in vitro in the presence 
of the growth factor: the macrophage colony-stimulating factor (M-CSF). Once differentiated, 
the mature BMMs are suitable for different types of experimental manipulations like 
transduction with recombinant lentiviral vectors even if these cells are not the easiest to 
transduce (Burke et al., 2002).  
 
 It also permits to study gene expression using flow cytometry. BMMs have the ability 
to be polarized. In response to the environment, macrophages undergo M1 “classically 
activated” pro-inflammatory or M2 “alternatively activated” anti-inflammatory activation states. 
These polarization states are defined by the inducing stimulus and by the ensuing patterns of 
gene expression, which determine the function. The cytokine interferon gamma (IFNγ) and 
the Toll like receptor activator lipopolysaccharide (LPS) polarize macrophages towards the 
M1 phenotype, which induces the release of a large amount of pro-inflammatory cytokines 
(tumour necrosis factor alpha: TNFα, interleukin 12 and 23: IL-12, IL-23) and expression of 
molecule like the cluster of differentiation 86 (CD86). M1 polarized macrophages drive 
antigen specific cells and are effective in killing microbes. But also they have the potential to 
cause toxicity and collateral tissue damage. Exposure of macrophages to the cytokine IL-4 
induces the M2 phenotype, which initiates the expression of anti-inflammatory cytokines such 
as interleukin 10 (IL-10) and interleukin 1-RA (IL-1RA), but also cell surface markers like the 
mannose receptor (MMR). Alternatively activated M2 macrophage appears to be involved in 
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immunosuppression, wound healing and tissue repair (Mantovani et al., 2004). Moreover, 
BMMs such as macrophages have a unique ability to ingest microbes via phagocytosis 
(Murray and Wynn, 2011; Weischenfeldt and Porse, 2008). The ability of the CB2 receptor to 
modulate the anti-inflammatory functions of BMMs was assessed during this study. 
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2 MATERIAL  
2.1 Equipment 
Technical instrument Identifier, Company 
Analytical balance BP 121 S, Sartorius 
Cell culture incubator Binder GmbH 
Centrifuges Biofuge fresco, Heraeus Instruments 
Biofuge pico, Heraeus Instruments 
Biofuge stratos, Heraeus Instruments 
Megafuge 1.0R, Heraeus Instruments 
Digital gel documentation ChemiDoc MP imaging systems, Bio-Rad 
Laboratories 
Electroporation System Gene pulser Xcell, Micropulser, Bio-Rad 
Laboratories 
Electrophoresis chamber Sub-Cell GT System, Bio-Rad 
Laboratories 
Film processing machine CP1000, AGFA 
Flow cytometer FACS Canto II, BD Biosciences 
Hybridization oven  HB-1000 Hybridizer UVP  
Laminar flow hood Herasafe, Kendro 
Liquid handling platform Janus®, Perkin Elmer 
Magnetic stirrer MR 3001 K, Heidolph, Fisher  
Microplate analyzer MRX TC II, Dynex Technologies 
Microscope Eclipse TS 1000, Nikon 
Axiovert 40 CEL, Zeiss 
Axio Imager M2, Zeiss 
PCR Cycler iCycler, Bio-Rad Laboratories 
pH meter inoLab, WTW  
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Real-time PCR Cycler 7900HT Fast Real-time PCR System, 
Applied Biosystems 
Spectrophotometer NanoDrop 1000 Thermo scientific 
Sterilizing oven Varioklav 25T, H+P Labortechnik 
UV crosslinker UV Stratalinker 2400, Stratagene 
UV lamp Bio-Rad 
Vacuum Blotter Bio-Rad 
Vortexer Vortex-Genie 2, Scientific Industries  
 
2.2 Chemical and reagents 
2.2.1 Kits 
2.2.1.1 Molecular biology kits 
 
Kits Company 
QiaPrep MiniPrep Buffers P1-P3 Qiagen 
GeneEluteTM HP Plasmid MidiPrep Kit Sigma 
peqGOLD Plasmid Miniprep Kit Peqlab 
peqGOLD Gel Extraction Kit Peqlab 
PCR DIG Labeling Mix Roche 
Surveyor® mutation detection kit for standard gel 
electrophoresis 
Transgenomic 
 
2.2.1.2 pRed/ET kits 
 
Kits Company 
BAC Subcloning Kit GenebridgesTM 
Quick & Easy Conditional Knockout Kit  
(FRT/FLPe) 
GenebridgesTM 
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2.2.1.3 Elisa kit 
 
Target Species  Company 
TNFα Mouse Ready-SET-Go! eBioscience 
 
2.2.1.4 TaqMan® Gene Expression Assays from Life Technologies 
 
Target mRNA Assay ID 
B2M Mm00437762_m1 
Cnr1 Mn00432621_S1 
Cnr2 Mn00438286_m1 
Gpr18 Mn01224541_m1 
 
2.2.2 Selection cassettes  
 
Selection cassette Company 
ColE1-amp minimal vector GenebridgesTM 
FRT-PGK-gb2-neo-FRT GenebridgesTM 
 
2.2.3 Molecular weight standards 
 
Marker Company 
DNA Molecular weight marker II Roche 
100 bp DNA ladder Invitrogen 
1 kb DNA ladder  Invitrogen 
 
2.2.4 Desoxyribonucleotides (dNTPs) 
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Marker Company 
PCR DIG Probe Synthesis Mix: dATP, 
dCTP, dGTP (2 mM each); 1.3 mM dTTP; 
0.7 mM DIG-11-dUTP, alkali-labile; pH 7.0 
Roche 
10 mM dNTP Mix  Invitrogen 
 
2.2.5 Enzymes and antibodies 
2.2.5.1 Enzymes 
 
Enzyme Company 
Proteinase K NEB 
Superscript II Reverse Transcriptase Invitrogen 
Taq Polymerase NEB 
Phusion® High-Fidelity DNA Polymerase NEB 
T4 DNA ligase Invitrogen 
Antarctic Phosphatase NEB 
Quick ligase NEB 
T7 endonuclease I NEB 
T4 DNA polymerase Enzymatics 
T4 Polynucleotide Kinase (PNK) NEB 
Mva1269I Fermentas 
PstI FastDigest Fermentas 
KpnI FastDigest Fermentas 
BbsI FastDigest Fermentas 
Restriction endonucleases enzymes NEB 
 
2.2.5.2 Antibodies 
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Antigen Species Conjugation Company 
Anti-Digoxigenin-AP, 
Fab fragments 
Sheep AP (Revealed with 
DCP-Star) 
Roche 
Alexa Fluor® 488 Donkey Alexa Fluor® 488 Invitrogen 
CD11b Rat APC eBioscience 
CD11b Rat Biotin BD Pharmingen 
CD11b Rat eFluor® 450 eBioscience 
CD11b Rat FITC Biozol 
CD11b Rat PE eBioscience 
CD40 Rat Biotin eBioscience 
CD86 Rat PE BD Pharmingen 
Cnr2 N-terminal Rabbit None Abcam (3561) 
Cnr2 N-terminal Rabbit None Thermo Scientific 
(PA1-744) 
Cnr2 C-terminal Rabbit None Abcam (45942) 
Fc-Block (CD16/CD32) Rat None Biozol 
MHCII Rat APC eBioscience 
MMR Rat Biotin Biozol 
Streptavidin Streptomyces PerCP-Cy5.5 BD Pharmingen 
 
2.2.6 Antibiotics 
 
Substance Company Working concentration 
Ampicillin Applichem 100 µg/ml 
Chloramphenicol Sigma Aldrich 15 µg/ml 
Kanamycin Applichem  50 µg/ml 
Tetracycline Applichem 10 µg/ml 
G418 Sigma-Aldrich 170 ng/ml 
 
2.2.7 CB2 receptor agonists 
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Substance Company Vehicule 
2-AG Tocris Bioscience 100 % EtOH 
β-caryophyllene Provided by Prof. Dr. Jürg Gertsch Tocrisolve 
JWH-133 Applichem  Tocrisolve 
 
2.2.8 Oligonucleotides 
All oligonucleotides sequences are provided in the supplemental material. 
2.2.8.1 Oligonucleotides 
Normal oligonucleotides were designed using Primer3 software. The optimal conditions 
chosen were: 20 bp for the size, a GC content of 50 % and a Tm of 58 °C. Oligonucleotides 
were ordered at Metabion GmbH. Desalted, scale of synthesis of 20 nmol, Desalted, 
lyophilised. When Primers arrived, they were dissolved at 100 pmol/μl as stock solution and 
diluted at 10 pmol/μl as working solution. 
2.2.8.2 Long oligonucleotides 
Long oligonucleotides were mainly used for cloning using the Red/ET technology. These 
oligos were designed with 50 bp used as homologous region followed by 25 bp for annealing 
and amplifying the desired DNA sequence. The oligos were ordered at Invitrogen. They were 
lyophilised, with a scale of synthesis of 200 nmol and PAGE purified. Oligonucleotides were 
dissolved at 100 pmol/μl as stock solution and diluted at 10 pmol/μl as working solution. 
2.2.9 Solutions 
All solutions were prepared with sterile deionized MilliQ water. If not stated otherwise, all 
chemicals and reagents used were purchased from Applichem, Invitrogen, Merck, Roth or 
Sigma-Aldrich. 
2.2.9.1 Cultivation of bacteria 
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LB medium    
H2O     
Tryptone 1 % (w/v) 
Yeast extract 0.5 % (w/v) 
NaCl 1 % (w/v) 
Autoclaved at 121 °C, 20 min   
 
LB agar    
LB medium     
Agarose 1.5 % 
 
2.2.9.2 DNA isolation 
 
Lysis buffer   
Tris/HCl pH 8 100 mM 
EDTA     5 mM 
NaCl 200 mM 
SDS 0.2 % (w/v) 
 
TE buffer   
Tris       10 mM 
EDTA, pH 8         1 mM 
Adjusted to pH 7.4   
 
2.2.9.3 Southern blot 
 
Depurination   
HCl 250 mM 
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Denaturation   
NaOH 500 mM 
NaCl 1.5 M 
 
Neutralization   
Tris/HCl, pH 7  500 mM 
NaCl 1.5 M 
 
SSC (20X)   
NaCl 3 M 
Na-citrate dihydrate 300 mM 
Adjusted to pH 7   
 
Maleic acid buffer   
Maleic acid 100 mM 
NaCl  150 mM 
Adjusted to pH 7.5   
 
Blocking solution (10X)   
Maleic acid buffer   
Blocking reagent (Roche) 10 % (w/v) 
Autoclaved at 121 °C, 20 min   
 
Hybridization buffer   
SSC (20X) 25 % (v/v) 
SDS 0.2 % (w/v) 
Blocking solution (10X) 10 % (v/v) 
N-lauroylsarcosine   1 % (w/v) 
 
26  Material 
Washing buffer   
Maleic acid buffer   
Tween 20  0.3 % (v/v) 
 
Detection buffer   
Tris/HCl, pH 9.5 100  mM 
NaCl   50  mM 
MgCl2   25  mM 
 
2.2.9.4 Agarose gel electrophoresis 
 
6X loading dye   
Glycerol 30 % (v/v) 
Orange G 0.4  % (w/v) 
 
TAE buffer (1X)   
Tris-acetate 40 mM 
EDTA, pH 8   1 mM 
 
2.2.9.5 Cell culture media 
If not stated otherwise, all the cell culture solutions and medi used were purchased from 
Gibco Life technologies. 
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MPI ES cell medium   
DMEM, high glucose   
FBS (ES cell approved) 20 % (v/v) 
Sodium pyruvate 1 % (v/v) 
Penicillin streptomycin mix 0.5 % (v/v) 
Nonessential amino acids (100X) 1 % (v/v) 
β-mercaptoethanol 70 nM 
LIF (Merck Millipore)  500 U/ml 
 
Bruce4 ES cell medium    
DMEM, high glucose   
FBS (ES cell approved) 12.5 % (v/v) 
Sodium pyruvate   1 % (v/v) 
Penicillin streptomycin mix   1 % (v/v) 
Nonessential amino acids (100X)   1 % (v/v) 
β-mercaptoethanol 0.1 mM 
LIF (Merck Millipore) 1000 U/ml 
 
RESGRO Culture Medium                    Merk Millipore 
L-Glutamine (200 mM) 2 % (v/v) 
 
Mouse embryonic fibroblast medium 
DMEM, high glucose   
FBS 10 % (v/v) 
Sodium pyruvate 0.5 % (v/v) 
 
Mitomycin solution   
Mouse embryonic fibroblast 
medium 
  
Mitomycin C (Sigma-Aldrich) 10  µg/ml 
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Freezing medium 10% DMSO   
DMEM, high glucose 40  % (v/v) 
FBS (ES cell approved) 50  % (v/v) 
DMSO  10  % (v/v) 
 
Freezing medium 20 % DMSO   
DMEM, high glucose 40  % (v/v) 
FBS (ES cell approved) 40  % (v/v) 
DMSO  20  % (v/v) 
 
Mouse bone marrow-derived 
macrophages medium  
  
RPMI 1640 (PAA)   
Inactivated FBS 10 % (v/v) 
Penicillin streptomycin mix 1 % (v/v) 
β-mercaptoethanol 50 μM 
M-CSF (Self prepared) 
Or M-CSF (eBioscience) 
15 
20 
% (v/v) 
ng/ml 
The solution was sterile filtrated 
before use. 
  
 
NIH3T3 medium    
DMEM, high glucose   
FBS 10 % (v/v) 
Sodium pyruvate   1 % (v/v) 
Penicillin streptomycin mix   1 % (v/v) 
 
Formaldehyde 4 %   
1X PBS   
Paraformaldehyde 4 % (v/v) 
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Slides mounting solution  
Dapi-Fluoromount-G SouthernBiotech 
 
2.2.9.6 Cell culture stimulants 
 
 
 
 
2.2.9.7 Cell transfection reagents 
 
Transfection reagents Company 
Lipofectamine 2000 Invitrogen 
X-tremeGENE 9 DNA transfection reagent Roche 
 
2.2.9.8 Elisa solutions 
 
Stimulant Species Company Concentration 
Interleukin-4 (IL-4) Mouse eBioscience 100 U/ml 
Interferon gamma (IFNγ) Mouse R & D Systems 20 ng/ml 
Lipopolysaccharide (LPS) E. coli  Invitrogen 100 ng/ml 
Stimulant Company 
Zymosan A S. cerevisiae BioParticles®, Fluorescein Conjugate Life Technologies 
Zymosan A Bioparticles® Opsonizing Reagent Life Technologies 
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Assay Solutions Provided Solutions Prepared Standard  
Concentration 
Mouse TNFα  
Ready-SET-Go! 
eBioscience 
Coating Solution 
5X Assay diluent 
Substrate Solution 
Wash Buffer 
(0.05 % TWEEN 20 in PBS 
1X) 
1 µg/ml 
  Stop Solution 
(1 M H3PO4) 
 
Mouse IL-1β  
Ready-SET-Go! 
eBioscience 
Coating Solution 
5X Assay diluent 
Substrate Solution 
Wash Buffer 
(0.05 % TWEEN 20 in PBS 
1X) 
1 µg/ml 
  Stop Solution 
(1 M H3PO4) 
 
 
2.2.9.9 FACS solutions 
 
FACS Buffer   
PBS 1X   
FBS  2 % 
 
FACS reagents: BD Cytofix/CytopermTM kit BD Biosciences  
BD Cytofix/Cytoperm solution  
BD Perm/Wash buffer 10X Diluted in sterile deionized 
MilliQ water 
 
2.3 BAC, plasmids 
2.3.1 BAC 
RPCIB731B063Q: Genomic clone renamed as mCB2 BAC containing the whole mouse 
Cnr2 genomic region and cloned into the pBACe3.6 vector. The vector contains an origin of 
replication and a chloramphenicol antibiotic resistance gene. The genomic clone is hosted in 
DH10B E. coli and was purchased from ImaGenes. 
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2.3.2 Original plasmids 
hCB2 GC without tag pcDNA3.1D V5-His-TOPO: This plasmid contains the human CB2 
open reading frame with the bases GG at position 189, encoding for an arginine at position 
63 in the human CB2 receptor protein. This plasmid was used to amplify the human CB2 
open reading frame by PCR. Plasmid cloned and provided by Dr Karsak. 
hCB2 AC without tag: pcDNA3.1D V5-His-TOPO: This plasmid contains the human CB2 
open reading frame with the bases AA at position 189, encoding for a glutamine at position 
63 in the human CB2 receptor protein. This plasmid was used to amplify the human CB2 
open reading frame by PCR. Plasmid cloned and provided by Dr Karsak. 
pLuc-1xIRES2EGFP-SV40pA: Plasmid provided by Dr. Bouabe from Max von Pettenkofer 
institute for Hygiene and Medical Microbiology (Bouabe et al., 2008). This plasmid was used 
to amplify the IRES2-eGFP fragment by PCR.  
pRed/ET: This plasmid encode the genes of a protein pair of 5' - 3' exonucleases under an 
arabinose-inducible promoter. Upon expression, these proteins mediate the recombination 
between regions of homology. The plasmid was provided in Genebridges kits. 
pX330-U6-Chimeric_BB-CBh-hSpCas9: This plasmid was used to clone small annealed 
oligonucleotides in order to be used as CRISPR/Cas9 system for generating targeted double 
strand breaks. This plasmid was purchased from Addgene. 
rrl-CMV-eGFP: Self inactivated vector construct provided by Dr. Zimmermann from Institute 
for Pharmacology and Toxicology. This vector contains an ampicillin resistance gene and 
was used to clone the human CB2 open reading frame linked or not to an IRES2-eGFP in 
order to generate lentiviral particles to transduce bone marrow derived-macrophages. 
TAL-BBL1-ID14, TAL-BBL1-ID43, TAL-BBL1-ID23: Level 1 plasmids used during the 
ligation independent cloning of TALEN assembly. These plasmids were purchased from 
Addgene. 
TAL-ID12-C, TAL-ID12-G: Level 2 plasmids used during the ligation independent cloning of 
TALEN assembly. These plasmids were purchased from Addgene. 
2.3.3 Cloned plasmids 
mCB2 ORF Subclone: Plasmid containing a 8619 bp fragment subcloned from the mCB2 
BAC into a destination vector containing the Cnr2 gene, an ampicillin resistance gene and an 
origin of replication sequence. 
hCB2Arg63 Subclone: The mCB2 ORF subclone plasmid was used as the original plasmid 
and the murine CB2 ORF was replaced by the human CB2 ORF (arginine variant). The 
plasmid contains the CNR2 ORF (arginine), an ampicillin resistance gene and an origin of 
replication sequence. 
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hCB2Gln63 Subclone: The mCB2 ORF subclone plasmid was used as the original plasmid 
and the murine CB2 ORF was replaced by the human CB2 ORF (glutamine variant). The 
plasmid contains the CNR2 ORF (glutamine), an ampicillin resistance gene and an origin of 
replication sequence. 
hCB2Arg63 targeting construct: The hCB2Arg63 subclone plasmid was used as the 
original plasmid. A FRT-PGK-gb2-neo-FRT cassette was inserted into it. The plasmid 
contains the CNR2 ORF (arginine variant), an ampicillin resistance gene, a kanamycin 
resistance gene and an origin of replication sequence. 
hCB2Gln63 targeting construct: The hCB2Gln63 subclone plasmid was used as the 
original plasmid. A FRT-PGK-gb2-neo-FRT cassette was inserted into it. The plasmid 
contains the CNR2 ORF (glutamine variant), an ampicillin resistance gene, a kanamycin 
resistance gene and an origin of replication sequence. 
mCB2-left-TALEN: Plasmid cloned from original level 2 plasmid (TAL-ID12-C) using the 
ligation independent cloning of TALEN assembly protocol. This plasmid contains an ampicilin 
resistance gene and was used in combination with the mCB2-right-TALEN to generate 
targeted DSBs within the Cnr2 ORF. 
mCB2-right-TALEN: Plasmid cloned from original level 2 plasmid (TAL-ID12-G) using the 
ligation independent cloning of TALEN assembly protocol. This plasmid contains an ampicilin 
resistance gene and was used in combination with the mCB2-left-TALEN to generate 
targeted DSBs within the Cnr2 ORF. 
px330-mCB2: Small annealed oligonucleotides containing a 20 bp homologous sequence to 
the Cnr2 ORF were cloned into the original pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid. 
The plasmid contains an ampicillin resistance gene. 
rrl-CMV-hCB2-Arg63: Vector construct cloned from the original rrl-CMV-eGFP vector 
construct. The eGFP ORF was replaced by the CNR2 ORF (arginine variant). The vector 
construct contains an ampicillin resistance gene. 
rrl-CMV-hCB2-Gln63: Vector construct cloned from the original rrl-CMV-eGFP vector 
construct. The eGFP ORF was replaced by the CNR2 ORF (glutamine variant). The vector 
construct contains an ampicillin resistance gene. 
rrl-CMV-hCB2-Arg63-IRES2-eGFP: Vector construct cloned from the original rrl-CMV-
hCB2-Arg63 vector construct. The IRES2-eGFP fragment was amplified from the original 
pLuc-1xIRES2EGFP-SV40pA plasmid and cloned adjacently to the CNR2 ORF (arginine 
variant). The vector construct contains an ampicillin resistance gene. 
rrl-CMV-hCB2-Gln63-IRES2-eGFP: Vector construct cloned from the original rrl-CMV-
hCB2-Gln63 vector construct. The IRES2-eGFP fragment was amplified from the original 
pLuc-1xIRES2EGFP-SV40pA plasmid and cloned adjacently to the CNR2 ORF (glutamine 
variant). The vector construct contains an ampicillin resistance gene. 
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2.4 Cells 
2.4.1 Bacteria 
DH10b: An E.coli strain harboring the unmodified BAC clones. The initial subcloning step 
was performed in this strain. Chemically competent DH10b bacterial cells were used for the 
ligation-independent cloning of TALENs. These bacteria were purchased from Invitrogen. 
Stbl3: Chemically competent bacteria purchased from Invitrogen. These bacteria were used 
to clone the px330 CRISPR/Cas9 plasmids. 
TOP10: Electrocompetent TOP10 was an E.coli strain used for the transformation of the 
different recombinant plasmids. These bacteria were purchased from Invitrogen. 
 
2.4.2 Embryonic Stem cells 
Bruce4 embryonic stem cells: An ES cell line derived from C57BL/6 mice (Kontgen et al. 
1993). The cell line was kindly provided by Ralf Kühn, Max-Planck Institute for Biochemistry, 
Martinsried, Germany. 
MPI2 embryonic stem cells: An ES cell line derived from 129/Sv mice. The cell line was 
generated at the Max Planck Institute Göttingen in the laboratories of Prof. P. Gruss (Voss et 
al. 1998). 
2.4.3 Cells 
Bone marrow-derived macrophages: These cells were prepared from 6 to 8 weeks old 
mice. A detailed description of the preparation is given in section 3.4.1. 
NIH3T3 cells: Mouse embryonic fibroblast derived from Swiss mouse embryo tissue. This 
cell line was isolated and initiated in 1962 at the New York University School of Medicine 
Department of Pathology. 
Primary mouse embryonic fibroblasts (MEF): These cells were used as feeder cells for 
the cultivation of ES cells. A detailed description of the preparation is given in section 3.2.1. 
 
2.5 Software 
Double Digest Finder: The software is provided by NEB and was used to find optimal buffer 
and temperature conditions for double restriction endonucleases digestion. 
(https://www.neb.com/tools-and-resources/interactive-tools/double-digest-finder). 
Flowjow: The software is required to analyse data obtained with the flow cytometer FACS 
Canto II, BD Biosciences. (www.flowjo.com). 
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ImageJ: The software was used to analyse and count engulfed zymosan particles in the 
phagocytosis assay. (http://rsbweb.nih.gov/ij/). 
LIC TALE gene Assembler Version 1.0: The software was used to pick the appropriate 2-
mer fragments that are required to assemble an 18.5 RVD TALEN construct. 
(http://www.hornunglab.de/Tassembly.html). 
Ligation Calculator: The software was used to calculate the amounts of vector and insert to 
perform DNA ligation. (http://www.insilico.uni-duesseldorf.de/Lig_Input.html) 
NEBcutter V2.0: The software is provided by NEB and was used to find or validate 
restriction endonucleases sequences. (http://tools.neb.com/NEBcutter2/index.php). 
Primer3: This software was used to design oligonucleotides for PCR reactions. 
(http://bioinfo.ut.ee/primer3-0.4.0/). 
Prism 5: Software commonly used to analyse and graph data. 
UCSC genome browser: The software was used to find sequences of gene of interest and 
validated the specificity of designed oligonucleotides. (http://genome.ucsc.edu/). 
Vector NTI® software: The software was used to design, clone, and align DNA sequences in 
silico. 
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3 METHODS 
This section is divided into four parts. The first part contains general molecular biology 
methods used to clone different plasmid vectors. The second and third parts deal with the 
cultivation and manipulation of the ES cells and NIH3T3 cells. And finally the fourth part 
contains methods to isolate, cultivate, transduce and characterize bone-marrow derived 
macrophages from mice. 
All manufacturers’ protocols mentioned are archived at the Institute of Molecular Psychiatry 
and are available upon request. 
 
3.1 Molecular biology methods 
Methods concerning the cultivation, transformation and long-term storage of E. coli were 
performed according to the protocols of Sambrook, Fritsch and Maniatis (Sambrook, Fritsch 
and Maniatis, 1989). Agarose gel electrophoresis and detection of DNA in agarose gels by 
ethidium bromide staining were conducted as described in Molecular Cloning by Sambrook 
and Russel (Sambrook and Russel, 2001). 
3.1.1 DNA  
3.1.1.1 DNA preparation from E.coli 
3.1.1.1.1 Mini preparation 
Two different methods were used to purify plasmid DNA from E.coli. The DNA preparation 
described in the technical protocol provided in the Quick & Easy Conditional Knockout Kit 
manual (Genebridges™) was the preferential method for analytical purposes (routine plasmid 
screenings like restriction analysis) whereas silica columns based miniprep kit was used to 
isolate pure plasmid DNA for further cloning steps or sequencing analysis. To isolate pure 
plasmid DNA using silica columns, peqGOLD Plasmid Miniprep kit I (Peqlab biotechnologies 
GmbH) was used following the manufacturer´s instructions. 
3.1.1.1.2 Midi preparation 
For Midi preparation, the GeneEluteTM HP Plasmid MidiPrep Kit (Sigma) was used following 
the manufacturer’s instructions. 
3.1.1.2 Purification of DNA fragments  
3.1.1.2.1 From agarose gel and PCR reactions 
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In order to purify DNA fragments from agarose gels, DNA was loaded on an 0,8 % agarose 
gel. After fifteen minutes incubation of the gel in an ethidium bromide bath, the DNA fragment 
of interest was excised using a UV light lamp. 
Before purifying DNA from PCR reactions, 5 μl were loaded on an agarose gel to verify the 
PCR results. The rest of the PCR reaction was purified. 
Purification of DNA fragments from agarose gels and PCR reactions was performed using 
peqGold Gel Extraction Kit (Peqlab biotechnologies GmbH) following the manufacturer´s 
instructions. 
3.1.1.2.2 Phenol-Chloroform extraction 
DNA fragments used for ES cell electroporation were purified by a phenol-chloroform 
extraction. The sample volume was filled up to 500 μl with Milli-Q water. The same volume 
(500 μl) of phenol/chloroform/isoamylalcohol (25:24:1) was added to the tube. After mixing by 
inversion for 1 minute followed by centrifugation (16000 g, 10 min), the supernatant was 
carefully pipetted and transferred into a fresh tube. The supernatant was supplemented with 
500 μl of chloroform followed by another mixing and centrifugation step. The supernatant was 
pipetted into a new fresh tube. The DNA was precipitated by adding 3 M sodium acetate pH 
7,2 (1:10) and 100 % ethanol (2.5:1). To improve the precipitation, tubes were placed one 
hour at -20°C. After centrifugation (16000 g, 20 min) and removal of the supernatant, the DNA 
pellet was washed twice with 70 % ethanol, air-dried and dissolved in TE buffer. 
3.1.1.3 DNA preparation from living cells 
Cultured ES cells or NIH3T3 cells were incubated minimum 2 hours in lysis buffer and 
proteinase K (1 mg/ml) at 55 °C. The DNA was precipitated by addition of one volume of 
isopropanol. After centrifugation (16000 g, 20 min) and removal of the supernatant, the DNA 
pellet was washed twice with 70 % ethanol, air-dried and dissolved in TE buffer. 
3.1.1.4 Measurement of DNA concentration 
DNA sample concentration was measured using a Nanodrop-1000 spectrophotometer. DNA 
absorbs ultraviolet light at a wavelength of 260 nm (A260). The absorbance of 1 unit at A260 is 
equivalent to a DNA concentration of 50 µg/ml. The purity of a DNA preparation is assessed 
by the ratio of absorbance at 260 and 280 nm. A pure DNA preparation exhibits an A260/A280 
ratio between 1,8 and 2. 
3.1.1.5 Digestion of DNA 
Sequence-specific cleavage of DNA was checked in silico using Vector NTI® software, 
NEBcutter V2.0 or Double Digest Finder in case of double restriction endonucleases digestion. 
Restriction digestion was performed according to manufacturers in recommended buffer 
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conditions. For analytical and cloning purposes, 1 to 5 μg of DNA were digested at the 
recommended enzyme temperature for minimum one hour in a water bath. To digest higher 
DNA amount (linearization of targeting constructs before ES cells electroporation, 60 μg) or for 
genomic DNA (Southern blot), DNA were digested during 8 hours or longer at the 
recommended temperature in a PCR cycler. 
3.1.1.6 DNA ligation 
Before DNA ligation, blunt end vectors were dephosphorylated using antarctic phosphatase 
during 15 minutes at 37 °C. The enzyme was then heat inactivated for 5 minutes at 70 °C as 
recommended by NEB. The ligation was performed by mixing 30 fmol of the vector and 90 
fmol of the insert (insert: vector molar ratio of 3:1) into T4 DNA ligase reaction buffer 
supplemented with 1 unit of T4 DNA ligase enzyme. Ligation was incubated overnight at 16 
°C. 5 to 20 μl of the ligation were used to transform 50 μl electrocompetent TOP10 bacteria. 
3.1.1.7 Amplification of DNA fragments by polymerase chain reaction 
For sequence specific amplification of DNA fragments, PCR was applied. For analytical 
purposes, PCR reactions were performed with Taq polymerase whereas for cloning purposes 
Phusion® High-Fidelity DNA polymerase was used. To increase specificity a hot start was 
applied when using the Taq polymerase enzyme. Each PCR reaction was specifically adapted 
to the annealing temperature requirements of the oligonucleotides and the length of the 
expected PCR product. Established PCR conditions and a list of oligonucleotides used are 
provided in the appendix. 
3.1.1.8 PCR reaction for Southern blot probes 
The Southern blot probes were labelled by digoxigenin-coupled nucleotides. 
 
3´ neo integration Southern blot probe for the identification of positive ES cell clones: 
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PCR setup (50 µl)   
MilliQ water 36 µl 
10X PCR-buffer  5  µl 
Forward primer (Fwd 3' CB2 probe, 10 µM) 1  µl 
Reverse primer (Rev 3' CB2 probe, 10 µM) 1  µl 
DIG labelled dNTPs  5  µl 
Taq polymerase 1  µl 
mCB2 BAC DNA (500 ng/µl) 1 µl 
 
5´ Human CB2 Southern blot probe for the identification of positive ES cell clones: 
 
PCR setup (50 µl)   
MilliQ water 36  µl 
10X PCR-buffer  5  µl 
Forward primer (Fwd 5´ hCB2 probe, 10 µM) 1  µl 
Reverse primer (Rev 5´ hCB2 probe, 10 µM) 1  µl 
DIG labelled dNTPs 5  µl 
Taq polymerase 1  µl 
mCB2 BAC DNA (500 ng/µl) 1  µl 
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Cycling parameters 
1 x Initial denaturation 95 °C   2 min 
     
25 x Denaturation 95 °C   15 s 
 Annealing 63 °C  15 s 
 Elongation 68 °C  45 s 
1 x Final elongation 68 °C  5 min 
     
 Cooling 4 °C   ∞ 
3.1.1.9 DNA sequencing 
Sample to be sequenced were send to Macrogen Company. Plasmid DNA was diluted to a 
concentration of 100 ng/μl and PCR to 50 ng/μl in a volume of 20 μl. Primers were sent at a 
concentration of 10 pmol/μl in 20µl (based on 5 samples). 
3.1.1.10 RNA preparation 
RNA was isolated from bone marrow derived-macrophages for subsequent quantitative gene 
expression analysis. Cells (1 x 106 cells per sample) were collected in TRIzol® and 
homogenized by pipetting up and down. 1-bromo-3-chloropropane (BCP) (1:5) was added and 
the samples were mixed well by sustained vortexing for 30 seconds. After 3 minutes 
incubation at room temperature and centrifugation (14000 g, 10 min, 4 °C), the upper phase 
containing RNA was transferred into a fresh tube. The RNA was then precipitated with 
isopropanol (1:1) and washed two times with ethanol (75 %). The air-dried RNA pellet cell-
isolation was eluted in 20 µl RNAse-free water and stored at -80 °C. 
3.1.1.11 Measurement of RNA concentration 
The concentration of the isolated RNA was measured using Nanodrop-1000 
spectrophotometer. RNA has an absorption maximum at a wavelength of 260 nm (A260). The 
absorbance of 1 unit at 260 nm is equivalent to a RNA concentration of 40 µg/ml. The purity of 
the RNA preparation is estimated by the ratio of absorbance at 260 and 280 nm. Pure RNA 
has an A260/A280 ratio of 2.0. 
3.1.1.12 Reverse transcriptase polymerase chain reaction (RT-PCR) 
Isolated RNA from bone marrow derived-macrophages was transcribed into cDNA by reverse 
transcription. Concentration of each sample was normalized with milliQ water to 770 ng in a 
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volume of 10 μl. Oligo(dt) primers (Invitrogen, 1 µl at 0.5 µg/µl) were added to each reaction. 
The cDNA synthesis was performed with the following master mix and an intermittent cycling 
program. 
 
Master mix per reaction:  
MilliQ water 1 µl 
5X first strand buffer 4 µl 
DTT (0.1 M) 2 µl 
dNTPs (10 mM) 1 µl 
  
Cycling parameters:  
10 µl RNA (200-1000 ng/ml, dissolved in RNAse-free water) + 1 µl Oligo(dt) primer 
70 °C  10 min 
4 °C  3 min 
  
add 8 µl master mix per sample 
42 °C 2 min 
4 °C 3 min 
 
add 1 µl reverse transcriptase per sample 
42 °C  60 min 
70 °C 15 min 
4 °C 10 min 
 
cDNA was adjusted to 11 ng/µl concentration and stored at -20 °C. 
3.1.1.13 Real-time reverse transcription-PCR (real-time RT-PCR)/ TaqMan gene expression 
analysis 
Real time RT-PCR is currently the most sensitive technique used to measure expression of a 
gene of interest. It is based on PCR technique. The cDNA generated as described in section 
3.1.1.12, was used as a template for amplification. The PCR product is amplified with non-
labelled primers designed by Applied Biosystems for the gene of interest. During the 
amplification, the amplicon is hybridized with a TaqMan probe at a target sequence. This 
probe is an oligonucleotide that has a fluorescent probe attached to the 5´ end (FAM) and a 
quencher to the 3´ end. Normally, when the probe is not bound, fluorescence resonance 
energy transfer between the fluorescent signal and the quencher prevents the detection of 
fluorescence. But once the probe is bound, and due to the 5´-nuclease activity of the 
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polymerase used for the amplification, the fluorescent signal can be detected. The intensity of 
the fluorescence increases proportionally to the number of the probe cleavage cycles. For 
relative quantification, the expression of the gene of interest is normalized with the expression 
of a housekeeping gene, which is constitutively expressed. Here the beta-2-microglobulin 
(B2M) housekeeping gene was chosen due to its stable expression in our cell model 
(Stephens et al., 2011). 
PCR setup for TaqMan gene expression analysis 
cDNA (11 ng/µl) 4  µl 
Taqman assay 0.5 µl 
Taqman assay master mix 5  µl 
MilliQ water  0.5 µl 
 
Cycling parameters 
1 x 95 °C 10 s 
   
40 x 95 °C  15 s 
60 °C 60 s 
3.1.2 Southern blot 
Identification of homologous recombined ES cell clones was performed by Southern blot. The 
technique relies on the design of a digoxigenin-labelled DNA probe and the establishment of a 
restriction digestion strategy in order to specifically detect DNA fragments. Genomic DNA 
prepared from ES cells was digested overnight with the appropriate restriction 
endonuclease(s). After separation on a 0,8 % agarose gel by electrophoresis, and a 15 
minutes incubation in an ethidium bromide bath, a picture was taken to verify that the DNA 
was correctly digested. The gel was subsequently submitted to a 250 mM HCl solution for 10 
minutes in order to depurinate the DNA, followed by an incubation in a denaturation and 
neutralisation solution for 30 minutes, respectively. The DNA contained in the gel was blotted 
on a nylon membrane at 5 mbar for 1.5 hours in 10X SSC. In order to fix the DNA on the 
membrane, UV cross-linking was performed. In order to avoid unspecific binding of the 
digoxigenin-labelled probe, the membrane was pre-incubated 1 hour at 68 °C in a 
hybridization oven with denatured salmon sperm DNA. The incubation with the probe was 
performed overnight on the same conditions. 
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 The next day, the membrane was washed first two times 10 minutes at room 
temperature with 2X SSC / 1 % SDS on an agitating shaker followed by three times 10 
minutes in an oven at 68 °C, containing a shaking plate, with 0.2X SSC/ 0.1 % SDS. The 
membrane was then equilibrated in maleic acid buffer pH 7.5 for a short time and then 
incubated with the blocking solution for 1 hour at room temperature. After being shortly 
centrifuged, the anti-digoxigenin antibody (1:20000) was added into the blocking solution and 
incubated for 45 minutes. Thereafter the membrane was washed three times 10 minutes with 
washing buffer before being equilibrated into the detection buffer solution for a short time. The 
membrane was then submitted to CDP-Star (Roche, 1:100 in detection buffer) for 5 minutes 
with slow circular movement in order to avoid stagnation of the solution. The membrane was 
placed in a developing cassette and a hyperfilm (Amersham, Pharmacia) was placed on the 
membrane for about one hour. The film was finally revealed in a film-processing machine. 
3.1.3 Cloning of targeting vectors by Red/ET recombination 
Targeting vectors were cloned using the Red®/ET® recombination technology from 
Genebridges and conventional cloning strategy based on restriction digestion/ligation. 
Concerning the Red®/ET® recombination technology, this method permits the precise 
engineering of DNA molecules of any size such as bacterial artificial chromosome (BACs) by 
HR in vivo in E. coli. HR is driven by a plasmid that encodes for a phage-derived protein pair 
that consists of a DNA annealing protein and a 5’3’ exonuclease. The second component 
required for the HR to occur is a DNA fragment with homology arms, which are stretches of 
DNA shared by the two molecules that recombine. To amplify this DNA fragment, touchdown 
PCR and specific oligonucleotides purchased from Invitrogen were used.  
 
PCR setup (50 µl)   
MilliQ water 36  µl 
5X Phusion HF buffer 10  µl 
Forward primer (75 bp long, 10 µM) 1  µl 
Reverse primer (75 bp long, 10 µM) 1  µl 
dNTPs 10 mM 1  µl 
Phusion polymerase 1  µl 
Plasmid DNA 1  µl 
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Cycling parameters 
1 x Initial denaturation 98 °C   1 min 
     
5 x Denaturation 98 °C   1 min 
 Annealing 62 °C  1 min 
              Decreasing 1 °C every cycle 
 Elongation 72 °C  2:30 min 
30 x Denaturation 98 °C   1 min 
 Annealing 57 °C  1 min 
 Elongation 72 °C  2:30 min 
1 x Final elongation 72 °C  10 min 
 Cooling 4 °C   ∞ 
 
 The oligonucleotides were 75 bp long, 25 bp for the annealing and amplification of the 
fragment and 50 bp as homology regions. The homology regions can be freely chosen at any 
position on a target molecule. 
 
 Two kits were used to clone the targeting vectors. First the BAC subcloning kit was 
used. Subcloning means moving the gene of interest from a parent vector, in our case the 
mCB2 BAC containing the mouse CB2 coding exon, into a destination vector in order to 
simplify the handling of the vector. Therefore a 9 kb fragment containing the mouse CB2 
coding exon, a left arm of 5 kb and a right arm of 1.8 kb for the HR in ES cells, was subcloned 
into a plasmid vector. The PCR fragment used for HR was provided in kit. It consists of a 
minimal vector containing an ampicillin resistance gene and a ColE1 origin of replication. 
Bacteria carrying the BAC were transformed with the pRedET plasmid. Expression, by this 
plasmid, of genes mediating HR was induced by stimulating bacteria with 10 % L-arabinose. 
Then the minimal vector amplified with stretches homologous to the fragment of the BAC was 
electroporated into the bacteria and after the HR occurred, clones carrying the subcloned 
fragment were identified by selection for ampicillin resistance. 
 
 The mouse coding exon was replaced by human coding exons by conventional cloning 
strategy (digestion/ligation) using BamHI and AatII restriction sites. The mouse DNA 
sequences surrounding the mouse coding exon 2 containing the two restriction sites were 
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added to the human by two consecutive PCRs using 75 bp primers and the conditions 
described previously. 
 
 The second kit used was the Quick & Easy Conditional Knockout Kit (FRT/FLPe). It 
allowed the insertion of a cassette containing kanamycin and neomycin resistance genes 
flanked by FRT sites. Kanamycin resistance gene was expressed under a prokaryotic 
promoter (gb2) for selection in E.coli whereas neomycin resistance gene was expressed under 
an eukaryotic promoter (PGK) for the selection of homologous recombined ES cells. This 
cassette was inserted on the 3´ arms, 933bp after the coding exons. 
Targeting constructs were linearized with EcoRV restriction enzyme before being 
electroporated into ES cells. 
3.1.4 Cloning of TALEN plasmids 
Transcription activator–like effector nucleases (TALEN) plasmids were cloned using ligation-
independent cloning (LIC) TALE assembly protocols (Schmid-Burgk et al., 2013). The TALEN 
were design and generated using the LIC TALE gene Assembler Version 1.0. 
 
 The ligation independent cloning is based on the 3´ exonuclease activity of T4 
polymerase in the presence of specific dNTPs (dATP or dTTP) to generate long, well define 
single stranded DNA overhangs called ID. By mixing different fragments with different 
complementary IDs, the ligation takes place with really high specificity between the 
complementary overhangs. A library containing 64 fragments composed of two consecutive 
TAL effector repeat units (2-mer) was used as minimal cloning unit. The assembly was 
performed into a 2 hierarchical assembly steps. In a first step, three 2-mer fragments were 
assembled into a 6-mer fragment inside a kanamycin resistant level 1 backbone. And in a 
second step, three 6-mer fragments were assembled into a 18-mer fragment inside an 
ampicillin resistant level 2 backbone. The level 2 backbone containing the 18-mer fragment is 
an expression-ready backbone with the last repeat unit and a C-terminal half nuclease domain 
of the FokI enzyme, giving rise to an 18.5 repeat variable di-residue (RVD) TALEN construct. 
The target specificity of the sequence is 5′-T(N)19-3′.  
 
 Fragments and backbone vectors were digested for 1 hour with the appropriate 
restriction enzymes at 37 °C. Backbone vectors were gel purified using peqGOLD Gel 
Extraction Kit. Fragments and backbone vectors were incubated with the appropriate stop 
dNTP (dATP or dTTP) and T4 DNA polymerase in order to generate the right IDs. This 
reaction was done at 27 °C for 5 minutes followed by 20 minutes at 75 °C. These reactions 
were diluted 20-fold using NEB buffer 2 before proceeding. Appropriate fragments and 
backbone vectors were mixed and incubated at 55 °C for 30 minutes and then at 25 °C for 3 
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hours. 2 μl of the assembly reaction was used to transform ice-cold chemically competent 
DH10b E. coli. Ampicillin Resistant clones were picked and mini preparations using peqGOLD 
Plasmid Miniprep kit I were performed. Plasmids were checked by restriction digestion using 
XhoI XbaI restriction enzymes and the right ones were send for sequencing at Macrogen. 
3.1.5 Cloning of CRISPR/Cas9 plasmids  
CRISPR plasmids were cloned using Zhang et al protocol published in 2013. Oligonucleotides 
were design using UCSC genome browser and purchased from Metabion. They were 
designed with a 4 bp overhangs compatible with BbsI digested overhangs. 1 μg backbone 
vector was digested with BbsI restriction enzyme for 30 minutes at 37 °C. The right fragment 
was gel purified using peqGOLD Gel Extraction Kit. Before proceeding with ligation, oligos 
were phosphorylated and annealed by mixing the two oligos with T4 PNK. 
 
Annealing and phosphorylation mix of oligos 
Fwd CB2 sgRNA 1 µl 
Rev CB2 sgRNA 1 µl 
10X T4 ligation Buffer (NEB) 1 µl 
MilliQ water  6.5 µl 
T4 PNK (NEB)  0.5 µl 
 
Cycling parameters 
1 x  37 °C 30 min 
1 x 95 °C 5 min 
14 x 95 °C Ramping down to 
25 °C at 5 °C/min 
  
Ligation was set up as described below and incubated at room temperature for 10 minutes. 
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Ligation reaction 
BbsI digested pX330 0.66 µl 
Phosphorylated and annealed 
oligo duplex previously diluted 
200-fold 
1 µl 
2X Quick ligation Buffer (NEB) 5 µl 
MilliQ water  3.34 µl 
Quick ligase (NEB)  1 µl 
 
The complete ligation reaction was transformed into Stbl3 Chemically competent bacteria. 
Plasmids were checked by PCR using the Human U6 seq F_Insert as forward primer and the 
reverse oligo used for the annealing step: Rev CB2 sgRNA. 
 
PCR setup (50 µl)   
MilliQ water 36  µl 
5X Phusion HF buffer  10  µl 
Forward primer (Human U6 seq F_Insert, 
10 µM) 
1  µl 
Reverse primer (Rev CB2 sgRNA, 10 µM) 1  µl 
dNTPs 10 mM 1  µl 
Phusion polymerase 1  µl 
Plasmid DNA 1  µl 
 
Cycling parameters 
1 x Initial denaturation 98 °C   30 sec 
     
35 x Denaturation 98 °C   10 s 
 Annealing 63 °C  30 s 
 Elongation 72 °C  15 s 
1 x Final elongation 72 °C  10 min 
     
 Cooling 4 °C   ∞ 
Correctly-recombined plasmids were sent for sequencing to Macrogen. 
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3.1.6 Cloning of vector constructs 
Self inactivated vector constructs were cloned using recommendations of Dr. Zimmermann 
from the Institute for Pharmacology and Toxicology. Once the vector constructs were ready, 
they were provided back to the Institute for Pharmacology and Toxicology in order to generate 
the viral particles (S2 safety conditions). The vectors constructs were transfected with 
packaging constructs into HEK 293 packaging cells in which proteins required for replication 
and assembly of the virions are expressed from the packaging construct, and the replicated 
vector genomes are encapsidated into virus particles to generate the recombinant lentiviral 
vectors which were used to transduced bone marrow-derived macrophages from mice. 
 
 The original self inactivated vector construct rrl-CMV-eGFP provided by Dr. 
Zimmermann, was digested with BamHI and SalI restriction enzymes at 37 °C for 1 hour 
followed by gel purification. The human CB2 coding exons were amplified by PCR using 
primers containing BamHI restriction site on the 5´side of the forward primer and a SalI 
restriction site on the 5´side of the reverse primer. After verifying amplification of right 
fragments on an agarose gel, PCR products were column purified and double digested with 
BamHI and SalI. Ligation was perform by mixing 30 fmol of vector, 90 fmol of insert (ratio 
vector: insert; 1:3) and T4 DNA ligase overnight at 14 °C. The next day, the ligation reaction 
was electroporated into electrocompetent Top10 cells. Colonies were picked and cultivated 
overnight in miniculture. DNA minipreps were performed. The right recombined clones called 
rrl-CMV-hCB2(Arg/Gln), were identified with double digestion using BamHI and SalI restriction 
enzymes and sent for sequencing at Macrogen. 
 
 The rrl-CMV-hCB2-IRES2-eGFP vector constructs were generated using SalI 
linearized previously generated rrl-CMV-hCB2 (Arg/Gln). The IRES2-eGFP fragment was 
amplified from pLuc-1xIRES2EGFP-SV40pA plasmid, by PCR, using primers containing SalI 
restriction sites. After SalI restriction digestion of the inserts, the ligation was performed 
overnight at 14 °C with T4 DNA ligase. The ligation reactions were electroporated into 
electrocompetent Top10 cells. Colonies were picked and cultivated overnight in miniculture. 
DNA minipreps were performed. The right recombined clones called rrl-CMV-hCB2(Arg/Gln)-
IRES2-eGFP, were identified with double digestion using BamHI and SalI restriction enzymes 
and sent for sequencing at Macrogen. 
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3.2 Embryonic Stem (ES) cells 
3.2.1 Cultivation of mouse embryonic fibroblasts (MEFs) 
Mitotically inactivated mouse embryonic fibroblasts (MEFs) have been used as feeder cell 
layers for the maintenance of embryonic stem cells in an undifferentiated state. MEFs were 
prepared by Anne Zimmer and Caroline Hamsch (Institute of Molecular Psychiatry). During ES 
cell culture experiments; homologously recombined clones are selected by addition of 
geneticin (G418) antibiotic in the ES cell culture medium (Bruce4 medium or MPI medium). 
MEFs have to be resistant to G418. For this purpose, pregnant mice carrying a neomycin 
resistance gene were scarified. Embryos at stage E13.5 were extracted from uterine horns 
and placed in ice-cold PBS. After removal of embryonic internal organs from the abdominal 
cavity using dissecting forceps, the rest of the embryos were transferred into a clean dish to 
be cut into small pieces. Tissues, up to 12 embryos, were incubated in 50 ml 0.25 % 
trypsin/EDTA for 20 minutes at 37 °C and 5 % CO2. Every third minutes the tube was gently 
inverted. Cells were then centrifuged (950 g, 2 min, 4 °C). The pellet was re-suspended in 
mouse embryonic fibroblast medium and plated on a 15 cm cell culture dish. At 80 - 90 % 
confluence, cells were split in a ratio of 1:4 in order to expand the culture. After this step, cells 
were deep-frozen for further use. 
 
 MEFs were inactivated by adding a mitomycin C solution (10 μg / ml) for 4 hours. After 
this incubation time, the cells were washed three times with HBSS and supplemented with 
mouse embryonic fibroblast medium. 
3.2.2 Cultivation of mouse embryonic stem cells 
ES cells were grown in appropriate cell culture medium on a layer of mitotically inactivated 
MEFs at 37 °C and 5 % CO2. ES cell culture medium was changed every day. At a confluence 
of 70 - 80 %, ES cells were passaged in a ratio of 1:5 to 1:10 in order to avoid contact 
between the ES cells. For passaging, cells were washed once with Hank’s buffered salt 
solution (HBSS) and incubated with 0.25 % trypsin/EDTA for 3 minutes at 37 °C and 5 % CO2. 
The same amount of ES cell medium was added to inactivate the trypsin. After pipetting up 
and down three times cells were transferred into a Falcon tube and centrifuged (950 g, 2 min, 
4 °C). The pellet was re-suspended by pipetting up and down three times with ES cell medium 
and distributed on cell culture dishes containing fresh mitotically inactivated MEFs. 
3.2.3 Deep-freezing and re-cultivation of ES cells 
For long-term storage, ES cells and MEFs were trypsinized and pelleted by centrifugation (950 
g, 2 min, 4 °C). Pellet was re-suspended in freezing medium (10 % DMSO) by pipetting up 
and down three times and transferred into cryopreservation vials. Tubes were then placed at 
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20 minutes at 4 °C then 1 hour at -20 °C and finally 3 days at -80 °C. After this the tube were 
transferred in a liquid nitrogen tank. 
 
 When cells were needed, tubes were quickly defrosted at 37 °C, re-suspended in ES 
cell medium and pelleted by centrifugation (950 g, 2 min, 4 °C). Cells were re-suspended in 
fresh ES cell medium by pipetting up and down three times and dispensed on new cell culture 
dishes. 
3.2.4 Electroporation and selection of ES cell clones 
Before proceeding to the electroporation, ES cells were expanded on a layer of mitotically 
inactivated MEFs in 15 cm cell culture dishes until a confluence of 70 %. Two hours before 
electroporation, the ES cell medium was changed by fresh one. Cells were harvested by 
trypsinization, centrifuged (950 g, 2 min, 4 °C) and washed twice with ice-cold HBSS. The tube 
containing the cells was kept on ice while counting using a hemocytometer. Cells were 
centrifuged and re-suspended with ice-cold HBSS at a concentration of 1.25 x 107 cells/ml. 0.8 
ml (1 x 107 cells) and transferred into an ice-cold electroporation cuvette which already 
contained 20 μl of the linearized plasmid DNA (1 μg/μl). Electroporation was performed at 250 
V, 500 μF. Afterwards the cuvette was placed on ice for 10 minutes. The mixture was then 
dispensed on a 15 cm cell culture dish supplied with fresh mitotically inactivated MEFs. 
 
 Homologously recombined clones were selected by adding geneticin (G418) at a 
concentration of 170 μg/ml into the ES cell medium (selection medium). The selection started 
24 hours after the electroporation and lasted for 7 to 9 days. Selection medium was changed 
daily. Just before picking surviving clones, the medium was replaced with HBSS. Each clone 
picked under a microscope with a 20 μl pipette was transferred into a well of a 96-well plate. 
The wells were filled with 100 μl 0.25 % trypsin/EDTA and the plate was incubated 3 minutes 
at 37 °C and 5 % CO2. 100 μl was added into the wells to inactivate the trypsin and the cells 
were pipetted up and down five times in order to obtain a single cell suspension. ES cells of 
one colony were then dispensed into a well of a 24-well plate containing fresh mitotically 
inactivated MEFs. Cells were expanded for 3 days and medium was changed daily. After this 
period, clones were trypsinized with 200 μl 0.25 % trypsin/EDTA and incubated 3 minutes at 
37 °C and 5 % CO2. After five times pipetting up and down, 700 μl of the cell suspension was 
transferred into a new 24-well plate. 700 μl of freezing medium (20 % DMSO) was added to 
each well and the plate was gently shacked before proceeding to the deep-freezing, as 
described previously. The rest of the cell suspension (300 µl) in the original well was 
completed with 700 μl of ES cell medium and cultivated for further DNA preparation. 
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3.2.5 RESGRO culture of positive ES cell clones 
RESGRO culture medium has the capacity to rescue established ES cell lines that have 
started drifting or have lost germ line transmission capability. Differentiation, which is present 
in the ES cells but not visible with traditional medium, will become recognizable when using 
RESGRO culture medium. 
 
 First, 10 ml of L-Glutamine Solution (200 mM) were added to 500 ml of RESGRO 
culture medium. ES cells were cultivated on mitotically inactivated MEFs with RESGRO 
culture medium for 2 passages. Afterwards cells were trypsinized with 0.25 % trypsin/EDTA 
and incubated 3 minutes at 37 °C and 5 % CO2. After centrifugation (950 g, 2 min, 4 °C), cells 
were resuspended with RESGRO culture medium and replated 1:3 – 1:5 on the same size 
plate without MEFs. After 2 days, a clear difference was observed between 3-dimensional 
(undifferentiated) and flat growing (differentiated) colonies. By tapping the plate, the 
undifferentiated colonies detached. The supernatant containing the undifferentiated cells was 
collected and centrifuged. Medium was removed and cells were re-suspended in 0.5 ml 0.25 
% trypsin/EDTA by pipetting up and down. The tube was placed in a water bath at 37 °C for 
1.5 minutes. Cells were pipetted up and down 10 times and 9.5 ml RESGRO culture medium 
was added. The tube was centrifuged and the medium removed. Cells were re-suspended in 
RESGRO culture medium and replated 1:3 – 1:6 on mitotically inactivated MEFs. When cells 
were confluent, they were deep-frozen until proceeding to blastocyst injection. 
3.3 Experiments requiring NIH3T3 cells 
3.3.1 Cultivation of NIH3T3 cells 
NIH3T3 cells were grown in plastic T75 flasks with NIH3T3 medium at 37 °C and 5 % CO2. 
Cells were passaged at 70 -80 % confluency. They were trypsinized with 0.25 % 
trypsin/EDTA, incubated 3 minutes at 37 °C and 5 % CO2 and centrifuged (950 g, 5 min, 4 °C). 
The medium was removed and the cells were re-suspended in NIH3T3 medium and replated 
at a ratio of 1:3. NIH3T3 cells were defrosted 2 weeks before transfection. 
3.3.2 Transfection of NIH3T3 cells 
NIH3T3 cells were transfected with X-tremeGENE 9 DNA transfection reagent. 18 – 24 hours 
before transfection, cells were plated in a 96-well plate at a density of 1.5 × 104 cells/well in 
100 μl medium. After overnight incubation, the medium in every well was changed and X-
tremeGENE 9 DNA transfection reagent was warmed at room temperature and vortex gently. 
200 μl of DMEM medium was pipetted into a sterile tube in which 6 μl of X-tremeGENE 9 DNA 
transfection reagent were added. After gently mixing, 2 μg of DNA (3:1 ratio of reagent to 
DNA) was added to the mixture and the tube was again gently mixed. The tube was incubated 
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at room temperature for 30 minutes to allowed complex formation. Different amounts of 
complexes (50 ng, 100 ng and 200 ng) were distributed drop-wise to different areas of the 
wells. Cells were incubated for 48 -72 hours before DNA was collected for further assay. 
3.3.3 SURVEYOR assay 
The TALEN or CRIPSR/Cas9 targeted regions were amplified from the genomic DNA by PCR 
using specific primers surrounding targeted regions.  
 
PCR setup (50 µl)   
MilliQ water 33.5  µl 
5X Phusion HF buffer  10  µl 
Forward primer (10 µM) 1  µl 
Reverse primer (10 µM) 1  µl 
dNTPs 10 mM 1  µl 
Phusion polymerase 1  µl 
DNA 2.5  µl 
 
Cycling parameters 
1 x Initial denaturation 98 °C   30 sec 
     
35 x Denaturation 98 °C   10 s 
 Annealing 63 °C  30 s 
 Elongation 72 °C  20 s 
1 x Final elongation 72 °C  10 min 
     
 Cooling 4 °C   ∞ 
 
The PCR amplicons were denatured by heating and re-annealed in order to form heteroduplex 
DNA.  
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Cycling parameters 
1 x  95 °C 10 min 
70 x 95 °C 1.40 min 
Ramping down to 
25 °C at 1 °C/min 
1 x 4 °C ∞ 
 
SURVEYOR Enhancer S (1 μl) and SURVEYOR Nuclease S (2 μl) were added to the PCR 
reaction mixture. Tubes were gently mixed and incubated at 42 °C for 60 minutes. The 
reaction was stopped by adding Stop solution (5.3 μl), gently mixed and subjected to 
electrophoresis in a 2 % agarose gel and visualized by staining with ethidium bromide. 
3.4 Mouse bone marrow-derived macrophages (BMMs) experiments 
3.4.1 Isolation and differentiation of myeloid stem cells into macrophages 
Myeloid stem cells were isolated from bone marrow of 6-8 weeks old mice. Mice were 
sacrificed by cervical dislocation. The abdomen and hind legs were sterilized with 70 % 
ethanol. An incision in the midline of the abdomen was performed. The bones (femur + tibia) 
were removed and transferred into a 10 cm cell culture dish containing ice-cold PBS. All 
muscle tissues were removed with scissors and forceps with caution to not cut the ends of the 
bones. Under the hood and in sterile conditions, both ends of the femur were cut with sterilized 
scissors. Bone marrow was flushed with ice-cold PBS using a 10 ml syringe and a 13 mm 
needle into a cell culture dish. The same procedure was performed with the tibia. Bone 
marrow was collected from both legs bones. Bone marrow was pipetted up and down several 
times with a Pasteur pipette until obtaining a single cells suspension. The cells were passed 
through a cell strainer into a sterile 50 ml conical tube. After adding ice-cold PBS to 50 ml, 
bone marrow cells were kept on ice and counted using a hemocytometer. Cells were 
centrifuged (950 g, 10 min, 4 °C) and resuspended in freshly filtrated mouse bone marrow 
derived-macrophages medium. Cells were plated in 10 cm Petri dishes at a density of 1.5 × 
106 cells in 10 ml medium and cultured at 37 °C, 5 % CO2. After 3 days in culture, 5 ml fresh 
medium was added to the plates. Bone marrow-derived macrophages were detached using a 
cell scraper and plated in 24 well plates at day 6. Analyses were performed on day 7. 
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3.4.2 Transduction of bone marrow-derived macrophages with recombinant 
lentiviral vectors 
Recombinant lentiviral vector derived from vector constructs were produced by Dr. Katrin 
Zimmermann in the Institute of Pharmacology and Toxicology, Bonn. Before transducing 
BMMs with the recombinant lentiviral vectors, the titer was determined using a non-functional 
titration method based on the measurement of reverse transcriptase (RT) activity using a 
colorimetric assay (ELISA). Measuring the activity of reverse transcriptase present in the 
virions is a valuable technique to estimates the titer but does not represent the functional titer. 
The functional titer, which is defined as the number of functional vector particles required to 
infect a cell present in a volume can be determined in different ways. A reliable method to 
calculate the functional titer consists of transducing live cells following limiting dilution of vector 
and subsequent evaluation of reporter protein activity (eGFP), or protein of interest 
measurement by flow cytometry. This method is best because it only accounts for functional 
particles. The formula used is: ((Number of cells at starting time)*(percent infection)) / volume 
virus solution added expressed in ml. It is reported in Transducable Units per millilitre, TU/ml. 
 
 Macrophages were seeded at a ratio of 1 × 105 cells per well in 24 well plates at day 6 
and incubated at 37 °C, 5 % CO2. The cells were transduced the next day, in the institute of 
Pharmacology and Toxicology (S2 laboratory). The mouse bone marrow-derived 
macrophages medium was removed and replaced with 300μl fresh one wherein the lentiviral 
vector particles were diluted. On day 8, medium was removed, cells were washed three times 
with PBS, and 1ml of fresh medium was added to each well. Cells were used for FACS 
analysis on day 10. 
3.4.3 Preparation of bone marrow-derived macrophages for fluorescence-
activated cell sorting (FACS) 
3.4.3.1 Extracellular labelling for transduction analysis  
After transduction cells were collected using a cell scraper into 1,5 ml Eppendorf tubes. After 
centrifugation (4500 rpm, 5 min, 4 °C), the pellet was resuspended by pipetting up and down 
three times with FACS buffer. Cells were centrifuged, and after discarding the buffer, 
resuspended in 45 μl FACS buffer containing CD16/32 (FC-Block) antibody diluted 1:300. This 
step is necessary to block unspecific binding of other used antibodies. Tubes were placed on 
ice in the dark for 15 minutes. 1 ml of FACS buffer was added to the cells followed by 
centrifugation and buffer discarding. Cells were resuspended with CD11b fluorochrome-
conjugated antibody 1:200 and primary CB2 polyclonal N-terminal antibodies 1:50 diluted into 
FACS buffer. When lentiviruses vectors expressing eGFP were used to transduce BMMs, only 
CD11b fluorochrome-conjugated antibody was used. Tubes were incubated on ice in the dark 
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for 15 minutes. When secondary antibodies were required, a last step was performed with 
antibodies diluted 1:200. FACS buffer was added and the cells centrifuged again. After 
discarding the buffer cells were resuspended in 500 μl FACS buffer filtered through a cell 
strainer (nylon mesh) to eliminate clumps and debris, and kept on ice before being analysed 
by FACS. All measurements were performed in triplicates. 
3.4.3.2 Intracellular labelling for transduction analysis using CB2 polyclonal C-terminal 
antibody 
Cells were collected and labelled for extracellular proteins as described previously. After the 
last washing step and discarding of the buffer, cells were resuspended in 45 μl BD 
Cytofix/Cytoperm solution and incubated for 20 minutes on ice in the dark. After incubation 
time, 1 ml of 1X BD Perm/Wash buffer was added to the cells that were then centrifuged (6000 
rpm, 3 min, 4 °C). Buffer was discarded and the same procedure as for extracellular labelling 
was performed again for intracellular labelling. Differences were that antibodies were diluted in 
1X BD Perm/Wash buffer at 1:100 for CD16/32, 1:50 for C-terminal CB2 antibody and 1:100 
for the secondary antibody. All centrifugation steps were performed at 6000 rpm, 3 min, 4 °C 
instead of 4500 rpm, 5 min, 4 °C. 
3.4.3.3 Extracellular labelling for polarization analysis 
Macrophages were seeded at a ratio of 2 × 105 cells per well in 24 well plates at day 6 and 
incubated at 37 °C, 5 % CO2. Cells were stimulated overnight with interferon-gamma (IFN-γ), 
lipopolysaccharide (LPS) and IFN-γ, or interleukin 4 (IL4). They were collected the next day 
using a cell scraper into 1,5 ml Eppendorf tubes. After centrifugation (4500 rpm, 5 min, 4 °C), 
the pellet was resuspended by pipetting up and down three times with FACS buffer. Cells 
were centrifuged, and after discarding the buffer, resuspended in 45 μl FACS buffer containing 
CD16/32 (FC-Block) antibody diluted 1:300. This step is necessary to block unspecific binding 
of other used antibodies. Tubes were placed on ice in the dark for 15 minutes. 1 ml of FACS 
buffer was added to the cells followed by centrifugation and buffer discarding. Cells were 
resuspended with fluorochrome-conjugated antibodies for cluster of differentiation 86 (CD86), 
major histocompatibility complex II (MHCII) and mannose receptor (MMR) 1:200 diluted into 
FACS buffer. Tubes were incubated on ice in the dark for 15 minutes. FACS buffer was added 
and the cells centrifuged again. After discarding the buffer cells were resuspended in 500 μl 
FACS buffer filtered through a cell strainer (nylon mesh) to eliminate clumps and debris, and 
kept on ice before being analysed by FACS. All measurements were performed in triplicates. 
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3.4.4 Analysis of cytokine release by enzyme-linked immunosorbent assay 
(ELISA) 
BMMs were seeded at a ratio of 2 × 105 cells per well in 24 well plates at day 6 and incubated 
at 37 °C, 5 % CO2. Macrophages were stimulated overnight with IFN-γ, LPS/IFN-γ and 
cannabinoid receptor 2 agonists: beta-caryophyllene and JWH-133. On Day 7, cell culture 
mediums were collected into 1,5 ml Eppendorf tubes. Tubes were deep-frozen into liquid 
nitrogen and placed at -80 °C for further analysis. ELISA kit for TNFα was performed 
according to the manufacturer's instructions. 
3.4.5 Analysis of cannabinoid receptors expression by real time PCR (TaqMan) 
BMMs were seeded at a ratio of 1 × 106 cells per well in 6 cm plates at day 6 and incubated at 
37 °C, 5 % CO2. On Day 7, RNA was isolated as described in section 3.1.1.10. After RT-PCR 
described in section 3.1.1.12, 4 μl of cDNA (11 ng/μl) were used for the assay. cDNA and 
master mixes were pipetted using the liquid handling platform Janus from Perkin Elmer. All 
measurements were performed in triplicates. 
3.4.6 Phagocytosis assay 
3.4.6.1 Phagocytosis assay 
BMMS were seeded at a ratio of 2 × 105 cells per well in 24 well plates at day 6 and incubated 
at 37 °C, 5 % CO2. At day 7, Zymosan A S. cerevisiae BioParticles® Fluorescein Conjugate 
were reconstituted according to the manufacturer's instructions. 2 hours before phagocytosis 
assay, zymosan particles were diluted in tissue culture grade PBS. The particles were gently 
swirled into suspension and then, vigorously vortex (3 x 15 sec at the highest setting). The 
concentration was determined by counting the particles with a hemocytometer and adjusted to 
4 × 105 particles/μl. The tube was protected from light and kept at 4 °C before starting the 
assay. Particles were vortex shortly before being used. 
 
 Particles (1 x 106) were pipetted directly into the BMMs medium. In order to allowed 
phagocytosis to occur, plates were incubated at 37 °C, 5 % CO2.  A plate was kept at 4 °C to 
measure passive phagocytosis and was used as a control. All experiments were performed in 
triplicates. 
3.4.6.2 Analysis of phagocytic activity by Fluorescence-activated cell sorting (FACS) 
After phagocytosis occurred, the medium was removed and cells were washed three times 
with ice-cold tissue culture grade PBS and finally resuspended in FACS buffer. The cells were 
collected using a cell scraper into 1,5 ml Eppendorf tubes. Cells were centrifuged (4500 rpm, 5 
min, 4 °C), and after discarding the buffer, resuspended in 45 μl FACS buffer containing 
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CD16/32 (FC-Block) antibody diluted 1:300. Tubes were placed on ice in the dark for 15 
minutes. 1 ml of FACS buffer was added to the cells followed by centrifugation and buffer 
discarding. Cells were resuspended with CD11b Pacific Blue-conjugated antibody 1:200 
diluted into FACS buffer. Tubes were incubated on ice in the dark for 15 minutes. FACS buffer 
was added and the cells centrifuged again. After discarding the buffer cells were resuspended 
into 500 μl FACS buffer filtered through a cell strainer (nylon mesh) to eliminate clumps and 
debris, and kept on ice before being analysed by FACS. All measurements were performed in 
triplicates. 
3.4.6.3 Analysis of phagocytic activity by microscopy 
Macrophages were seeded at a ratio of 2 × 105 cells on cover slips in 24 well plates at day 6 
and incubated at 37 °C, 5 % CO2.The phagocytosis assay was performed exactly as for the 
FACS analysis. After phagocytosis occurred, the cover slips were washed twice, and roughly 
with tissue culture grade PBS. The cover slips were fixed in 4 % formaldehyde solution for 20 
minutes at room temperature. They were washed again twice with PBS and mounted on slides 
with Dapi-Fluoromount-G. Preparations were air dried for 5 minutes before being examined 
under fluorescence microscope (Axio Imager M2). Experiments were performed in triplicates 
(3 cover slips per treatment condition) and six pictures per coverslip were taken from different 
regions. Engulfed particles were analysed and counted from the pictures using ImageJ 
software. 
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4 RESULTS 
The results part is divided into three parts. In a first part, the results obtained for the 
humanization of the mouse CB2 locus are presented. In a second part, the results made in the 
generation of human CB2 recombinant lentiviral vectors are described. Finally a functional 
analysis of the CB2 receptor activation in mouse bone marrow derived-macrophages was 
performed and presented in the last part. 
4.1 Humanizing the Cnr2 locus 
4.1.1 Generation of hCB2 targeting constructs 
For the present thesis, the strategy to generate humanized CB2 mice aimed to exchange the 
mouse ORF located in exon 2 by the human counter parts. Humanized CB2 targeting vectors 
were cloned using the same cloning strategy performed in three steps. First a subcloning step 
was completed followed by the replacement of the murine ORF by the human ones and finally 
insertion of a cassette for selection in bacteria and ES cells. Each cloning step was verified by 
specific restriction pattern analysis. 
4.1.1.1 Subcloning 
The subcloning step was performed using the GenebridgesTM Subcloning kit. The E.coli mCB2 
BAC host previously transformed with the Red/ET expression plasmid (Wang and Zhang, 
2005) was next  transformed with the linear ColE1-amp minimal vector flanked by homology 
arms to achieve HR in bacteria. The linear minimal vector was generated by PCR using 75 bp 
oligonucleotides primers called forward and reverse mCB2 subcloning (figure 4A). These long 
oligonucleotides consist of 25 bp sequences necessary for the annealing and amplification of 
the pColE1-amp cassette and 50 bp homology arms required for HR. The 50 bp homology 
arms surrounding a fragment of 8619 bp were chosen in order to subclone the desired 
fragment from the mCB2 BAC into the mCB2 ORF subclone. After HR had occurred, clones 
carrying the subcloned fragment were identified by selection for ampicillin resistance that was 
conferred via expression of the ampicillin resistance gene (ampR) incorporated in the minimal 
vector (figure 5). 
58  Results 
 
Figure 4: PCR amplification of the minimal vector. 
A) PCR strategy to amplify the minimal vector cassette. Red lines represent the 50 bp homology regions 
chosen for homologous recombination to occur in bacteria. Blue lines represent the 25 bp sequence 
required for the amplification of the pColE1-amp cassette B) Representative picture of the pColE1-amp 
PCR product of 2735 bp checked on an 1 % agarose gel stained with ethidium bromide (lane 1). M: 1 kb 
marker. ampR: ampicillin resistance gene, ori: origin of replication sequence. 
 
 As shown in figure 4B, the fragment was successfully amplified and further used for 
subcloning a DNA fragment of 8625 bp from the mCB2 BAC by in vivo HR using the Red/ET 
technology. 
 
Figure 5: Subcloning of the 8625 bp DNA fragment from the mCB2 BAC  
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Schematic representation of the subcloning step using the Red/ET technology. The host bacteria 
harbouring the mCB2 BAC was electroporated with the linear minimal vector fragment containing 
homology arms (red lines). This resulted in the generation of the mCB2 ORF subclone via homologous 
recombination. ampR: ampicillin resistance gene, pBACe3.6: vector containing an origin of replication 
and a cmR: chloramphenicol antibiotic resistance gene, ori: origin of replication sequence, ORF: Open 
reading frame. 
4.1.1.2 Verification of the subcloning step 
Ampicillin resistant clones were picked and verified by MfeI restriction analysis. MfeI restriction 
sites were introduced into the oligonucleotides sequences used for the amplification of the 
pColE1-amp cassette (figure 6A). As shown in figure 6B, a mCB2 ORF subclone was 
identified by a two bands pattern of 8619 bp and 2641 bp, which corresponds to the expected 
band size after MfeI restriction. 
 
 
Figure 6: Subcloning step checked by MfeI restriction analysis 
A) Schematic localisation of MfeI restriction sites in the mCB2 ORF subclone. ampR: ampicillin 
resistance gene, ori: origin of replication sequence, ORF: Open reading frame. B) Representative 
picture of the restriction digest checked on an 1 % agarose gel stained with ethidium bromide. M: 1 kb 
marker; lane1: undigested plasmid DNA from an ampicillin resistant clone; lane 2: Digestion of the 
mCB2 ORF subclone by MfeI resulted in the generation of the expected fragments of 8619 bp and 2641 
bp. 
 
4.1.1.3 Replacement of the murine ORF 
The replacement of the murine to the human ORFs was performed using a conventional 
cloning strategy with digestion and ligation steps. The vector was obtained by digesting the 
mCB2 ORF subclone obtained previously with AatII and BamHI restriction enzymes (figure 
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7A) which results in the production of a two bands pattern of 10119 bp and 1141 bp. The 
upper band of 10119 bp (figure 7B) representing the vector was extracted from the gel and 
purified for subsequent ligation. 
 
 
Figure 7: Double digestion of the mCB2 ORF subclone with the enzymes AatII and BamHI 
A) Schematic localisation of AatII and BamHI restriction sites in the mCB2 ORF subclone. ampR: 
ampicillin resistance gene, ori: origin of replication sequence, ORF: Open reading frame. B) The 0.8 % 
agarose gel was stained with ethidium bromide. M: 1 kb marker; lane 1: mCB2 ORF subclone digested 
with AatII and BamHI resulted in two bands of 10119 bp and 1141 bp. The upper band was extracted 
from the gel further proceed with the ligation step. 
 
 In order to sustain the 5' and 3' untranslated regions flanking the 1044 bp sequence of 
the mouse CB2 ORF, the human CB2 ORFs with a length of 1083 bp were amplified by two 
successive PCRs. In a first PCR step, primers (Fwd and Rev hCB2 flanked HA first) were 
used to add 50 bp mouse DNA stretches to the human ORFs to introduce the BamHI 
restriction site on the 3´ end. This led to the generation of 1183 bp PCR fragments (figure 8).  
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Figure 8: First PCR amplification of the hCB2 ORFs 
A) Schematic representation of the first PCR performed to generate the human ORFs inserts. In this 
first PCR 75 bp primers were used (depicted with red and blue lines). The blue lines represent the 25 bp 
used to anneal and amplify the human ORFs. The red lines represent the 50 bp sequences that were 
homologous to the sequences adjacent to the murine ORF. B) First PCR reaction checked on an 1 % 
agarose gel stained with ethidium bromide. M: 1 kb marker; lane 1: hCB2Arg63 ORF + 50 bp on both 
sides; lane 2: hCB2Gln63 ORF + 50 bp on both sides. PCR product size for both ORFs: 1183 bp. The 
BamHI restriction site is integrated at the 3´ end of the human ORFs. 
 
 In a second PCR step, primers (Fwd and Rev hCB2 flanked HA second) were used  to 
add 50 bp mouse DNA stretches to the previously amplified fragments to integrate an AatII 
restriction site on the 5´ end (figure 9). This amplification resulted in fragments of 1283 bp. The 
CNR2 ORFs PCR products generated after the two successive PCRs were digested with AatII 
and BamHI before proceeding with ligations. 
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Figure 9: Second PCR amplification of the hCB2 ORFs 
A) Schematic representation of the second PCR performed to generate the human ORFs inserts. The 
two ORFs of the human variants were amplified using 75 bp primers (depicted with red and blue lines). 
The blue lines represent the 25 bp used to anneal and amplify the 1183 bp fragments. The red parts 
represent the 50 bp that was homologous to the sequences adjacent to the previously added 50 bp 
DNA sequences. B) Second PCR reaction checked on an 1 % agarose gel stained with ethidium 
bromide. M: 1 kb marker; lane 1: hCB2Arg63 ORF + 100 bp on both sides; lane 2: hCB2Arg63 ORF + 
100 bp on both sides. PCR product size for both ORFs+100 bp DNA sequences on both sides: 1283 bp. 
The AatII restriction site is integrated on the 5´ end of the amplified fragments. The PCR fragments were 
digested with AatII and BamHI before proceeding with ligations. 
 
 As a result of the two PCRs, 100 base pairs were added that were homologous to the 
sequences flanking the mCB2 ORF. Ligations were performed by combining gel-purified 
vector and human ORF previously digested with AatII and BamHI. 
4.1.1.4 Cloning of Human ORF subclones 
After ligations of digested mCB2 ORF subclone and human ORFs flanked with mouse DNA 
stretches, the DNA was electroporated into TOP10 electrocompetent bacteria. DNA from 
Ampicillin resistant clones was prepared and checked by enzymatic restriction digestions 
using two enzymes: SpeI and MfeI. The SpeI restriction site is only present in the human CB2, 
but not in the murine ORF (figure 10A). Thus, correctly ligated clones exhibit three fragments 
with a size of 5450 bp, 3208 bp and 2641 bp after digestion. As seen in figure 10B and 10C, 
several recombined clones were identified for both CB2 variants. 
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Figure 10: Verification of ligations 
A) Schematic localisation of the restriction sites for both hCB2 variants. ampR: ampicillin resistance 
gene, ori: origin of replication sequence, ORF: Open reading frame. B) The 1 % agarose gel was 
stained with ethidium bromide. M: 1 kb marker; lane 1-10: hCB2Arg63 subclones digested with MfeI and 
SpeI and correctly recombined as indicated by the presence of the three fragments of 5450 bp, 3208 bp 
and 2641 bp. C) The 1 % agarose gel was stained with ethidium bromide. M: 1 kb marker; lane 1-6,8-
10: hCB2Gln63 subclones digested with MfeI and SpeI and correctly recombined as indicated by the 
presence of the three fragments of 5450 bp, 3208 bp and 2641 bp, lane 7: incorrectly ligated clone. 
4.1.1.5 Insertion of the FRT-PGK-gb2-neo-FRT cassette for selection 
The last step of the targeting constructs generation was the insertion of a selection cassette. 
This cassette encodes the neomycin/kanamycin resistance gene, which combines a 
prokaryotic promoter (gb2) for expression of kanamycin resistance in recombined E.coli clones 
with an eukaryotic promoter (PGK) for expression of neomycin resistance gene in recombined 
ES cells. The selection cassette was flanked by FRT sites for further excision by the Flp-
recombinase. The insertion site of the cassette was chosen 933bp downstream to the CNR2 
ORFs. The cassette was generated via PCR using respective primers (Fwd and Rev FRT-neo-
FRT) through which the homology arms were added. The resulting fragment of 1737 bp was 
used for Red/ET HR (Figure 11). 
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Figure 11: FRT-PGK-gb2-neo-FRT fragment generation 
A) The FRT-PGK-gb2-neo-FRT fragment was generated by PCR using 75 bp primers (red and blue 
lines). The blue line represents the 25 bp used to anneal and amplify the FRT-PGK-gb2-neo-FRT 
cassette. The red line represents the homology arms (50 bp) necessary for homologous recombination. 
B) M: 1 kb marker; lane 1: the PCR product size (1737 bp) was checked on an 1 % agarose gel stained 
with ethidium bromide. FRT: flippase recognition target site, PGK: phosphoglycerate kinase eukaryotic 
promoter, gb2: E. coli prokaryotic promoter, kanR: Kanamycin resistance gene, neoR: neomycin 
resistance gene, pA: polyadenylation signal. 
 
 The E.coli hCB2Arg63 and E.coli hCB2Gln63 subclones, previously electroporated with 
the Red/ET expression plasmid, were next electroporated with the linear FRT-PGK-gb2-neo-
FRT cassette flanked with homology arms (figure 12). 
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Figure 12: Recombination of FRT-PGK-gb2-neo-FRT cassette for selection in bacteria and ES 
cells 
Schematic representation of the homologous recombination using the Red/ET technology. 
Recombination of the hCB2 subclones with the linear FRT-PGK-gb2-neo-FRT cassette result in the 
generation of final targeting constructs. Red lines represent the homology region chosen for the 
insertion of the cassette into the hCB2 subclones. ampR: ampicillin resistance gene, kanR: kanamycin 
resistance gene, neoR: neomycin resistant gene, ori: origin of replication sequence, ORF: Open reading 
frame. 
 
 After HR had occurred, clones carrying the recombined fragment were identified by 
selection for ampicillin and kanamycin resistance. 
 
4.1.1.6 Verification of targeting constructs 
Kanamycin and ampicillin resistant clones were analysed by double restriction digestions 
using MfeI and SpeI enzymes (figure 13A). The targeting constructs contained two MfeI 
restriction sites and two SpeI restriction sites. Therefore, enzymatic digestion was supposed to 
result in the generation of 4 DNA fragments (5450 bp, 3080 bp, 2641 bp and 1765 bp). As 
shown in figure 13B, these fragments were detectable after digestion of the constructs.  
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Figure 13: Targeting construct checked by MfeI and SpeI restriction analysis 
A) Schematic localisation of the restriction sites MfeI and SpeI used for checking the targeting 
constructs. B) Restriction digestion checked on an 1 % agarose gel stained with ethidium bromide. M: 1 
kb marker; lane1,2: hCB2Arg63 targeting construct double digested with MfeI SpeI; lane 3,4: 
hCB2Gln63 targeting construct double digested with MfeI SpeI. All clones were correctly recombined as 
indicated by the presence of four fragments of 5450 bp, 3080 bp, 2641 bp and 1765 bp. ampR: 
ampicillin resistance gene, kanR: kanamycin resistance gene, neoR: neomycin resistant gene, ori: origin 
of replication sequence, ORF: Open reading frame. 
 
The human CB2 ORFs inserts were verified by sequence analysis (Macrogen Corporation). 
4.1.2 Screening strategies for targeted mutagenesis of the Cnr2 gene locus 
After linearization with EcoRV, the targeting constructs were electroporated into ES cells. 
Positive ES cell clones were selected via G418 resistance (conferred by the neoR gene) and 
screened for HR by PCR and Southern blot. For both techniques, two strategies were 
developed to verify the correct integration of the flanked neo cassette and the human ORFs. 
4.1.2.1 PCR 
The first PCR strategy was used to check if the neo gene was present at the correct location 
and a second one to confirm the presence of the human CB2 ORF. 
4.1.2.1.1 PCR strategy for validation of neo gene integration 
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To exclude ectopic recombination, primers called Fwd and Rev ES cell check, were designed 
to bind at the 3´end of the flanked neo cassette and within the 3´ genomic region, which was 
not included in the targeting construct (figure 14A). The PCR product resulting from the 
targeted gene locus comprised a fragment of 1953 bp whereas amplification of the non-
targeted locus exhibits no band (figure 14B). 
 
 
Figure 14: PCR strategy to check the FRT-neo-FRT integration in ES cells 
A) PCR strategy. The red arrows represent the primers used. The wild type allele (top) led to no PCR 
product, whereas after homologous recombination of the targeting construct (centre), the presence of 
the neo cassette in the targeted gene locus (bottom) generated a fragment of 1.9 kb. ORF: open 
reading frame, neo: neo resistance gene, FRT: flippase recognition target site. B) 1 % agarose gel 
stained with ethidium bromide. M: 1 kb marker; lane 1,3: negative Bruce4 ES cell clones, lane 2,4,5: 
positive Bruce4 ES cell clones; lane 6: homologously recombined ES cell clone previously identified 
used as positive control; lane 7: water control.  
4.1.2.1.2 PCR strategy for validation of the human ORF integration 
The human ORF integration PCR was used to confirm the presence of the human ORFs in ES 
cells. In a first time and as depicted in figure 15A, fragments of 1212 bp for the mouse ORF or 
1251 bp for the human ORF were amplified by PCR using primers flanking the ORFs (Fwd 
and Rev seq hCB2). Then amplicons were digested with SpeI. Due to the fact that the 
restriction site is only present in the human ORF, the restriction pattern revealed a single band 
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of 1212 bp for the mouse ORF and a double band of 605 bp and 646 bp when the human 
ORF is present (figure 15B). 
 
Figure 15: PCR strategy to check the human ORF integration in ES cells 
A) Verification of targeted ES cell clones using PCR followed by SpeI restriction digestion. The red 
arrows represent the primers used. The wild type allele (top) led to a PCR product of 1212 bp, whereas 
after homologous recombination of the targeting construct (centre), the presence of the human ORF in 
the targeted gene locus (bottom) generated a fragment of 1251 bp. ORF: open reading frame, neo: neo 
resistance gene, FRT: flippase recognition target site. The SpeI restriction site is only present in the 
human CB2 ORF. Thus the amplification of the murine ORF followed by SpeI restriction digestion result 
in a fragment of 1212 bp, while the presence of the human ORF is indicated by two fragments of 605 bp 
and 646 bp. B) 1 % agarose gel stained with ethidium bromide. M: 1 kb marker; lane 1,2,4: ES cell 
clone negative for the human ORF integration; lane 3: ES cell clone positive for the human ORF 
integration; lane 5: WT ES cell DNA used as negative control. 
 
 When the human ORF is integrated, only one band is visible. In fact the double bands 
of 605 and 646 bp cannot be separated using a 1 % agarose gel. A gel with a higher 
percentage of agarose could have been used to separate these two bands, but the main 
purpose of this PCR was to rapidly identified clones which possibly contained the human 
ORFs. In fact the positive clones containing the human ORFs were further verified using the 
southern blot strategy described in section 4.1.2.2.2. 
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4.1.2.2 Southern Blot 
Southern blot strategies were designed and used to confirm the positive clones that were 
identified by PCR. The sequence-specific probes were located within genomic regions at the 
3´ and 5´ end, respectively (figure 16 and 17 part A). These regions were not included in the 
targeting constructs to exclude the detection of false positives due to ectopic recombination  
4.1.2.2.1 Targeted mutagenesis of the Cnr2 gene locus on the 3' side 
As shown in figure 16B, digestion of selected ES cell clones with PstI resulted in a 8.5 kb 
fragment for the mouse wild type locus. Upon HR at the 3’ end, digestion with PstI led to a 
smaller fragment of 3.9 kb due to the additional restriction site present in the neo cassette. 
After confirmation of HR at the 3´ end the ES cell clones were further checked for HR at the 5´ 
end. 
 
 
Figure 16: Southern blot strategy to analyse 3´ homologous integration 
A) Schematic representation of the 3´ Southern blot strategy. The Cnr2 wild type gene locus is 
illustrated in the upper scheme. The targeting construct (centre) consisted of the human CB2 ORF 
(orange) and a FRT (green vertical lines) flanked neo cassette (green arrow). Homologous 
recombination resulted in the targeted gene locus (bottom). Homologous recombination was verified by 
PstI digestion and subsequent Southern blot using the probe shown in red. The red vertical lines 
indicate the limits of the targeting construct integration. B) Southern Blot analysis of the 3′ homologous 
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integration revealed correct targeting in the hCB2-Arg 31 ES clones (lane 4) whereas three other ES 
cell clones (lane 1-3) showed no targeted integration. M: DNA molecular weight marker II (Roche). 
4.1.2.2.2 Targeted mutagenesis of the Cnr2 gene locus on the 5' side 
As shown in figure 17B, double digestion of selected ES cell clones with PacI and SpeI 
resulted in a large fragment of 22 kb for the mouse wild type locus. Upon HR at the 5’ end, 
digestion at a SpeI restriction site present in human ORFs, led to a smaller fragment of 8.9 kb. 
 
Figure 17: Southern blot strategy to analyse 5´ homologous integration 
A) Schematic representation of the 3´ Southern blot strategy. Murine CB2 wild type gene locus is 
illustrated in the upper scheme. The targeting construct (centre) consisted of the human CB2 ORF 
(orange) and a FRT (green vertical lines) flanked neo cassette (green arrow). Homologous 
recombination resulted in the targeted gene locus (bottom). Homologous recombination was verified by 
PacI and SpeI digestion and subsequent Southern blot using the probe shown in red. The red vertical 
lines indicate the limits of the targeting construct integration. B) Analysis of 5′ homologous integration 
revealed correct targeting in the hCB2-Arg31 ES cell clone (lane 1) and in the hCB2-Gln7 ES cell clone 
(lane 2). M: DNA molecular weight marker II. 
 
 ES cell clones that exhibited HR for both the 3’ and 5´ ends were further used for 
blastocyst injections. 
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4.1.3 Cloning of new genetic engineering technologies to humanized the Cnr2 
locus 
Three new genetic engineering technologies emerged during the last 5 years: zinc finger, 
transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced 
short palindromic repeats (CRISPR) coupled to a Cas9 enzyme (CRISPR/Cas9 system). All 
these nucleases share the ability to induce site-specific DSBs within the DNA. The aim was to 
design a guide RNA (gRNA) to target the Cas9 enzyme and a TALEN pair to produce DSBs 
within the Cnr2 ORF, but not in the CNR2 ORF, present in the targeting constructs previously 
generated. Therefore, first the sequences of the CNR2-ORF of coding exon 2 from both 
species were aligned (figure 18 and 21). 
4.1.3.1 TALEN pair design and generation 
4.1.3.1.1 TALEN design 
TALENs are a combination of transcription activator-like (TAL) effectors with the non-specific 
DNA cleavage domain from the end of the FokI nuclease. TALENs bind and cleave DNA in 
pairs as the FokI domain functions as a dimer. Therefore TALEN binding sites and the number 
of bases between the two individual (left and right) TALENs, also called spacer region, appear 
to be important parameters for achieving high levels of activity (Schmid-Burgk et al., 2013). 
Therefore, a TALEN pair was designed respecting both, the mismatches criteria between 
mouse and human CNR2-ORF sequences and the size of the spacer region (figure 18). 
 
 
Figure 18: Design of a TALEN pair to target the mouse CB2 ORF  
Sequence alignment of the human and mouse CNR2-ORF revealed several mismatches, which are 
highlighted by the dark red background colour. Yellow background letters represent the spacer region of 
14 bp. The left and right TALEN targets represent the binding sites of the left-mCB2-TALEN and the 
right-mCB2-TALEN. 
 
 After in silico design of a desired Cnr2 targeting TALEN pair, the cloning was 
performed using a high-fidelity ligation-independent cloning technique. 
4.1.3.1.2 Two steps generation of TALENs plasmids 
The laboratory of Professor Dr. Veit Hornung from the Institute for Clinical Chemistry and 
Clinical Pharmacology developed a high-fidelity ligation-independent cloning (LIC) technique 
that enables generation of TALE genes requiring only the combinatorial mixing of fluids in 
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order to clone a desired TALEN pair. They generated a LIC-ready TALE repeat unit library of 
2-mer fragments that can be assembled in 2 hierarchical assembly steps. The software LIC 
TALE gene Assembler Version 1.0 developed by the team was used to decide on the 
appropriate 2-mer fragments that are required to assemble an 18.5 RVD TALEN construct. 
The resulting TALEN contains 18.5 TAL effector repeat units and has a target specificity of the 
sequence 5′-T(N)19-3′ 
 
 In the first assembly reaction, three 2-mer fragments are assembled into a 6-mer 
fragment in a kanamycin resistant level 1 backbone plasmid (figure 19A). The first step of the 
TALE LIC assembly was followed by transformation and selection of kanamycin resistant 
clones. Validation of the 6-mer assemblies was performed by digestion of positive clones with 
the Mva1269I restriction enzyme. When the ligation was successful, a band of ≈ 650 bp 
appeared (figure 19B). The lower bands show a slight difference in size which is due to the 
different ID length used for the ligation-independent cloning, described in section 3.1.4. 
 
 
Figure 19: First step of LIC TALE assembly 
A) Schematic representation of the first LIC TALE assemblies required for one individual TALEN pair. 
Each 2-mer required to target 2 nucleobases are represented in the upper part of the figure by coloured 
boxes. After defining the target sequence, the 2-mer were chosen and digested with Mva1269I from 
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their ampicillin resistant (ampR) plasmids in which they were contained. Then they were assembled into 
6-mer fragments inside a kanamycin resistant (kanR) level 1 backbone using the ligation-independent 
cloning technique. B) 1 % agarose gel stained with ethidium bromide. Verification of 2-mer fragments 
assemblies contained in level 1 backbone via Mva1269I restriction digestion. M: 1 kb marker. Left 
TALEN; Lane 1: First 6-mer fragment, lane 2: second 6-mer fragment, lane 3: third 6-mer fragment. 
Right TALEN; Lane 4: First 6-mer fragment, lane 5: second 6-mer fragment, lane 6: third 6-mer 
fragment. The size of fragments is around 650 bp. 
 
 In a second step, three 6-mer fragments were assembled into an 18-mer fragment 
contained into an ampicillin resistant level 2 backbone plasmid, giving rise to an 18.5 RVD 
TALEN construct (figure 20A). After digestion of the 6-mer fragments with Mva1269I restriction 
enzyme, the fragments were assembled and transformed. Ampicillin resistant clones were 
picked and DNA was prepared. Positive clones were verified with double restriction digestion 
using XhoI and XbaI restriction enzymes. Correctly assembled clones show a pattern of 2 
bands of 6kb and 3.2 kb as seen in figure 20B and were verified by sequencing (Macrogen 
Corporation). 
 
 
 
Figure 20: Second step of the LIC TALE assembly 
A) Schematic representation of the second LIC TALE assemblies required for one individual 18.5 RVD 
TALEN construct. After Mva1269I restriction digestion of the level 1 plasmids containing the 6-mer 
fragments, three of the 6-mer (upper part) were assembled into a 18-mer fragment into an ampicillin 
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resistant level 2 backbone plasmid, giving rise to an 18.5 RVD TALEN construct (lower part). B) 1 % 
agarose gel stained with ethidium bromide. Verification of 6-mer fragments assemblies contained in 
level 2 backbone via XhoI and XbaI restriction digestion. M: 1 kb marker. Left TALEN; Lane 1,2,4,6,7,8: 
successful assembled 18.5 RVD TALEN left construct, lane 3,5: incorrectly assembled clones.  Right 
TALEN; lane 9,10,11,12,13,14: successfully assembled 18.5 RVD TALEN right construct represented 
by a pattern of 2 bands of 6kb for the backbone and 3.2 kb for the correct insert. 
 
 The generated, 18,5 RVD TALEN constructs targeting the Cnr2 (called left-mCB2-
TALEN and right-mCB2-TALEN) were then lipofected into NIH3T3 cells in order to test its 
ability as a TALEN pair, to generate targeted DSBs within the Cnr2 ORF. The surveyor assay 
was used to assessed this ability. 
4.1.3.2 Design and Generation of CRISPR/Cas plasmid 
4.1.3.2.1 CRISPR/Cas system design 
An important requirement for the CRISPR/Cas system to produce DSBs is a short NGG 
protospacer-adjacent motif (PAM) located immediately after the guide sequence to be 
targeted. This NGG motive adjacent to a sequence that was highly divergent between mouse 
and human was identified using USCS genome browser (Figure 21). Also, the 6 mismatches 
in 20 base pairs were located at both ends of the sequence, which were reported to be more 
important for target specificity of gRNAs than the central nucleotides (Cong et al., 2013). This 
gRNA sequence target therefore appeared to be suitable as a target for a gRNA. The 
corresponding oligonucleotides (Fwd and Rev CB2 sgRNA) were cloned into the px330 
plasmid to obtain the px330-mCB2 construct. This is the only cloning step required to direct 
the CRISPR/Cas9 system to the Cnr2 gene locus. 
 
 
Figure 21: Design of a CRISPR/Cas9 system to target the mouse CB2 ORF  
Sequence alignment of the human and mouse CNR2-ORF revealed several mismatches, which are 
highlighted by the dark red background colour. Red letters represent the proto-spacer adjacent motifs 
(PAM).  
 
4.1.3.2.2 CRISPR/CAS plasmid cloning 
Oligonucleotides, Fwd and Rev CB2 sgRNA, were simply annealed and cloned into BbsI 
digested pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid. After ligation and transformation, 
bacteria containing ligated clones were selected for ampicillin resistance (figure 22). 
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Figure 22: Cloning strategy for CRISPR/Cas9 pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid. 
A) The oligonucleotides containing the target sequence with 4 bp BbsI-compatible overhangs were 
cloned into the BbsI site of the plasmid px330 represented by the vertical red lines. The horizontal red 
line represents the sequence encoding the trans-activating crRNA (tracrRNA). U6: polymerase III 
promoter; CBh: hybrid form of the cytomegalovirus (CMV) and the chicken β-actin (CBA) promoters; 
NLS: nuclear localization sequence; hSpCas9: humanized S. pyogenes Cas9; bGHpA: bovine growth 
hormone polyadenylation signal. 
 
 After transformation and selection for ampicilin resistance, correct clones were 
identified by PCR. A forward primer, Human U6 seq F Ins, that anneals in the U6 promoter 
was used in combination with the reverse oligonucleotides (Rev CB2 sgRNA) used for cloning 
into the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (figure 23A). The forward primer was 
also used for sequencing to check the correct insertion of the oligonucleotides. A faint band of 
approximately 200 bp appeared for correct clones whereas no band was seen in BbsI 
digested-religated pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid (figure 23B). The plasmid 
obtained was verified by sequence analysis (Macrogen Corporation) and is herein after 
referred to as px330-mCB2.  
 
 
Figure 23: Verification of px330-mCB2 cloning. 
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A) Schematic representation of the PCR strategy used to check the oligonucleotides ligation. The small 
salmon lines represent the primers used for the PCR reaction. The blue line depicts the target sequence 
and the red line the sequence encoding the trans-activating crRNA (tracrRNA) B) 1 % agarose gel 
stained with ethidium bromide. M: 100 bp marker; lane 1,2,3,4: 4 positive clones ligated correctly 
represented by a band of approximately 200 bp; lane 5: BbsI digested/re-ligated pX330-U6-
Chimeric_BB-CBh-hSpCas9 plasmid used as negative control. 
 
 The generated, px330-mCB2 construct expressing the two component of the 
CRISPR/Cas9 system, the gRNA and the Cas9 enzyme, was lipofected into NIH3T3 cells in 
order to test its ability to generate targeted DSBs within the Cnr2 ORF. The surveyor assay 
was used to assessed this ability. 
4.1.3.3 Surveyor assay 
The surveyor mutation detection kit (Transgenomics, Inc) uses a mismatch-specific DNA 
endonuclease to detect mutation in heteroduplex DNA. In principle, a DNA mix fragments that 
contain two different DNA fragments differing by a single point mutation or a huge region 
deletion, are amplified by PCR, denaturated and then re-annealed. Then, those PCR 
fragments which are composed of homoduplex and heteroduplex, are submitted to the 
surveyor endonuclease that recognize the mismatch and produce a cleavage of the fragment. 
Cleavage which can be easily observed on an agarose gel stained with ethidium bromide. 
 
 In order to establish the PCR conditions which were used for every surveyor assays, 
and moreover to validate that the endonuclease activity would not be disturbed in the PCR 
mix, the control experiment provided in the kit was performed as follows: the two control 
plasmids DNAs called C and G, differing at a single base pair, were amplified with provided 
primers. Amplicons were denatured, re-annealed and treated with the surveyor nuclease. 
When denatured - re-annealed amplicons from C and G were mixed; surveyor nuclease 
cleaved the heteroduplex and generates two fragments of 217 and 416 bp as seen in figure 
24, lane 2 whereas no cleavage was observed for C/C denatured - re-annealed amplicons 
treated with Surveyor nuclease (figure 24, lane 3). 
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Figure 24: Surveyor control experiment 
2 % agarose gel stained with ethidium bromide. M: 100 bp marker. Lane 1: C/C denatured and re-
annealed amplicons not treated with the surveyor nuclease as negative control: 633 bp; Lane 2: G/C 
denatured and re-annealed amplicons treated with Surveyor nuclease. Heteroduplex DNA fragments 
were efficiently cleaved by the endonuclease at the single base pair point mutation revealing two 
fragments of 217 bp and 416 bp; Lane 3: C/C denatured and re-annealed amplicons treated with 
Surveyor nuclease: 633 bp 
 
 The control experiment confirmed that the surveyor endonuclease activity is not 
disturbed by the PCR mix conditions. The efficiency of the designed TALEN pair and 
CRISPR/Cas9 system, both targeting and inducing double-strand break within the Cnr2 ORF 
were tested in vitro in NIH3T3 cells and validated with the surveyor assay. 
 
 DSBs induced by nucleases are repaired and while the reparation process, insertions 
or deletions occur. This is leading to sequence heterogeneity of a mixed transfected NIH3T3 
cell population. The sequence heterogeneity was detected by the surveyor nuclease. A primer 
pair (Fwd and Rev sgRNA Surveyor) flanking the TALEN pair target region and the px330-
mCB2 target sites was selected to generate an amplicon of 688 bp (figure 25A). After 
denaturation and re-annealing of the amplified DNA fragments, amplicons were treated with 
the surveyor nuclease. As seen in figure 25A, efficient cleavage of the TALEN pair should 
reveal a cleavage of the 688 bp wild type fragment into two fragments of 405 bp and 283 bp. 
Surveyor nuclease treated DNA from NIH3T3 cells transfected with the TALEN pair constructs 
was not cleaved (figure 25B) supposing no activity of the TALEN pair. Interestingly, surveyor 
nuclease treated DNA of NIH3T3 cells transfected with the px330-mCB2 construct exhibits the 
expected wild type band of 688 bp and a faint band around 500 bp. In order to confirm the 
targeting efficiency of the designed CRISPR/Cas9 system, an additional surveyor assay was 
performed. 
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Figure 25: Surveyor assay with DNAs of NIH3T3 cells transfected with TALEN pair or px-330 
A) Schematic representation of the PCR strategy used to detect double strand breaks induced by the 
TALENs or the CRISPR/Cas9 system within the mCB2 ORF. The blue line depicts the px330-mCB2 
target sequence and the red line the TALEN pair target sequence. B) 2 % agarose gel stained with 
ethidium bromide. M: 100 bp marker. Lane 1,3,5,7,9,11: The specificity of the PCR was checked by 
loading on the gel non surveyor nuclease treated amplicons as negative control. Lane 2: TALEN pair 
transfected NIH3T3 cells DNA denaturated and re-annealed followed by surveyor nuclease treatment 
did not revealed additional band, lane 4: Mock TALEN constructs transfected NIH3T3 cells DNA 
denaturated re-annealed followed by surveyor nuclease treatment, lane 6: px330-mCB2 construct 
transfected cells DNA denaturated and re-annealed followed by surveyor nuclease treatment revealed a 
faint band around 500 bp, lane 8: pX330-U6-Chimeric_BB-CBh-hSpCas9 mock plasmid (without guide 
sequence) transfected cells DNA denaturated and re-annealed followed by surveyor nuclease treatment 
revealed no additional band, lane: 10: WT NIH3T3 cells DNA denaturated and re-annealed followed by 
surveyor nuclease treatment. 
 
 To validate the capacity of the CRISPR/Cas9 system to induce DSBs within the mCB2 
ORF, another surveyor assay was performed using DNA from NIH3T3 cells transfected with 
the px330-mCB2 plasmid. In order to test whether the amount of genomic DNA used for the 
PCR could improve the resolution, two volumes (2,5 μl and 5 μl) of genomic DNA were used 
for the PCR amplification. As shown in figure 26B , fragments of 525 bp and of 688 bp were 
detected after surveyor assay performed with DNA of transfected NIH3T3 cells with the px330-
mCB2 construct, thus indicating an efficient generation of DSBs at the target sequence. The 
signal from the 163 bp cleaved fragment was too faint for visualization. 
Results  79 
 
Figure 26: Surveyor assay with NIH3T3 cells transfected with px330-mCB2. 
A) Schematic representation of the PCR strategy used to detect double strand breaks induced by the 
CRISPR/Cas9 system within the mCB2 ORF. The blue line depicts the px330-mCB2 target sequence. 
B) 2 % agarose gel stained with ethidium bromide. M: 100 bp marker. Lane 1 and 2: Surveyor treated 
DNA from NIH3T3 cells transfected with the px330-mCB2 construct revealed an additional band of 
approximately 525 bp. Lane 1: 2.5 μl of genomic DNA were used for the PCR amplification; lane 2: 5 μl 
of genomic DNA were used for the PCR amplification; lanes 3 and 4: 2.5 µl and 5 µl genomic DNA from 
NIH3T3 cells transfected with the pX330-U6-Chimeric_BB-CBh-hSpCas9 mock plasmid (without guide 
sequence); lanes 5 and 6: 2.5µl and 5 µl genomic DNA from wild type NIH3T3 cells. 
 
 The obtained surveyor assay result for the CRISPR/Cas9 system was further 
confirmed using a functional assay based on the ability of DSBs to enhance HR, when a donor 
fragment is provided. 
4.1.4 Efficiency comparison to humanized the Cnr2 locus 
4.1.4.1 Generation of chimeric mice to produce humanized CB2 mice 
Homologous recombinant ES cell clones were obtained for both targeting constructs, which 
were repeatedly injected into blastocysts. A total of seventeen electroporations were 
performed for the hCB2-Arg targeting construct and eleven for the hCB2-Gln one, using two 
different ES cell lines: MPI2 (129Sv) and Bruce4 (C57BL/6).  
 
 An electroporation for each targeting construct was performed in MP12 ES cells and a 
total of 465 clones were checked by 3´ southern blot strategy. No recombined ES cell clone 
was detected for neither of the targeting constructs (Supplementary table 3). This ES cells line 
was excluded from further studies and Bruce4 ES cells were chosen. 
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 Two different batches of Bruce4 ES cells were used for electroporations. Using a first 
batch of Bruce4 ES cells for electroporations, 624 clones for hCB2-Arg and 564 clones for 
hCB2-Gln were verified for homologous recombination (summary table 1). One positive clone 
for each targeting construct was identified. The hCB2-Arg93 and the hCB2-Gln59. Injection of 
these two positive clones into BALB/c blastocysts led to the generation of chimeric mice. The 
degree of chimerism was judged by (a mix of black: from C57BL/6 and white: from BALB/c) 
coat colour. Injection of the positive ES cell clone recombined with hCB2-Arg resulted in four 
chimeric males with chimerism degrees of 75 %, 75 %, 70 % and 50 %. The positive ES cell 
clone recombined with hCB2-Gln resulted in two males’ chimeras with a chimerism degree of 
70 % and 60 %. A photo of one of those chimeras is depicted figure 27A. Germ-line 
transmission is deduced from the coat colour of the offspring. For C57BL/6 ES cells, germ-line 
transmission was indicated by black fur. Although the chimeric animals for both targeting 
construct displayed a relatively high percentage of fur chimerism, the genetic modifications 
were not transmitted to its progenies.  
 
Table 1: Summary of electroporations performed with Bruce4 ES cells 
Bruce4 ES cells   
Targeting construct: Number of ES cell clones checked: 
hCB2-Arg 624 
hCB2-Gln 564 
 
 In a second round of electroporations a new batch of Bruce4 ES cells was used. 408 
clones for hCB2-Arg and 288 clones for hCB2-Gln were verified (summary table 2). 
Homologous recombined ES cell clones obtained were then injected into (C3H x BALB/c) F1 
hybrid blastocysts. These blastocyst were used because (C3H x BALB/c) F1 mice produce 
more blastocysts than BALB/c mice and moreover, these blastocysts show a higher germ line 
frequency compared to pure BALB/c blastocysts (Pacholczyk et al., 2008). C3H mouse has an 
agouti fur colour. Since it was difficult to distinguish between black and agouti fur colour, it was 
not possible to determine the precise degree of chimerism by coat colour. Thus Chimeras 
were identified by the presence of black patches of coat (figure 27B). One ES cell clones 
recombined with hCB2-Arg was identified, called hCB2-Arg31R ES cell clone and injected. 
The R indicates that the correctly recombined ES cells clones were cultivated into RESGRO 
medium before being injected into blastocysts. 5 males ´chimeras were obtained. Two 
correctly recombined ES cell clones for the hCB2-Gln variant (hCB2-Gln7R and hCB2-Gln29R 
ES cell clones) resulted in two and five chimeric males respectively. However the genetic 
modifications were not transmitted to its progenies. 
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Table 2: Summary of electroporations performed in new batch of Bruce4 ES cells 
New bench of Bruce4 ES cells   
Targeting construct: Number of ES cell clones checked: 
hCB2-Arg 408 
hCB2-Gln 288 
 
 Altogether, a total of 26 electroporations into Bruce4 ES cells were performed with the 
two targeting constructs and 1884 neomycin resistant clones were isolated (supplementary 
summary table 2). Of those, 5 were identified as homologous recombinants, indicating a 
targeting frequency of 1:377, or 0.27 % 
 
 
Figure 27: Chimeric animals obtained from blastocyst injection. 
A) Chimeric animals obtained from injection of C57BL/6 ES cell clone (hCB2-Arg93) into BALB/c 
blastocysts displayed black-white mixed fur. B) Injection of C57BL/6 ES cells clone (hCB2-Gln29R) into 
(C3H x BALB/c) F1 blastocysts resulted in chimeras with brown fur. Chimeras were identified by the 
presence of black patches of coat (black arrows). 
4.1.4.2 Testing the CRIPR/Cas system to enhance the humanization of the Cnr2 locus 
As DSBs enhance HR, when a donor fragment is provided, two Bruce4 ES cells 
electroporations were performed: one with the linearized hCB2-Arg targeting construct alone 
and another one that also contained the px330-mCB2 construct. From each condition, 94 
individual clones were harvested and analysed after G418 antibiotic selection. Figure 28A 
shows the two different PCR strategies, previously described, were used to confirm that the 
CRISPR/Cas9 system could enhance the HR frequency. The first PCR strategy was used to 
confirm the neo gene integration as revealed with a band of 1,9 kb. The second PCR strategy 
was used to amplify the ORF and was followed by a SpeI restriction enzyme digestion in order 
to confirm the bi-allelic human ORF integration. As shown in Figure 28C, PCR analysis of the 
neo gene integration identified no positive clones after electroporation of the hCB2Arg63 
targeting construct alone, whereas 63 clones contained a targeted Cnr2 locus after co-
electroporation with the px330-mCB2 construct and revealed by a specific band of 1,9 kb 
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(figure28D) This corresponds to a targeting frequency of 1:1.5, or 67 %. The CB2 ORF of the 
63 positive identified clones for the neo gene integration were amplified by PCR and the 
products were digested with the SpeI restriction enzyme, because this restriction site is only 
present in the human sequence. Four of the 63 clones contain the human, but not the mouse 
sequence, thus indicating that both alleles were targeted. An example of DNA amplified and 
digested from two clones is depicted figure28B. The clone 46' DNA contains only the double 
bands of 605 bp and 646 bp reflecting a bi-allelic recombination of the murine CB2 ORF by the 
human one whereas the clone number 48 contains both, the murine and the human CB2 ORF. 
As explained previously, only one band of approximately 650 bp is visible due to the 
impossibility to separate the two bands of 605 and 646 bp using a 1 % agarose gel. 
 
Figure 28: Detection of homologous recombination. 
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A) Schematic representation of the PCR strategy used to check the homologous FRT-neo-FRT 
integration in ES cells and bi-allelic recombination. WT represents the mouse wild type allele with a non-
coding exon 1 and the open reading frame of exon 2. The small red bar and the red arrow at the 
beginning of the mouse CB2 open reading frame represent the guide sequence target. The targeting 
construct, hCB2-neo, is depicted with the human CB2 ORF in salmon colour and the 
neomycin/kanamycin cassette in blue flanked by FRT sites represented by green bars. Crosses indicate 
the regions of homologous recombination. ES FRT indicated the “humanized” allele after homologous 
recombination with the targeting construct. Primers used for the analysis of the bi-allelic recombination 
are indicated as blue lines, while the yellow line indicate primers used for the analysis of the neo 
integration. B) PCR amplification of the CB2 ORF followed by SpeI digestion results in a 1212 bp 
fragment indicative of the mouse ORF, or two similar size fragments (605 and 646 bp) indicative of the 
humanized ORF. Please note that sample 46 contained only the humanized ORF, suggesting a bi-allelic 
homologous recombination. C) Electroporation with the linearized hCB2-neo did not produce a PCR 
product of 1953 bp, indicative of no homologous recombination, in any of the 94 selected ES cell 
clones. D) After electroporation of the linearized hCB2-neo with the circular px330-mCB2 vector, 
numerous ES cell clones show the expected 1953 bp fragment indicating homologous recombination. + 
denotes a recombined ES cell clone identified previously as a positive control and W indicates a 
negative water control.  
 
 The CRISPR/Cas9 system designed to target the murine CB2 showed a really high 
efficiency to target the desired region and more importantly improved significantly homologous 
recombination frequency when a donor fragment was provided. 
4.2 Generation of human CB2 recombinant lentiviral vectors 
The functional difference existing between the human CB2 variants could be assessed in vivo 
with the generation of humanized transgenic animals but also in vitro, using different 
strategies. One strategy consists in the delivery of the human CB2 variants into CB2 deficient 
murine cells using lentiviruses. In order to achieve this, viral vectors expressing the human 
CB2 variants alone or the human CB2 variants and eGFP on one transcript were generated in 
order to be used for bone marrow-derived macrophages transduction. This part described the 
cloning of the different lentiviral vectors. 
4.2.1 rrl-CMV-hCB2 vector construct generation 
rrl-CMV-eGFP self inactivated vector construct provided by Dr. Katrin Zimmermann from the 
Institute for Pharmacology and Toxicology was first digested with BamHI and SalI restriction 
enzymes in order to exchange the eGFP ORF with the human CB2 ORF variants (figure 29A). 
The vector represented by the upper band of 6682 bp (figure 29B) was isolated by gel 
purification. The inserts consist of the two ORFs of the human variants. They were amplified 
by PCR using oligonucleotides named Fwd hCB2 ORF BamHI and Rev hCB2 ORF SalI, 
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containing the two restriction sites: BamHI on the forward one and SalI on the reverse one, as 
depicted in figure 29C. First, PCR amplified fragments were checked for their size of 1.1 kb on 
agarose gel as showed on figure 29D, followed by a digestion with BamHI and SalI restriction 
enzymes. Finally, insert and vectors were ligated and electoporated into bacteria which were 
selected for ampicillin resistance. 
 
Figure 29: rrl-CMV-hCB2 vector constructs generation. 
A) Schematic representation of the rrl-CMV-eGFP vector construct. B) 0.8 % agarose gel stained with 
ethidium bromide. M: 1 kb marker; lane 1: rrl-CMV-eGFP digested with BamHI and SalI; restriction 
pattern: two bands of 6682 bp and 748 bp. C) Schematic representation of the PCR strategy used to 
amplify the ORFs of the human variants. The two restriction sites sequences were added on the 5´ 
sides of the oligonucleotides used to amplify the fragment. D) 1 % agarose gel stained with ethidium 
bromide. M: 1 kb marker; lane 1 and 2: human CB2-Arg63 ORF flanked by BamHI and SalI restriction 
sites; lane 3 and 4: human CB2-Gln63 ORF flanked by BamHI and SalI restriction sites. PCR product 
size: 1.1 kb. CMV: Cytomegalovirus promoter, Ψ: Viral vector packaging signal, LTR: Long terminal 
repeat, WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element. 
 
 Ampicillin resistant clones were picked from agar plates and correctly ligated DNA was 
verified by digesting the plasmid DNA with StuI restriction enzyme. As seen in the lower parts 
of figure 30A and B, one positive clone was identified for the rrl-CMV-hCB2-Arg63 and two for 
the rrl-CMV-hCB2-Gln63 represented by the expected patterns of two bands of 6272 bp and 
1505 bp. The positive clones were verified by sequence analysis (Macrogen Corporation). 
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Figure 30: rrl-CMV-hCB2 vector constructs validation using StuI restriction analysis 
A) Upper part: schematic representation of the rrl-CMV-hCB2-Arg63 vector construct and StuI restriction 
sites localisations. Lower part: 1 % agarose gel stained with ethidium bromide. M: 1 kb marker. Lane 
1,2,3,4,5,6,8,9,10: re-ligated clones which do not contain the insert; restriction pattern: one single band 
of 6272 bp or more. Lane 7: positive ligated clone; restriction pattern: one band of 6272 bp and one of 
1505 bp. B) Upper part: schematic representation of the rrl-CMV-hCB2-Gln63 vector construct and StuI 
restriction sites localisations. Lower part: 1 % agarose gel stained with ethidium bromide. M: 1 kb 
marker. Lane 1,2,3,4,5,7,9,10: re-ligated clones which do not contain the insert; restriction pattern: one 
single band of 6272 bp or more. Lane 6 and 8: positive ligated clone; restriction pattern: one band of 
6272 bp and one of 1505 bp. CMV: Cytomegalovirus promoter, Ψ: Viral vector packaging signal, LTR: 
Long terminal repeat, WPRE: Woodchuck hepatitis virus posttranscriptional regulatory element. 
4.2.2 rrl-CMV-hCB2-IRES2-eGFP vector constructs generation 
Additional vector constructs were generated to express the human CB2 variants and eGFP 
bicistronically. To achieve this, a fragment containing the second version of an internal 
ribosome entry site (IRES2) coupled to an enhanced green florescent protein (eGFP) ORF 
was cloned into the previously generated rrl-CMV-hCB2 vector constructs. The IRES2 is the a 
nucleotide sequence that allows the translation of the two proteins, hCB2 and eGFP, within 
one mRNA transcript. The vector constructs rrl-CMV-hCB2 were linearized with SalI restriction 
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enzymes and used as vector (figure 31A). The insert sequence consisting of the IRES2 
followed by the eGFP ORF was amplified by PCR using oligonucleotides named Fwd and Rev 
IRES2-eGFP SalI, containing the restriction sites: SalI on the forward and reverse one, as 
depicted in figure 31B. PCR fragment size of 1334 bp was verified on an agarose gel (figure 
31C) and purified after gel extraction. The IRES2 nucleotide sequence is a GC reach 
sequence leading to unpredictable secondary structures during the PCR procedure. The gel 
purification of the fragment was necessary due to the unspecific additional band appearing 
bellow the 500 bp. SalI digested vector and inserts were ligated and electroporated into 
bacteria followed by ampicillin selection. 
 
Figure 31: rrl-CMV-hCB2-IRES2-eGFP vector constructs generation 
A) Schematic representation of the rrl-CMV-hCB2 vector constructs and SalI restriction site localisation. 
B) Schematic representation of the PCR strategy used to amplify the IRES2-eGFP fragment. The two 
SalI restriction sites sequences were added at the 5´ sides of the oligonucleotides used to amplify the 
fragment. C) 1 % agarose gel stained with ethidium bromide. M: 1 kb marker; lane 1: the band of 1334 
represent the IRES2-eGFP PCR fragment flanked by SalI restriction sites and the band of less than 500 
bp represent an unspecific amplified fragment. CMV: Cytomegalovirus promoter, Ψ: Viral vector 
packaging signal, LTR: Long terminal repeat, WPRE: Woodchuck hepatitis virus posttranscriptional 
regulatory element, IRES2: Internal ribosome entry site version 2, eGFP: Enhanced green fluorescent 
protein. 
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 Ampicillin resistant clones were picked from agar plates and ligation was verified by 
digesting the plasmid DNA contained into ampicillin resistant bacteria with StuI restriction 
enzyme. As seen in the lower parts of figure 32A and B, eight positive clones were identified 
for the rrl-CMV-hCB2-Arg63-IRES2-eGFP and six for the rrl-CMV-hCB2-Gln63-IRES2-eGFP 
represented by the expected patterns of two bands of 6272 bp and 2813 bp.. The sequence  
of the inserts in positive clones was verified by sequence analysis (Macrogen Corporation). 
 
Figure 32: rrl-CMV-hCB2-IRES2-eGFP vector constructs validation using StuI restriction 
analysis 
A) Upper part: schematic representation of the rrl-CMV-hCB2-Arg63-IRES2-eGFP lentiviral vector and 
localisation of StuI restriction sites. Lower part: 1 % agarose gel stained with ethidium bromide. M: 1 kb 
marker. Lane 1,3,4,5,6,7,8,9: ligated clones identified with a restriction pattern of one band of 6272 bp 
and one of 2813 bp. Lane 2,10: clones which contain the insert in the wrong orientation. B) Upper part: 
schematic representation of the rrl-CMV-hCB2-Gln63-IRES2-eGFP lentiviral vector and localisation of 
StuI restriction sites. Lower part: 1 % agarose gel stained with ethidium bromide. M: 1 kb marker. Lane 
1,2,6,8,9,10: ligated clones identified with a restriction pattern of one band of 6272 bp and one of 2813 
bp. Lane 3,4,5,7: clones which contain the insert in the wrong orientation or more than one insert. CMV: 
Cytomegalovirus promoter, Ψ: Viral vector packaging signal, LTR: Long terminal repeat, WPRE: 
Woodchuck hepatitis virus posttranscriptional regulatory element, IRES2: Internal ribosome entry site 
version 2, eGFP: Enhanced green fluorescent protein. 
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 Vector construct DNA from each construct was provided to the Institute for 
Pharmacology and Toxicology where recombinant lentiviral vectors were produced and further 
used for the transduction of bone marrow derived macrophages. 
4.2.3 Mouse bone marrow-derived macrophages expressing the human CB2 
receptors variants 
The transduction efficiency of cells with lentiviral particles is commonly assessed by 
fluorescence-activated cell sorting (FACS), using a fluorescent reporter gene as for example 
eGFP or a specific antibody directly linked or not to a fluorochrome and directed against the 
protein of interest. The first lentiviral vectors that were generated with the human CB2 variants 
alone did not contain any reporter gene. For this purpose, different CB2 antibodies were 
tested for their specificity using BMMs from CB2 knockout mice. At the end of this part, 
recombinant viral vectors expressing both CB2 and eGFP were used to assessed the 
transduction efficiency of the recombinant lentiviral vectors in BMMs without sorting the use of 
antibodies. 
4.2.3.1 Specificity control of CB2 polyclonal N-Terminal antibody 
The specificity of the CB2 polyclonal N-Terminal antibody (1-32 amino acids, Abcam 3561) 
was analyzed by flow cytometry using wild type and CB2 knockout BMMs. First auto 
fluorescence of BMMs was controlled by sorting the cells without submitting them to any 
antibody staining (unstained control). As seen in the figure.33, in the two dot plot of the first 
row, the cells are depicted in the bottom left quadrant which indicates less auto fluorescence 
of BMMs. Then BMMs were stained with an antibody coupled to an eFluor® 450 fluorochrome 
and directed against CD11b, and with the primary N-terminal CB2 antibody revealed by an 
Alexa Fluor® 488 secondary antibody. CD11b or cluster of differentiation molecule 11b 
(integrin αM) forms with the cluster of differentiation molecule 18 (CD18 or integrin β2) the 
macrophage-1 antigen (or integrin αM β2). CD11b is expressed on the surface of many 
leukocytes including monocytes, neutrophils, natural killer cells, granulocytes and 
macrophages. The CD11b marker is commonly used to assessed macrophage colony 
stimulating factor (M-CSF) induced differentiation of hematopoietic stem cells contained in 
bone marrow into macrophages using FACS. As depicted in the middle column of figure 33, 
the representation of BMMS stained with CD11b antibody and N-terminal CB2 antibody 
revealed with a secondary antibody was exactly the same in wild type BMMs and CB2 
knockout BMMs indicating unspecificity of the tested CB2 antibody. The cells are depicted in 
the upper right quadrant of the dot plot with the equivalent distribution of 75-77 %. To verify 
that the unspecificity observed for the CB2 antibody was not due to unspecificity of the 
secondary antibody, BMMs from wild type and CB2 knockout animals were labelled only with 
the CD11b antibody and the secondary antibody (secondary antibody control). As depicted in 
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the last row of figure 33, only approximately 1 % of the cells were not specifically labelled by 
the secondary antibody confirming that the N-terminal CB2 receptor antibody tested was not 
specific. 
 
 
Figure 33: Specificity control of the CB2 receptor polyclonal antibody (1-32 amino acids, N-
terminus) in BMMs 
Representative flow cytometry dot plots of CD11b vs. CB2 expression in WT and CB2
-/-
 BMMs. First 
row: unstained BMMs. Second row: BMMs stained with CD11b eFluor® 450, CB2 N-terminal antibody 
and secondary Alexa Fluor® 488 secondary antibody. Third row: BMMs stained with CD11b eFluor® 
450 and Alexa Fluor® 488 secondary antibody. CD11b: cluster of differentiation molecule 11b, WT: wild 
type, CB2
-/-
: CB2 knockout animal, BMMs: bone marrow-derived macrophages. 
 
 As the first N-terminal antibody tested was not specific for the CB2 receptor in FACS 
experiment, another CB2 polyclonal N-terminal antibody (1-33 amino acids, Thermo Scientific 
PA1-744), reported to be specific for the human CB2 receptor, was tested for its specificity in 
FACS. The first and last rows of figure 34 depict unstained and secondary antibody controls, 
respectively. In this experiment, the secondary antibody shows a non-specific binding in 
approximately 30 % of the cells as depicted in the last row of the figure 34. This particular N-
terminal CB2 antibody was never tested in FACS experiment, that is why different  dilutions of 
1/10, 1/25 and 1/50 of the antibody were tested. Despite the non-specificity of the secondary 
antibody and the different dilutions tested for the CB2 polyclonal N-Terminal antibody, BMMs 
from wild type and CB2 knockout animals exhibit the same pattern in the different dot blots. 
Approximately 90 % of the cells were positive for CD11b and CB2 in wild type and in CB2 
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knockout BMMs indicating that the antibody is not specific for the human CB2 receptor in a 
relative pure macrophages population. 
 
 
Figure 34: Specificity control of cannabinoid the CB2 receptor antibody (1-33 amino acids, N-
terminus) in BMMs 
Representative flow cytometry dot plots of CD11b vs. CB2 expression in WT and CB2
-/-
 BMMs. First 
row: unstained BMMs. Second, third and forth rows: BMMs stained with CD11b eFluor® 450, different 
dilutions of the CB2 N-terminal antibody (1/10, 1/25 and 1/50) and the secondary Alexa Fluor® 488 
antibody. Fifth row: BMMs stained with the CD11b eFluor® 450 antibody and the Alexa Fluor® 488 
secondary antibody. CD11b: cluster of differentiation molecule 11b, WT: wild type, CB2
-/-
: CB2 knockout 
animal, BMMs: bone marrow-derived macrophages. 
 
 Both CB2 polyclonal N-terminal antibodies previously tested showed no specificity for 
the CB2 receptor protein by FACS. Finally a C-terminal antibody was tested for its specificity 
toward the CB2 receptor protein. 
4.2.3.2 Specificity control of CB2 polyclonal C-Terminal antibody 
A last polyclonal antibody directed against the C-terminal part of the mouse CB2 receptor 
protein was tested for its specificity (200-300 amino acids, Abcam 45942). To allow access of 
the antibody to the intracellular C-terminus of the CB2 protein, cells were fixed and 
permeabilized in an additional step, leading to an important cell loss as observed in the 
different dot plots of figure 35 compared with the dot plots of figure 33 or 34. The secondary 
antibody control depicted in the last row did not show unspecific binding as less than 3 % of 
the cells were labelled (last row of the figure 35). As depicted in the middle row, BMMs from 
wild type and CB2 knockout animals were labelled for the CB2 and CD11b in the same 
proportion of approximately 90 % indicating a relatively pure macrophages population but no 
specificity for the C-terminal antibody tested by FACS. 
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Figure 35: Specificity control of the CB2 receptor antibody (200-300 amino acids, C-terminus) 
in BMMs 
Representative flow cytometry dot plot of CD11b vs. CB2 expression in WT and CB2
-/-
 BMMs. First row: 
unstained BMMs. Second row: BMMs stained with CD11b eFluor® 450, CB2 N-terminal antibody and 
secondary Alexa Fluor® 488 secondary antibody. Third row: BMMs stained with CD11b eFluor® 450 
and Alexa Fluor® 488 secondary antibody. CD11b: Cluster of differentiation molecule 11B, WT: wild 
type, CB2
-/-
: CB2 knockout animal, BMMs: bone marrow-derived macrophages. 
 
 Unfortunately CB2 polyclonal N-terminal and C-terminal antibodies tested showed non-
specific binding in CB2 knockout BMMS measured by FACS. The fact that no real specific 
CB2 antibody exists was published two years later after the experiment was performed and 
confirmed the negative results obtained by flow cytometry (Baek et al., 2013). 
4.2.3.3 Measurement of transduction efficiency independent of CB2 antibody use 
Due to the lack of specificity of all CB2 antibody tested, recombinant lentiviral vectors 
containing human CB2 variants coupled to an IRES2 and eGFP were used. This allowed to 
circumvent the use of CB2 antibody and allowed the physical titer measurement of the 
transduction efficiency of BMMs by the recombinant lentiviral vectors using FACS. First, 
recombinant lentiviral vectors generated from rrl-CMV-eGFP vector construct was used to 
control the transduction efficiency of BMMs from CB2 knockout mice. To calculate the physical 
titer, numbers from data between 1-10 % infection rates were used (second row of the figure 
36). Physical titer for BMMS transduced with recombinant lentiviral vector generated from the 
rrl-CMV-eGFP vector construct was calculated using the formula: ((# cells at starting 
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time)*(percent infection)) / vol virus solution added expressed in ml , (100000*0,055)/0.0001= 
5.5*107 TU/ml. 
 
Figure 36: Figure : eGFP lentiviral vector infection rate in CB2-/- transduced BMMs 
Representative flow cytometry dot plot of CD11b vs. eGFP expression in CB2
-/-
 BMMs transduced with 
rrl-CMV-eGFP. CD11b: Cluster of differentiation molecule 11B, WT: wild type, CB2
-/-
: CB2 knockout 
animal, BMMs: bone marrow-derived macrophages. 
 
 Physical titers were determined for BMMs from CB2 knockout animals transduced with 
recombinant lentiviral vectors generated from rrl-CMV-hCB2-Arg-IRES2-eGFP and rrl-CMV-
hCB2-Gln-IRES2-eGFP vectors constructs using the same formula. Infection rate between 1 
and 10 % were observed for BMMs transduced with 10 μl lentiviral vectors (first row figure 37) 
giving a titer of: 
- rrl-CMV-hCB2-Arg-IRES2-eGFP titer: (100000*0.043)/0.01= 4.3*105 TU/ml. 
- rrl-CMV-hCB2-Gln-IRES2-eGFP titer: (100000*0.0145)/0.01=1.45*105 TU/ml. 
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Figure 37: Human CB2-IRES2-eGFP lentiviral vectors infection rates in CB2-/- transduced 
BMMs 
Representative flow cytometry dot plot of CD11b vs. eGFP expression in CB2
-/-
 BMMs transduced with 
rrl-CMV-hCB2-Arg-IRES2-eGFP and rrl-CMV-hCB2-Gln-IRES2-eGFP. CD11b: Cluster of differentiation 
molecule 11B, WT: wild type, CB2
-/-
: CB2 knockout animal, BMMs: bone marrow-derived macrophages. 
 
 The titers measured for BMMs transduced with recombinant lentiviral vectors 
generated from the vector constructs rrl-CMV-hCB2-Arg63-IRES2-eGFP and rrl-CMV-hCB2-
Gln63-IRES2-eGFP were 1000 times lower than the titer measured from BMMs transduced 
with recombinant lentiviral vector generated from rrl-CMV-eGFP vector construct. 
4.3 Functional analysis of CB2 receptor activation in mouse bone 
marrow derived-macrophages 
This result part is divided into two parts. BMMs were characterized for their two main 
properties, which are the ability to be driven into different activation states in response to pro- 
or anti-inflammatory substances in a first part and the ability to engulf zymosan particles by 
phagocytosis in second part. 
4.3.1 Activation state analysis of mouse bone marrow-derived-macrophages 
4.3.1.1 Markers expression analysis 
To ensure that BMMs undergo M1 or M2 activation states, they were stimulated with different 
concentrations of IFNγ (5, 10 and 20 ng/ml), LPS/IFNγ (10/5, 50/10, 100/20 ng/ml) and IL-4 
(10, 50 and 100 ng/ml). Three markers: CD86, the major histocompatibility complex class II 
molecule (MHCII) and MMR expression, respectively were analysed by flow cytometry. CD86 
expression was found to be upregulated after stimulation with IFNγ and even greater with a 
combination of LPS/ IFNγ, whereas IL-4 showed no effect on CD86 expression (figure 38, left 
graphic). The expression of major histocompatibility complex (MHC) class II molecules by 
BMMs was upregulated by interferon IFNγ. LPS in combination with IFNγ showed a lower 
upregulation of MHC class II expression induced by IFNγ. And IL-4 stimulation had no effect 
on MHCII expression (figure 38, middle graphic). When BMMs were overnight stimulated with 
IL-4, MMR was upregulated whereas stimulation with IFNγ or LPS/IFNγ at the highest 
concentrations showed a slight downregulation (figure 38, right graphic). 
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Figure 38: Cell surface marker molecules associated with activation of BMMs tested by flow 
cytometry. 
CD86, MHCII, and MMR mean fluorescence intensity (MFI) relative to unstimulated controls. CD86: 
cluster of Differentiation 86 detected with PE labelled antibody, MHCII: major histocompatibility complex 
class II molecules detected with APC labelled antibody, MMR: mannose receptor detected with a biotin 
preliminary antibody revealed by a PerCP-Cy5.5 labelled secondary antibody. IFNg: Interferon-gamma 
(IFNγ), LPS: lipopolysaccharide, IL-4: Interleukin 4, MFI: mean fluorescent intensity. Concentration are 
expressed in ng/ml. 
 
 BMMs underwent into M1 phenotypes after IFNγ or combination of LPS/IFNγ overnight 
stimulation or in M2 phenotype after IL-4 overnight stimulation. The M1 phenotypes was 
clearly observable by the upregulation of CD86 and MHCII markers expression whereas the 
effect of IL-4 stimulation on MMR expression was a moderate effect observed by the slight 
upregulation.  
4.3.1.2 Effect of CB2 agonists on pro-inflammatory cytokine release 
Cannabinoid receptor 2 specific agonists such as beta-caryophyllene (BCP) and the 
compound JWH-133 were tested for their abilities to modulate the pro-inflammatory cytokine 
TNFα release by BMMs polarized into M1 state. BMMs were stimulated overnight with 
LPS/IFNγ and different CB2 specific agonists and the pro-inflammatory cytokine TNFα 
released was measured by ELISA. High TNFα amounts were released upon LPS/IFNγ and 
LPS/IFNγ tocrisolve as observed in figure 39. Tocrisolve (1:4 ratio of soya oil/water) was the 
vehicle used to solubilise the two CB2 specific agonists. 
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Figure 39: Effect of CB2 agonist on TNFα pro-inflammatory cytokine release by a LPS/IFNγ 
overnight stimulated BMMs 
Measurement of TNFα release in the supernatant by Elisa. IFNg: Interferon-gamma (IFNγ), LPS: 
lipopolysaccharide, BCP: Beta-Caryophyllene. Statistical analysis: one-way ANOVA followed by post-
hoc Bonferroni test: F8,9=52.00; p<0.001. 
 CB2 specific agonists, BCP and JWH-133, had no statistical effect on the pro-
inflammatory cytokine TNFα release. 
4.3.1.3 Cannabinoid receptors real time expression 
M1 polarizing stimulus effects on cannabinoid receptor 1, cannabinoid receptor 2 and GRP18 
receptor expressions were analysed by real time PCR using TaqMan assays. As depicted in 
the left part of the figure 40, the CB1 receptor expression was downregulated upon IFNγ, LPS 
and combination of LPS/IFNγ stimulations. CB2 receptor expression was slightly 
downregulated when BMMs were stimulated with IFNγ. This effect was more pronounced 
when LPS/IFNγ and LPS were used (middle part of figure 40). In contrast to CB1 and CB2, 
GPR18 was slightly upregulated when BMMs were stimulated with IFNγ and more than 10 
times upregulated when LPS/IFNγ and LPS were used (right part of figure 40). 
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Figure 40: Quantitative cannabinoid receptor expression analysis by real-time PCR (RT-PCR). 
Stimulated BMMs were tested for altered gene expression of CB1, CB2, and GPR18, Statistical 
analysis: one-way ANOVA followed by post-hoc Bonferroni test. CB1: F3,32=5.188; p<0.01. CB2: 
F3,32=107.8; p<0.001. GPR18: F3,32=145.4; p<0.001. Values represent mean ± SEM, * p < 0.05 vs. 
unstimulated control, ** p < 0.01 vs. unstimulated control, *** p < 0.001 vs. unstimulated control. ddCt: 
delta-delta-Ct, IFN: Interferon gamma (IFNγ), LPS: lipopolysaccharide. 
 
 BMMS stimulated with IFNγ, combination of LPS/IFNγ or LPS undergone into M1 
phenotype (pro-inflammatory) show a change in cannabinoid receptors expressions. The CB1 
and CB2 receptors are downregulated whereas GPR18 is upregulated in M1 macrophages. 
 
4.3.2 Analysis of zymosan phagocytosis by BMMs 
As an antigen-presenting cell, macrophage has the ability to phagocyte (Wang et al., 2013a; 
Weischenfeldt and Porse, 2008). The effect of cannabinoid receptor 2 agonists on 
phagocytosis of fluorescein isothiocyanate (FITC)-labelled zymosan by BMMs was measured 
by FACS and by fluorescence microscopy. 
4.3.2.1 Zymosan phagocytosis by BMMS upon CB2 agonists stimulation measured by FACS 
The effect of cannabinoid receptor 2 agonists was tested on BMMs phagocytosis of zymosan 
particles at three time points of incubation (30, 60 and 90 minutes). Tocrisolve was used to 
solubilize JWH-133 and BCP and showed no effect on zymosan phagocytosis in all the assays 
performed. Two selective CB2 agonists were tested: beta-caryophyllene (BCP) and JWH-133. 
Giving JWH-133 and zymosan particles at the same time (figure 41A) or JWH-133 one hour 
before zymosan particles (figure 41B) had no statistical treatment effect on phagocytosis after 
30, 60 or 90 minutes of incubation but a statistical time effect was observed. 
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Figure 41: Flow cytometry measurement of JWH-133 effects on zymosan particles 
phagocytosis by BMMs. 
A) Zymosan particles and agonist were given at the same time. B) Agonist was given one hour before 
providing the zymosan particles. Fluorescein isothiocyanate (FITC)-labelled zymosan particles were 
used. MFI: mean fluorescence intensity. Statistical analysis: Two-way ANOVA followed by post-hoc 
Bonferroni test. A) Treatment F2,12=4.427; p>0.05, Treatment x time F4,12=0.8184; p>0.05, Time 
F2,12=145.9; p<0.001. B) Treatment F2,12=1.312; p>0.05, Treatment x time F4,12=0.4167; p>0.05, Time 
F2,12=138.3 ; p<0.001. 
 
 Giving BCP and zymosan particles at the same time (figure42A) or BCP one hour 
before zymosan particles (figure 42B) showed also no statistical treatment effect on 
phagocytosis after 30, 60 or 90 minutes of incubation but a statistical time effect was 
observed. 
 
Figure 42: Flow cytometry measurement of beta-caryophyllene effects on zymosan particles 
phagocytosis by BMMs. 
Fluorescein isothiocyanate (FITC)-labelled zymosan particles were used. BCP: beta-caryophyllene, 
MFI: mean fluorescence intensity. Statistical analysis: Two-way ANOVA followed by post-hoc Bonferroni 
test. A) Treatment F2,12=0.2678; p>0.05, Treatment x time F4,12=0.2452; p>0.05, Time F2,12=68.52 ; 
p<0.001. B) Treatment F2,12=4.091; p>0.05, Treatment x time F4,12=0.3184; p>0.05, Time F2,12=106.6 ; 
p<0.001. 
 
 As specific CB2 agonists had no effect on zymosan phagocytosis, the 
endocannabinoid 2-AG, ligand for the cannabinoid receptors (CB1 and CB2) was diluted in 
100 % ethanol (vehicle) and tested for its effect on zymosan phagocytosis by BMMs. The 
vehicle showed no effect on phagocytosis in all the assays performed. 2-AG had no statistical 
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effect on phagocytosis of zymosan particles by BMMs figure 43 and didn´t show any statistical 
treatment effect after 60 and 90 minutes incubation. A statistical time effect was observed 
 
Figure 43: Flow cytometry measurement of 2-arachidonylglycerol (2-AG) effects on zymosan 
particles phagocytosis by BMMs. 
Fluorescein isothiocyanate (FITC)-labelled zymosan particles were used. The vehicle control used was 
100 % ethanol. 2-AG: 2-arachidonylglycerol, MFI: mean fluorescence intensity. Statistical analysis: Two-
way ANOVA followed by post-hoc Bonferroni test. Treatment F2,6=0.3065; p>0.05, Treatment x time 
F2,6=0.8254; p>0.05, Time F1,6=80.84 ; p<0.001. 
 
 BMMs were starved 24hours before performing the phagocytosis assay for the 
macrophage colony-stimulating factor (M-CSF) used to differentiate myeloid progenitors into 
cells of the macrophage/monocyte lineage like BMMs. Starving BMMs for this differentiating 
factor was thought to be responsible for the non observable effect of cannabinoid agonists on 
zymosan phagocytosis by BMMs. As seen in figure 44 starving the cells leads to an global 
statistical increase of zymosan phagocytosis by BMMs. This effect was observed after 60 
minutes incubation in the presence, or not, of the vehicle (100 % ethanol) in which 2-AG was 
initially dissolved. 
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Figure 44: Flow cytometry comparison of BMMS starved or not for M-CSF 24h before 
phagocytosis assay 
Fluorescein isothiocyanate (FITC)-labelled zymosan particles were used. The vehicle control: 100 % 
ethanol. MFI: mean fluorescence intensity. Statistical analysis: One-way ANOVA followed by post-hoc 
Bonferroni test: F3,10=75.37; p<0.001. Values represent mean ± SEM, *** p < 0.001 vs. M-CSF treated 
BMMs, ### p < 0.001 vs. M-CSF vehicle treated BMMs. 
 
 After finding a modulation of zymosan phagocytosis activity due to the starvation of 
BMM for M-CSF, 2-AG was tested for its ability to modulate the zymosan phagocytosis activity 
of BMMS after they starved for M-CSF 24 hours before performing the phagocytosis assay. As 
depicted in figure 45 no statistical treatment effect was observed, as the statistical time effect 
was still present. 
 
Figure 45: Flow cytometry measurement of 2-arachidonylglycerol (2-AG) effects on zymosan 
particles phagocytosis by BMMs. 
Fluorescein isothiocyanate (FITC)-labelled zymosan particles were used. The vehicle control: 100 % 
ethanol. 2-AG: 2-arachidonylglycerol, MFI: mean fluorescence intensity. Statistical analysis: Two-way 
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ANOVA followed by post-hoc Bonferroni test. Treatment F2,6=3.378; p>0.05, Treatment x time 
F2,6=1.151; p>0.05, Time F1,6=214.7; p<0.001. 
 
 As no effect was observed with usually used 2-AG concentrations in cell culture 
experiments, the effect of a high concentration (10 μM) was tested on zymosan phagocytosis 
of M-CSF starved BMMs. As seen in Figure 46 no statistical difference in zymosan 
phagocytosis by BMMs was observed between vehicle and 2-AG treatment after 60 minutes 
incubation. 
 
Figure 46: Flow cytometry measurement of 2-arachidonylglycérol (2-AG) effects on zymosan 
particles phagocytosis by BMMs. 
Fluorescein isothiocyanate (FITC)-labelled zymosan particles were used. The vehicle control used was 
100 % ethanol. 2-AG: 2-arachidonylglycerol, MFI: mean fluorescence intensity. Statistical analysis: 
Mann Whitney test p>0.05 
 
 Finally a commercial available M-CSF was used instead of our “self made” M-CSF to 
differentiate myeloid stem cells from bone marrow into macrophages as a possible reason for 
the non response of BMM on phagocytosis after cannabinoid agonists treatment. Cells were 
starved 24 hour before starting the phagocytosis assay, which was performed during 60 
minutes. No statistical difference was observed while comparing 2-AG treated BMMs vehicle 
reference treated BMMs (figure 47). 
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Figure 47: Flow cytometry measurement of 2-arachidonylglycérol (2-AG) effects on zymosan 
particles phagocytosis by BMMs. 
Fluorescein isothiocyanate (FITC)-labelled zymosan particles were used. The vehicle control used was 
100 % ethanol. 2-AG: 2-arachidonylglycerol, MFI: mean fluorescence intensity. Statistical analysis: One-
way ANOVA followed by Bonferroni´s post-hoc comparison to Zymosan vehicle: F3,12=2.017; p>0.05. 
 
 To confirm the results obtain previously by flow cytometry, a phagocytosis assay was 
performed using fluorescence microscopy. 
4.3.2.2 Zymosan phagocytosis by BMMS upon CB2 agonists stimulation measured by 
fluorescence microscopy 
BMM were treated in the same way than for flow cytometry experiments, but instead using the 
fluorescence-activated cell sorting to measure phagocytosis activity, fluorescence microscopy 
was used. A seen in the two pictures figure 48A, B, DAPI labelling (blue) of nucleus allowed 
the identification of the cells and the FITC zymosan particles (green) engulfed by BMMS were 
counted on six different areas of a cover slip and three cover slips per treatment condition 
were analyzed. BMMs engulfed the same relative number of zymosan particles under vehicle 
or 2-AG treatments (figure 49A). The two-way ANOVA followed by post-hoc Bonferroni test 
revealed a statistical difference in the number of particles, and a treatment x particles 
interaction. Furthermore the post-hoc Bonferroni test showed a significance difference 
between the number of macrophages engulfing more than 5 zymosan particles after vehicle or 
2-AG (5 μM) treatments (figure 49B). 
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Figure 48: Example of pictures used to count engulfed zymosan particles by BMMs 
40X magnification of zymosan particles engulfed by BMMs under vehicle (A) and 2-AG 5 μM (B) after 
60 minutes of incubation. Nucleus of macrophages: DAPI (blue); Zymosan particles: FITC (green). 
 
Figure 49: Fluorescence microscopy analysis of zymosan particles engulfed by BMMs 
A) Comparison of relative number of engulfed zymosan particles by BMMs after vehicle or 2-AG 5 μM 
treatments. Statistical analysis: Mann Whitney test p>0.05 B) Relative amount of macrophages which 
after treatments, engulfed no particles, 1,2,3,4,5 or more than 5 zymosan particles. Statistical analysis: 
Two-way ANOVA followed by post-hoc Bonferroni test. Treatment F1,28=0.0; p>0.05, Treatment x 
particles F6,28=2.612; p<0.05, Particles F6,28=47.59 ; p<0.001. * p<0.05. 
 
 The cannabinoid agonist 2-AG had no effect on zymosan phagocytosis by BMMs 
measured by flow cytometry, but a statistical effect was observed for the phagocytosis of more 
than five zymosan particles by BMMS using fluorescence microscopy. 
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5 DISCUSSION 
The first aim of this thesis work was to generate humanized CB2 receptor mouse lines. 
Therefore, humanized targeting vectors were generated and subsequently used for the 
generation of chimeric mice by injecting targeted ES cells into blastocysts. Due to the lack of 
germ-line transmission, new engineering technologies (CRISPR/Cas9 system and TALENs) 
were designed and tested for their ability to target the Cnr2 locus and improve HR efficiency in 
ES cells.  
 
 The second aim was the establishment of an in vitro model to characterize the 
functional difference between the two human CB2 receptor variants. In a first step, 
recombinant lentiviral vectors were generated to express the human CB2 receptor variants 
and used to transduce BMMs. In a second step BMMs were characterized for their two main 
properties, which are the ability to be driven into different activation states in response to pro- 
or anti-inflammatory substances and the ability to engulf zymosan particles by phagocytosis. 
To determine the CB2 receptor´s role in macrophages, different CB2 agonists were tested for 
their capacity to modulate the characterized functions of BMMs. 
5.1 Humanizing the mouse CB2 locus 
For the generation of the humanized cannabinoid receptor 2 mice, targeting constructs were 
generated. The design of both targeting construct was identical and based on several 
considerations. First the length of DNA homology arms required for HR to occur was chosen 
on minimum size recommendations of 4 kb and 1kb for the long and shorts arms, respectively, 
as recommended in the literature (Hasty et al., 1991). This was achieved using a BAC and the 
Red/ET recombineering method to subclone the fragment of interest. On the 5´ side of the 
mouse ORF, a long arm of 4.3 kb was chosen. This long arm consists of the region located 
between the EcoRV restriction site used to linearize the targeting constructs and the last base 
before the starting codon of the ORF. On the 3´ side of the ORF, the short arm was designed 
such as the homology arm located directly after the insertion point of the selection cassette to 
the end of the targeting constructs measure 1.7 kb. The mouse CB2 ORF was replaced by the 
human ones keeping intact the 5´and 3´ untranslated regions surrounding the mouse CB2 
ORF, in order to not disturb the expression. Finally a selection cassette flanked by FRT sites 
was inserted 933 bp after the ORF´s stop codon in order to select for homologously 
recombined ES cells clones. 
 
 In a first step, both targeting constructs were electroporated into MPI12 ES cells (129sv 
background), as well as into Bruce4 ES cells (C57Bl/6 background). First electroporations 
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were performed into MPI12 ES cells. No homologous recombined ES cells were obtained 
using this ES cell line, which can be due to the fact that the targeting constructs were 
generated from C57BL/6 DNA and the different genetic background of the two strains could 
account for the absence of HR. 129sv-derived ES cells are the most wildly used ES cells for 
generation of genetically modified mice, mainly for their ability to generate chimeras and for 
their good germ line transmission rates. But these ES cell lines due to their 129sv background 
have a major inconvenient. In fact the peripheral CB2 receptor was characterized to be 
involved in immune response, and immunologists mainly rely on the extensively characterized 
C57BL/6 immune response (Bauler et al., 2007; Rolink et al., 2004; Schwarz et al., 2003). If 
germ line transmitted mice would have been obtained using MPI12 ES cells, they would have 
to be breed and subsequent backcross to C57BL/6 background to generate congenic strains. 
The breeding and backcrossing steps can take a long time: 30-36 month. In order to reduce 
the breeding time to 15-18 months, a marker-assisted breeding strategy (speed congenic) 
based on a microsatellite marker panel polymorphic between C57BL/6 and 129sv has been 
developed. The major inconvenient of the speed congenic is the extreme cost that it represent. 
 
 MPI12 ES cells were no further used and targeting constructs were then electroporated 
into Bruce4 ES cells, to avoid extensive backcrossing steps and costs. Moreover, C57BL/6-
derived ES cell lines represent a valuable tool for the generation of mouse models due to the 
fact that the genome of C57BL/6 mouse is available as the RPCI-23 (RP23) BAC library and 
completely sequenced (Osoegawa et al., 2000), making the design and the development of 
sequence-specific targeting constructs more convenient. A total of 26 electroporations were 
performed for both targeting constructs and 1884 neomycin resistant clones were isolated. Of 
those, 5 were identified as completely homologously recombined clones, indicating a targeting 
frequency of 1:377, or 0,27 %, which is lower than HR rates reported in the literature (Seong 
et al., 2004). The absolute frequencies of recombination are locus-dependent, as differences 
in chromatin structure can influence the accessibility of the required enzymatic machinery 
(Muller, 1999; te Riele et al., 1992). The low recombination frequency observed can also be 
explained by the difficulty to obtain recombination of the human ORF and the FRT-neo-FRT 
sequence in one recombination event. In fact many positive clones identified with the neo 
integration strategy were negative for the human PCR/digestion, which indicates that the FRT 
floxed neo cassette was recombined, but not the human ORF. This is the reason why positive 
clones were first identified using the neo integration PCR strategy and confirmed for the 
human CB2 ORF recombination using the PCR/digestion strategy. PCR reactions were 
pipetted using a liquid handling system to automate the process and simplify handling of 
numerous clones to check. The positive identified clones were further confirmed using the 
5´and 3´southern blot strategies before being injected into blastocysts. At last, improvement 
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could have been done to diminish the number of ES cell clones to check by inserting a 
negative selection marker (e.g. thymidine kinase, TK) into the targeting construct. This 
negative selection marker would have probably diminished tremendously the number of ES 
cells clones to verified but probably not improve the recombination in the same time of the 
human CB2 ORF and the FRT-neo-FRT sequence. 
 
 Repeated blastocyst injections were performed with the identified positive clones and 
various chimeric animals were born. 9 chimeras from two recombined clones were obtained 
for the human CB2-Arg variant as well as 9 chimeras out of three recombined clones for the 
human CB2-Gln variant. It is generally recommended to breed chimera males and wait for 
them to produce 6 or more litters in order to observe germ line transmission. After the 18 
chimera males produced 100 pups, and the genetic modifications were not passed to its 
progeny, they were not likely to go germline and were discarded. C57BL/6 ES cell lines are 
known to be less efficient in producing genetically modified mice compared to ES cells on a 
129Sv background (Nagy et al. 1993). They are reputed for their susceptibility to become 
aneuploid and this genetic instability decreases their germ line transmission potency (Hughes 
et al., 2007; Longo et al., 1997). In addition, maintaining Bruce4 ES cells into culture is quite 
demanding. The RESGRO medium was used in order to improve chimera generation and 
germ line transmission potency of our identified Bruce4 ES cells clones. This culture medium 
is described as able to rescue established ES cell lines that have started drifting, generate low 
percentage chimeras or have lost germ line transmission capability. It allows separation of 
differentiated and undifferentiated clones into culture, and sub-clone specifically 
undifferentiated ES cells to further use them for blastocyst injections. RESGRO medium 
rescuing of our positive identified ES cell clones did not improved germ line transmission. 
Mouse ES cell lines have the main disadvantage to be demanding for culture conditions and 
even if these ES cell lines are used for the generation of transgenic mice since the late 
eighties (Robertson et al., 1986; Thompson et al., 1989), for other species like for example 
rats, the story just begin with the establishment in 2008 of the first ES cell line for transgenic 
models generation (Li et al., 2008). 
 
 While the efforts to generate transgenic mice using ES cells, new DNA engineering 
technologies were developed and interest among the scientific community for these new tools 
emerged. Moreover, these technologies exhibit a great potential for the generation of 
transgenic animals without resorting to ES cells. These technologies known as ZFNs, TALENs 
and CRISPR/Cas9 system are based on two main components: a designed sequence-specific 
DNA-binding module(s) linked to a non-specific DNA cleavage domain. Thus when a small 
double-stranded or single stranded template of DNA are supplied consecutively to these DNA 
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engineering tools, HR is stimulated by DSBs and lead to precise genetic engineering 
(Hockemeyer et al., 2011; Wang et al., 2013b). HR initiates with extensive 5' to 3' end-
processing at broken end, which in eukaryotic cells is regulated by the MRE11/RAD50/NBS1 
(MRN) complex, histone H2AX, Breast cancer 1 (BRCA1), Breast cancer 2 (BRCA2), DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), and ataxia telangiectasia-mutated 
(ATM) kinase. The resulting 3' single strand DNA (ssDNA) tails are bound by the replication 
protein A (RPA), which is replaced with Rad51 in a reaction mediated by Rad52. The resulting 
Rad51 nucleoprotein filament searches for and invades a homologous sequence. The Srs2 
helicase is thought to dissociate Rad51 from ssDNA, allowing normal base pairing of the 
invading and complementary donor strands and subsequent strand extension by DNA 
polymerase. Both ends may invade producing a double-Holliday junction that is resolved to 
yield crossover or non-crossover recombinants. Once intermediates are resolved, the 
remaining ssDNA gaps and nicks are repaired by DNA polymerase and ligase (Shrivastav et 
al., 2008). 
 
 As ZFNs were reported to have a potential cytotoxic activity, presumably due to 
cleavage at non-targeted sites (Cornu et al., 2008; Pruett-Miller et al., 2008; Radecke et al., 
2010), efforts were only concentrated on the generation and testing of one TALEN pair and a 
CRISPR/Cas9 system, both targeting the Cnr2 locus. An important factor for the generation of 
TALENs is the spacer region, which is defined as the region separating the two TALENs after 
binding on the genomic sequence. As reported by Schmid-Burgk et al, a spacer region of 14-
15 bp showed the highest TALENs efficiency (Schmid-Burgk et al., 2013). Due to this 
consideration one TALENs pair was designed to target the murine CB2 ORF 300 bp after the 
start codon with a spacer region of 14 bp. The TALEN pair was also designed to avoid 
targeting of the human CB2 ORF and activity of the TALENs in the targeting construct. 
Unfortunately the TALEN pair designed did not show any activity in the mouse locus using the 
surveyor assay. It would have increase the chance to target the Cnr2 locus by designing more 
than one TALENs pair. Due to the sequence requirements (spacer and sequence 
heterogeneity) this was not possible. Moreover, the LIC assembly of TALENs, which is 
supposed to simplify the construction of TALEN pairs in a really short time, is certainly more 
convenient than the PCR/Golden gate cloning method (Sanjana et al., 2012) but is still time 
consuming. The ligation independent cloning assembly of TALEN remains a valuable high 
throughput technique that enables the semi-automated generation of TALE genes using liquid 
handling systems for the establishment of TALE gene library. 
 
 Since 2012 the CRIPSR/Cas9 system offered a faster and more efficient way to edit 
the genome. This system is based on two distinct components: a synthetic guide RNA (gRNA) 
Discussion  107 
and the bacterial CRISPR associated (Cas) nuclease, Cas9. The gRNA consists in the fusion 
of the CRISPR RNA (crRNA), responsible for the targeting specificity and the trans-activating 
crRNA (tracrRNA) that is involved in the recruitment of the Cas9. The system has only one 
requirement that is necessary for nuclease activity. The target site needs to be flanked on the 
3´end by a 3 bp NGG called protospacer-adjacent motif (PAM). A well-suited 20 bp sequence 
located 25 bp after the start codon of the murine CB2 ORF was found and this sequence 
differs in 6 bp between mouse and human ORFs. These mismatches are located at both ends 
of the targeted sequence, which were reported to be important for targeting specificity of 
gRNA than the central nucleotides (Cong et al., 2013). It can be speculated that the designed 
CRISPR/Cas9 system will have activity only in the murine ORF and not in the human ORF 
present in the targeting constructs. The only required cloning step to build this system is the 
ligation of a double stranded oligonucleotide containing sticky ends compatible with the 
restriction site used to linearize the CRIPR/Cas9 plasmid. The plasmid successfully cloned 
was called px330-mCB2. This plasmid expresses the gRNA targeting the murine ORF and the 
Cas9 when lipofected or electroporated into cells. The ability to mediate double strand breaks 
of our designed CRISPR/Cas9 system was first assessed and confirmed by surveyor assay. 
But to further confirm that this system is relevant for the generation of transgenic mice, HDR 
process was tested in the Bruce4 ES cells previously used for Cnr2 locus targeting by 
homologous recombination. The results suggest that CRISPR/Cas-mediated double strand 
breaks at the Cnr2 locus dramatically increased the frequency of homologous recombination 
in neomycin resistant ES clones from 0.27 % to 67 % meaning an increase of more than 200 
fold. Furthermore, 4 % of all clones showed a bi-allelic recombination. It is thus possible to 
generate completely humanized cell lines with a single electroporation and normal selection 
conditions. Moreover, with this super-efficient system, modifications can be introduced by 
directly injecting RNAs encoding the Cas9 protein, the gRNA targeting the mCB2 ORF and the 
targeting constructs into developing mouse embryos. This eliminates the long and laborious 
processes of transfecting and selecting mouse ES cells that are required to create targeted 
mutant mice using classical homologous recombination techniques. Finally It has to be taken 
into consideration that the CRISPR/Cas9 system, as well as TALENs, induce also mutations 
at non-specific loci also called off-site effects. For the moment these mutations can be difficult 
to identify and require to scan the genome for mutations at sites with sequence similarities to 
the gRNA or the TALEN pair. In the optic of transgenic animal generation, the experimenter 
could get rid of these non-specific mutations after some subsequent breeding steps with wild 
type animals. 
 
 Previous studies showed the utility of CRISPR/Cas9 system or TALENs technologies 
to enhance the frequency of HDR with short single-stranded DNA sequences in mice (Wang et 
108  Discussion 
al.). In addition, CRISPR/Cas-mediated double strand breaks also enhanced the frequency of 
homologous recombination in plants and C. elegans (Chen et al., 2013; Dickinson et al., 2013; 
Li et al., 2013b) with double-stranded DNA. Here it was demonstrated that this technology also 
boost gene replacements with large DNA constructs in the mouse genome. This new and 
simple technology thus holds a great promise to improve genetic engineering of the mouse, 
apes and even human genome. It remains to be determined if the CRISPR/Cas9 technology is 
more efficient than TALENs (Cong et al., 2013; Yu et al., 2014) to stimulate homologous 
recombination. Anyhow, considering the easiness to clone guide sequences in comparison to 
the rather cumbersome task of engineering TALENs, it will be much easier to experiment 
different gRNAs, if necessary. It should be taken into consideration that it might be required to 
design the guide sequence such that it does not direct double strand breaks within the 
targeting construct. In practice, this should also not impose any problems, because it should 
always be possible to utilize sequences where the targeting construct diverges from the target 
locus for example when humanizing a mouse gene or using the loxP site of a floxed gene. 
5.2 Functional analysis 
In this section, in vitro assays were developed to assess the functional difference between the 
two human variants. Carrasquer et al did not find any difference in binding of cannabinoid 
ligands and signal transduction between the two human CB2 variants but revealed a 
difference in ligand-induced cyclic AMP accumulation (Carrasquer et al., 2010). Based on this 
observation and the fact that CB2 receptor is well accepted among the scientific community to 
play a role in immune functions, two components necessary for the assay were developed and 
tested. First, recombinant lentiviral vectors expressing each of the human variants were 
designed and cloned in order to transduce CB2-/- BMMs. In a second step murine BMMs were 
checked for their ability to turn into pro or anti-inflammatory phenotypes called M1 and M2, 
and also to check, as it was previously reported (Shiratsuchi et al., 2008), the influence of 
cannabinoid ligands on zymosan phagocytosis. 
5.2.1 Recombinant lentiviral vectors expressing the human CB2 variants 
After cloning the hCB2 ORF variants into distinct vector constructs, recombinant lentiviral 
vectors were produced in collaboration with Dr. Katrin Zimmermann from the Institute of 
Pharmacology and Toxicology, Bonn. Our collaborators also determined the titer of these 
newly produced lentiviral particles by measuring the reverse transcriptase (RT) activity using a 
cell free colorimetric assay (ELISA). Measuring the activity of reverse transcriptase present in 
the virions is a valuable technique to estimates or predicts a functional titer. But since the 
functional titer is dependent on the vector construct and the cell type used for transduction, the 
transgene expression levels in transduced cells had to be determined by FACS. As the first 
vector constructs designed did not contained fluorescent gene, establishment of CB2 
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antibodies had to be performed. Different antibodies binding either at the N or C-terminal of 
the protein were established and tested for FACS measurement. As recommended by Ashton 
et al., the specificity of these antibodies were tested in CB2 knockout BMMS (Ashton, 2011) . 
The non-specificity of commercially available CB2 antibodies is often debated in the literature 
(Baek et al., 2013) and remain today one of the biggest issue in the endocannabinoid field. 
This is mainly due to the fact that the detection or quantification of the CB2 protein is for the 
moment not reliable. Our data confirmed that the CB2 protein detection by FACS using the 
most used CB2 antibodies is not possible due to a lack of specificity. To overcome the use of 
CB2 antibodies, recombinant lentiviral vectors were generated with an IRES version2 and an 
eGFP gene. It was then possible to assess the transduction efficiencies of the generated 
recombinant lentiviral vectors into BMMs. The functional titer of 5.5*107 TU/ml measured for 
the eGFP recombinant lentiviral vector indicates a good transduction efficiency of BMMs. 
However, titration measured for the hCB2-IRES2-eGFP recombinant lentiviral vectors were 
one hundred times lower which indicate a low transduction efficiency. The recombinant 
lentiviral vectors eGFP and  the hCB2-IRES2-eGFP were produced in the same manner by 
our collaborators of the Institute of Pharmacology and Toxicology, Bonn. Production of 
recombinant lentiviral vectors using the hCB2-IRES2-eGFP vector constructs were repeated 
and gave always rise to a low transduction efficiency. This low titer could be explained by 
either the nature of the constructs which is interfering with the transduction ability or by the fact 
that the CB2 receptor expression into 293T cells may affect the HIV-1 replication machinery as 
reported previously (Ramirez et al., 2013) during the recombinant lentiviral vector production 
in these cells. Considering the considerable amount of viruses that had to be used to obtain 
transduction of BMMs, lentiviruses expressing in parallel the human CB2 variants and eGFP 
were not further used. 
 
 Now that a functional CRISPR/Cas9 system was developed and tested to target the 
Cnr2 locus, it could be reasonable to imagine transfecting BMMs with the px330-mCB2 in 
combination with targeting constructs expressing eGFP paralleling the human CB2 variants to 
study the functional difference between the two human variants. Even if BMMs are known to 
be hard-to-transfect cells, some protocols exist (Weischenfeldt and Porse, 2008). Avoiding the 
use of lentiviruses in favour of transfection with DNA plasmids, also decrease the time of 
BMMs in culture, which is a point of importance when testing these macrophages with a 
functional assay such as phagocytosis for example. 
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5.2.2 Functional analysis of CB2 receptor activation in mouse bone marrow derived-
macrophages 
The cannabinoid receptor 2 is expressed in many macrophage-derived cells. These include 
microglia, many circulating macrophages, osteocytes and osteoclasts, dendritic cells, and 
hepatic Kupffer cells (Atwood et al., 2012). Macrophages play a key role in the polarized 
innate and adaptive immune response. As an antigen presenting cells and in order to initiate 
the adaptive response, they are able to phagocyte (Murray and Wynn, 2011). Moreover they 
can be stimulated with different substances to drive them into different activation states 
characterized by different cell surface markers expression and cytokine release (Mantovani et 
al., 2004). These functional abilities with regards to a possible modulation by the CB2 receptor 
were investigated in BMMs. 
5.2.2.1 Bone marrow macrophages phenotypes 
BMMs were driven into M1 activation state due to high expression of CD86 cell surface marker 
observed after overnight stimulation with IFNγ or a combination of LPS/IFNγ. The MHCII cell 
surface marker normally expressed by both M1 and M2 macrophages was only observed after 
IFNγ or combination of LPS/IFNγ stimulations. Only a slight upregulation of this cell surface 
marker was observed after IL-4 overnight stimulation. Expression of MMR was also 
significantly increased after overnight stimulation with IL-4. The effects of IL-4 could maybe be 
improved by a longer exposure of 48 hours instead of 16 hours, as reported in the literature 
(Guzman-Morales et al., 2011; Ruffell et al., 2011). Furthermore, once the BMMs were 
activated into M1 phenotype, they release high amount of the pro-inflammatory cytokine TNFα 
after overnight stimulation with a combination of LPS/IFNγ and no effect of CB2 agonists such 
as BCP or JWH-133 was observed on the TNFα release. As reported in the literature (Ehrhart 
et al., 2005; Romero-Sandoval et al., 2009), the stimulation of the CB2 receptor suppresses 
microglial activation in vitro. It was shown that incubation with the CB2 agonist JWH-015 is 
able to suppress microglial TNFα production induced by IFNγ (Ehrhart et al., 2005). In the 
present study, it was found that the expression of the CB2 receptor was down regulated after 
overnight incubation of BMMS with LPS or combination of LPS/ IFNγ. Which indicates that 
LPS stimulation is maybe the factor responsible for the no effect of CB2 agonists on TNFα 
release. As the CB2 receptor expression in BMMs was only slightly down regulated after 
overnight stimulation with IFNγ, it is reasonable to imagine an effect of CB2 agonists on TNFα 
release by BMMs after IFNγ overnight stimulation. While CB2 expression was down regulated 
in BMMs after pro-inflammatory stimulations, GPR18 expression was highly up regulated. As 
reported in an immortalized microglia cell line (BV-2), GPR18 plays a role in the migration of 
this cells (McHugh et al., 2012). The increased expression in BMMs under pro-inflammatory 
conditions could indicate a role for this GPCR in the migration ability of macrophages during 
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inflammation. Even if CB1 receptor expression is reported as low in immune cells (Kaplan, 
2013; Nong et al., 2001), the down regulation in its expression after overnight pro-
inflammatory stimulations indicate that this receptor could also play a role in immune cells. 
Finally, efforts should be concentrated maybe on expression patterns of the different 
cannabinoid receptors in pro and anti-inflammatory situations more than concentrated only on 
single receptor expression and its possible effect. 
5.2.2.2 Zymosan phagocytosis 
Shiratsuchi and colleagues investigated phagocytosis of zymosan by murine elicited peritoneal 
macrophages (Shiratsuchi et al., 2008). They found that 2-AG or CP55 940, agonists for both 
CB1 and CB2 receptors, increase phagocytosis of zymosan. Moreover they showed that both, 
the number of zymosan particles engulfed by macrophages and the ratio of macrophages that 
had engulfed zymosan, increased in the presence of 2-AG. Based on the observed result that 
cannabinoid receptors stimulation increases the phagocytosis ability of macrophages, the 
same functionality was tested in BMMs. The time points of 30, 60 and 90 minutes were 
chosen to not miss any effect on an increase or a decrease in phagocytosis activity. Generally, 
the phagocytosis assay is performed after 60 minutes incubation (Weischenfeldt and Porse, 
2008). Furthermore, starving the differentiated BMMs for M-CSF, 24 hours before performing 
the phagocytosis assay induces an increase in the phagocytosis ability of BMMs, which 
indicates that the phagocytosis activity of BMMs can be modulated. To confirm the results 
obtain by Shiratsuchi et al., different CB2 specific agonists such as beta caryophyllene and 
JWH-133, and agonist for both CB1 and CB2 such as 2-AG were used at different 
concentrations. Unfortunately cannabinoid agonists did not show any modulation of the 
phagocytosis activity analyzed by flow cytometry or fluorescence microscopy. The only 
significant result found was an increase in the relative amount of macrophages that had 
engulfed more than five zymosan particles after 2-AG treatment by fluorescence microscopy. 
But the relative number of engulfed zymosan remained the same with our without 2-AG. This 
effect could be due to a loss of control of BMMs in engulfing more than five zymosan particles 
after 2-AG treatment. Flow cytometry result did not indicate such of loss of control, which may 
indicates that this result is an artefact. 
 As our result did not confirm those observed by Shiratsuchi and colleagues, it is 
reasonable to wonder if there are any differences between bone marrow-derived 
macrophages and thioglycolate-elicited peritoneal macrophages. It was recently showed that 
peritoneal macrophages and BMMs differ even if they are used in same functional assays 
such as phagocytosis assay. Peritoneal macrophages appear to be more mature than bone 
marrow derived macrophages based on their morphology and surface molecular 
characteristics (Wang et al., 2013a). Furthermore BMMs showed a stronger capacity in both 
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proliferation and phagocytosis than peritoneal macrophages (Wang et al., 2013a) which could 
encounter for the difficulties to observe any modulation by the CB2 receptor stimulation in 
BMMs. As 2-AG has an effect on zymosan phagocytosis by peritoneal macrophages but not 
by BMMs, it could be that BMMs are too naïve or that they have to be previously stimulated in 
order to activate their potential to respond to cannabinoid stimulation.
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7 APPENDIX 
7.1 Supplemental material 
Supplementary table 1: Summary of electroporations performed in MPI ES cells 
MPI ES cells 
Electroporation 
number 
Number of 
checked clones 
Targeting construct: hCB2-Arg 1 232 
Targeting construct: hCB2-Gln 2 233 
Supplementary table 2: Summary of all electroporations performed in Bruce4ES cells 
Bruce 4 ES cells 
Electroporation 
number 
Number of 
checked clones 
Targeting construct: hCB2-Arg 3 214 
 
5 16 
 
6 2 
 
9 153 
 
14 27 
 
15 17 
 
16 52 
 
17 34 
 
18 40 
 
19 36 
 
20 33 
 
TOTAL 624 
   
Bruce 4 ES cells 
Electroporation 
number 
Number of 
checked clones 
Targeting construct: hCB2-Gln 4 157 
 
7 26 
 
8 34 
 
10 171 
 
11 87 
 
12 42 
 
13 47 
 
TOTAL 564 
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New Bruce 4 ES cells 
Electroporation 
number 
Number of 
checked clones 
Targeting construct: hCB2-Arg 21 96 
 
23 96 
 
25 24 
 
27 96 
 
28 96 
 
TOTAL 408 
   
New Bruce 4 ES cells 
Electroporation 
number 
Number of 
checked clones 
Targeting construct: hCB2-Gln 22 96 
 
24 96 
 
26 96 
 
TOTAL 288 
 
Oligonucleotides used during the study: 
 
Targeting construct cloning: 
 
Fwd mCB2 subcloning 
GTGCCTTCTAGAAGACCTATTTCTAGGGCAAGGATGTGT
TTGATGTATAACAATTGACAGCTTGTCTGTAAGCGGATG 
Rev mCB2 subcloning 
GTTTAAGTTCCTCGGAGTTCTTGTTAAGTTCAACGGACA
AAAGATAGACTCAATTGGCTCTCCTGAGTAGGACAAATC 
  
Fwd hCB2 flanked HA first 
ACAGCCCAGTCTTCTGGGACAGCTCCAGTAGAAGAAGC
CAAAGCCCATCCATGGAGGAATGCTGGGTGACAGAG 
Rev hCB2 flanked HA first 
GACAGGTGGTGTCAGCAGTTGGAGCAGCCTGGAGTTCT
GGATCCTGGCTCTCAGCAATCAGAGAGGTCTAGATC 
  
Fwd hCB2 flanked HA second 
GCTCTCAGTTGACGTCATCACCTGTTAACATTCAAGGAT
TGTTTTCTCCTTGCCCACAGCCCAGTCTTCTGGGACAGC
T 
Rev hCB2 flanked HA second 
CTCTTCGAGGGAGTGAACTGAACGGACTTCTGACTCGG
GCTGTTTCCAGTAGAAAGACAGGTGGTGTCAGCAGTTG
GAG 
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Fwd FRT-neo-FRT 
CACTATCCCAGTCTTGCCTAGCTTCAGTACAAAGCAAGA
TATTCACACAGAATTAACCCTCACTAAAGGGCG 
Rev FRT-neo-FRT 
CAGTGGGGCTGAGTCAAGCATCACTGGGAACAGCCTAG
GACCCAAAGAATTAATACGACTCACTATAGGGCTC 
 
Targeting strategies: 
 
Fwd ES cell check TTTCATGATCTGTGTGTTGG 
Rev ES cell check GAGTTGCCGAAGAGATTGA 
    
Fwd seq hCB2 CTTGATTGGTGTCAGCTCTC 
Rev seq hCB2 ACAGGTGGTGTCAGCAGTT 
  
Fwd 3' CB2 probe TCTCCCAGTTTTCCCCACAC 
Rev 3' CB2 probe GAGTAACGATTGGCTTGGAAGG 
  
Fwd 5' hCB2 probe TTCCATCCCCAGTACACACA 
Rev 5' hCB2 probe GAAAAGGTGTGGCAGGTTGT 
 
CRISPR/Cas9 cloning and checking: 
 
Fwd CB2 sgRNA CACCGTGACCAACGGCTCCAACGG 
Rev CB2 sgRNA AAACCCGTTGGAGCCGTTGGTCAC 
  
Human U6 seq F Ins ACTATCATATGCTTACCGTAAC 
Rev CB2 sgRNA AAACCCGTTGGAGCCGTTGGTCAC 
  
Fwd sgRNA Surveyor CTTGATTGGTGTCAGCTCTC 
Rev sgRNA Surveyor TAGTCGTTAGGGATCAGTGG 
Viral vector construct generation: 
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Fwd hCB2 ORF BamHI 
TCTAGAGGATCCGCCACCATGGAGGAATGCTGGGTGA
CAGAG 
Rev hCB2 ORF SalI TTGATTGTCGACTCAGCAATCAGAGAGGTCTAGATC 
  
Fwd IRES2-eGFP SalI TCTAGAGTCGACGCCCCTCTCCCTCCCCCCCCCCTAAC 
Rev IRES2-eGFP SalI TTGATTGTCGACTTACTTGTACAGCTCGTCCATGCC 
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